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1. Introduction 
 
1.1 The genetic basis of leukemia: 
Cancer is a genetic disease. It is caused by genetic abnormalities or 
mutations that are commonly somatically acquired rather than 
inherited. Leukemia arises from the malignant transformation of 
hematopoietic stem or progenitor cells in the bone marrow. As a 
result of specific genetic abnormalities, the transformed cell exhibit 
unregulated growth, leading to acute or chronic leukemia. 
Untreated leukemia, especially acute leukemia, is invariably fatal. 
Approximately 29,000 adults and 2000 children are diagnosed with 
leukemia in United States every year (Weir et al., 2003). Leukemia, 
like all other cancers, is a complex disease. It is the results of a 
multistep process involving the acquisition of several mutations. 
These mutations can be of different kinds: Point mutations, i.e. 
single nucleotide changes such as base substitution, insertions and 
deletions, gross chromosomal rearrangements, which include gene 
deletions, gene amplification, chromosomal translocations and also 
epigenetic changes in the promoter and enhancer regions of genes 
(Lin and Aplan, 2004). Presently, there is no evidence that the 
mutation of a single gene can lead to a fully transformed leukemic 
cell. Different mutations collaborate with each other and promote 
abnormal cell proliferation, differentiation and survival (Gilliland and 
Tallman, 2002). In contrast to epithelial tumors, which often have a 
complex pattern of numerical and structural chromosomal 
aberrations, hematological neoplasms show a much simpler picture, 
sometimes with none or only one chromosomal abnormality such as 
a single balanced translocation. It is likely that fewer mutations are 
required to transform a hematopoietic cell than an epithelial cell. 
Gilliland and Tallman postulated that at least two cooperating 
mutations are required for leukemic transformation with one 
mutation causing increased proliferation and the other disrupting 
cellular differentiation (Gilliland and Tallman, 2002).  
1.2 Chromosomal translocations and leukemia 
Among all the mutations found in leukemia, recurrent chromosomal 
translocations have been studied most extensively. Chromosomal 
translocations or inversions are found in up to 65% of the acute and 
chronic leukemias (Raimondi, 1993; Solomon et al., 1991). 
Chromosomal translocations involve the exchange of chromosomal 
regions between non-homologous chromosomes. Translocations are 
classified as reciprocal or non-reciprocal. In reciprocal or balanced 
translocations no genetic material is lost, while non-reciprocal or 
unbalanced translocations lead to the net loss or gain of genetic 
material. 
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1.3 The causes of chromosomal translocations 
Chromosomal translocation can originate from double strand DNA 
breaks. If two breaks occur simultaneously on different 
chromosomes, and the two breaks from non-homologous 
chromosomes are joined together, a chromosomal translocation 
results. Several molecular mechanisms have been proposed to 
explain recurrent translocations found in leukemia. These 
mechanisms include: illegitimate V(D)J recombination; short or long 
interspersed nuclear element (SINEs, LINEs) mediated 
recombination; DNA topoisomerase II subunit exchange, 
homologous and error prone non-homologous end joining after a 
DNA double strand break. Some regions in the genome also show 
an increased susceptibility to DNA double strand breaks, for 
example regions containing stretches of pyrimidine-purine repeat 
sequences, scaffold and matrix attachment regions, and DNA 
topoisomerase II cleavage sites (Aplan, 2006). However, there still 
remain many questions regarding the causes of recurrent 
translocations and their occurrence in specific types of leukemia. 
Recently, using next-generation sequencing techniques, very 
complicated genomic rearrangements have been analyzed in detail 
in certain cancer cells. In these rearrangements, a large number of 
translocations, deletions, and inversion involving a single or several 
chromosomes were found in a cell. It is thought that these 
complicated events result from the faulty repair of a single 
“chromosome shattering” event. The literal translation of 
“chromosome shattering” into Greek is “chromothripsis” (Stephens 
et al., 2011). One of the causes of chromothrispsis might be a 
chromosome segregation error during mitosis with the formation of 
micronuclei in which the localized shattering and re-ligation of DNA 
fragments take place (Holland and Cleveland, 2012; Stephens et 
al., 2011).  
Several inherited syndromes are associated with increased genetic 
instability and predispose to chromosomal translocations. For 
example, patients with ataxia telangiectasia, which is caused by a 
mutation in the ATM gene, are prone to acquire chromosomal 
rearrangements involving T cell or immunoglobulin antigen-receptor 
loci (Rotman and Shiloh, 1998). ATM is a protein, which plays an 
important role in DNA double strand break recognition and repair. 
Nijmegen’s breakage syndrome is another genetic instability disease 
caused by mutations in the NBS1 gene, which encodes the DNA 
double strand break repair enzyme NBS1. Patients with this disease 
are also predisposed to chromosomal translocation and lymphoid 
malignancies (Digweed and Sperling, 2004).  
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1.4 Possible consequences of chromosomal translocations 
Translocations can have either of two consequences. They can bring 
the coding region of one gene into close proximity of the promoter 
or enhancer region of another gene resulting in the overexpression 
or ectopic expression of the former gene. The example of such an 
event is translocation t(8;14)(q24;q32) found in Burkitt’s 
lymphoma and the t(14;18)(q32;q21) found in follicular lymphoma. 
As a result of these translocations, the expression levels of MYC and 
BCL2, respectively, are greatly increased since they are juxtaposed 
to the immunoglobulin heavy chain gene enhancer, which are very 
active in B cells.  
Translocations can also give rise to chimeric or fusion genes which 
act as oncogenes. An example of such an event is the translocation 
t(9,22) (Rowley, 1973), which results in the formation of the 
oncogenic fusion BCR/ABL (Heisterkamp et al., 1990) 
1.5 Importance of studying chromosomal translocations 
Chromosomal translocations have been shown to be causal in 
hematological malignancies and also in several solid tumors. The 
analysis of recurrent, non-random chromosomal translocations has 
been very useful in understanding the pathogenesis of 
hematological malignancies leading to improved diagnosis and 
classifications and to the development of novel targeted therapies 
(Rowley, 1999, 2001).  
1.6 The CALM/AF10 fusion 
The t(10;11)(p13;q14) translocation is a rare but recurring 
translocation, which results in the in-frame fusion of the the AF10 
gene on chromosome 10, band p13, with the CALM gene on 
chromosome 11, band q14, generating both a CALM/AF10 fusion 
transcript and a CALM/AF10 fusion protein and a reciprocal 
AF10/CALM fusion (Dreyling et al., 1996). The CALM/AF10 fusion 
transcript encodes for almost the entire CALM and AF10 proteins, 
whereas the reciprocal AF10/CALM fusion transcript encodes only 
for the first 80 amino acids from AF10 and last 4 amino acids from 
the CALM gene due to the asymmetric positioning of the 
breakpoints in the AF10 and CALM genes. The CALM/AF10 fusion 
transcript has been detected consistently in all patients with a 
t(10;11)(p13;q14), whereas the reciprocal AF10/CALM transcript is 
not always present. This suggests that the CALM/AF10 fusion 
transcript and the resulting CALM/AF10 fusion protein is the 
important driving force of the leukemias in these patients 
(Bohlander et al., 2000;Carlson et al., 2000; Narita et al., 1999). 
Due to alternative breakpoints, both in AF10 and in CALM, several 
different CALM/AF10 fusion transcripts have been detected in 
patients (Bohlander et al., 2000;Kumon et al., 1999; Silliman et al., 
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1998). Four breakpoints in the AF10 gene and at least two 
breakpoints in the CALM gene have so far been reported. There is 
no indication that the different CALM/AF10 fusion transcripts result 
in different disease phenotypes. Identical fusion transcipts have 
been reported in AML and in ALL patients (Bohlander et al., 2000). 
 
Fig 1.1: Translocation t(10,11)(p13;q14) leading to the in-frame fusion of the 
CALM gene on chromosome 11 with the AF10 gene on chromosome 10. The 
arrows indicate the breakpoints and the direction of the gene. (Figure kindly 
provided by Stefan Bohlander) 
Originally, the CALM/AF10 fusion gene was cloned from the 
monocytic cell line U937 (Dreyling et al., 1996). The U937 cell line 
was derived from a patient with diffuse histiocytic lymphoma with 
some monocytic features (Sundstrom and Nilsson, 1976). The 
CALM/AF10 fusion is found in patients with undifferentiated acute 
myeloid leukemia (AML) (FAB M0, M1), acute lymphoblastic 
leukemia (ALL), and malignant lymphoma (Dreyling et al., 1998; 
Kumon et al., 1999; Narita et al., 1999). The CALM/AF10 fusion has 
been identified in mixed-lineage leukemia with the co-expression of 
lymphoid (T-cell) and myeloid antigens (Kumon et al., 1999; Narita 
et al., 1999). Some cases of more mature AML with CALM/AF10 
fusion have also been reported (FAB M4, M5, M7)(Abdou et al., 
2002; Carlson et al., 2000; Jones et al., 2001; Nakamura et al., 
2003; Salmon-Nguyen et al., 2000). The CALM/AF10 fusion 
transcript is predominantly found in children and young adult 
patients (Dreyling et al., 1998; Kobayashi et al., 1997; Kumon et 
al., 1999; Silliman et al., 1998) and is frequently associated with 
difficult to treat cases and a very poor prognosis (Kumon et al., 
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1999; Narita et al., 1999). In T-ALL with TCR γδ rearrangement, 
CALM/AF10 is the most frequent chromosomal abnormality with up 
to 30% cases being positive for this fusion (Asnafi et al., 2003). 
 
Fig 1.2: Schematic diagram of the full length CALM and AF10 gene with their 
domains. Red arrows indicate the different breakpoints on each gene. The 
CALM/AF10 fusion and the reciprocal AF10/CALM fusion, which is rarely present 
among patients, are also shown. ENTH-Epsin N terminal homology domain, NES- 
nuclear export signal; OM/LZ- octapeptide motif/leucine zipper; PHD- plant homeo 
domain; NLS- nuclear localization signal, TAD-transactivation domain, CATS-
CALM/AF10 interacting protein expressed in thymus and spleen 
1.7 Clathrin Assembly Lymphoid Myeloid gene (CALM or 
PICALM) 
The CALM or PICALM gene encodes for a 652 amino acid long 
protein with extensive homologies to the neuronal-specific endocytic 
protein AP180 (Morris et al., 1993). It is a ubiquitously expressed 
protein, which is predominantly cytoplasmic but is known to shuttle 
between nucleus and cytoplasm (Archangelo et al., 2006; Tebar et 
al., 1999; Vecchi et al., 2001). CALM plays a role in the endocytic 
machinery, specifically in the adaptor protein 2 (AP2)-mediated 
formation of the clathrin-coated vesicles from cell membranes 
(Tebar et al., 1999). It interacts with the clathrin heavy chain via its 
C-terminal third and with phosphoinositides via its AP180 N terminal 
homology domain (ENTH) facilitating the assembly of clathrin 
triskelia into clathrin cages (Ford et al., 2002; Ford et al., 2001). 
Overexpression and downregulation of CALM have been implicated 
in the inhibition of receptor-mediated endocytosis and impaired 
endosome trafficking in the trans-golgi network (Huang et al., 
2004; Tebar et al., 1999). fit1 mutant mice carry a nonsense point 
mutation in the mouse ortholog of the CALM gene, and these mice 
show hematopoietic abnormalities, growth retardation and 
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abnormal iron metabolism and a shortened life span (Klebig et al., 
2003). The human CALM gene has also been shown to play an 
important role in iron homeostasis and cell proliferation (Scotland et 
al., 2012). The clathrin-binding domain at the carboxy terminus of 
CALM is critical for CALM/AF10-mediated leukemogenesis. 
(Deshpande et al., 2011; Stoddart et al., 2012). Another recent 
study showed that the nuclear export signal (aa 544-553) within 
the clathrin-binding domain of CALM is important and sufficient for 
leukemogenesis when fused to the AF10 protein. (Conway et al., 
2013) 
1.8 AF10 (MLLT10)  
AF10 (MLLT10 or ALL1-fused gene from chromosome 10) is a 
putative transcription factor, which was identified as a fusion 
partner of MLL (Mixed Lineage Leukemia), the human homolog of 
the Drosophila Trithorax gene (Yu et al., 1998). The 
t(10;11)(p13;q23) MLL-AF10 fusion was initially detected in a 
patient diagnosed with  AML-M5 (Chaplin et al., 1995). In this 
translocation, AF10 and MLL are often involved in complex 
rearrangements like inversion/insertion because they are 
transcribed in opposite directions with respect to the centromere-
telomere orientation (Beverloo et al., 1995). The MLL gene on 
11q23 is frequently involved in translocations in leukemia and has 
over 50 different partner genes (Meyer et al., 2013). Interestingly, 
AF10 is the only fusion partner of MLL, which independently 
rearranges with a third gene, CALM (Dreyling et al., 1996). Of note, 
the CALM/AF10 fusion is associated both with myeloid and lymphoid 
hematological malignancies while the MLL/AF10 fusion is exclusively 
found in AML (Chaplin et al., 1995). 
AF10 encodes for a 1084 amino acid long protein. Like the MLL 
protein, AF10 also has a conserved LAP/PHD finger domain at its N 
terminal end (Aasland et al., 1995; Saha et al., 1995). In the C 
terminal region, AF10 contains an octapeptide motif followed by a 
leucine zipper (OM/LZ) domain. AF10 has a nuclear localization 
signal (NLS) (Chaplin et al., 1995; Linder et al., 2000). Due to 
breakpoint variability, there are different MLL/AF10 and CALM/AF10 
fusion transcripts, however, the OM/LZ domain of AF10 is retained 
in all fusions (Bohlander et al., 2000; Narita et al., 1999). The 
OM/LZ domain of AF10 has been shown to interact with many 
interesting proteins, which play important roles in the hematopoietic 
development and chromatin regulation. The histone H3 lysine 79 
(H3K79) methyletransferase hDOT1L interacts with AF10 via the 
OM/LZ domain. CALM/AF10-mediated leukemia is marked by a 
global hypomethylation of H3K79 but locally H3K79 
hypermethylated loci like certain HoxA loci (Lin et al., 2009; Okada 
et al., 2005; Okada et al., 2006).  It is proposed that the 
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deregulation of the global H3K79 methylation in CALM/AF10 
leukemia is due to the disruption of the AF10 mediated association 
of hDOT1L with chromatin (Lin et al., 2009). Among the other 
interactors of the OM/LZ domain of AF10, the lymphoid 
transcriptional regulator Ikaros (IKZF1) is significant (Greif et al., 
2008). Ikaros interacts with chromatin remodeling factors and is 
known to play a key role in the transcriptional regulation and cell 
cycle control during lymphoid differentiation (Georgopoulos et al., 
1992; Gomez-del Arco et al., 2005; Gomez-del Arco et al., 2004).  
The OM/LZ domain of AF10 is required for CALM/AF10-mediated 
leukemogenesis (Deshpande et al., 2011). Another OM/LZ 
interaction partner of AF10 is GAS41; GAS41 is known to interact 
with INI1, the human homologue of yeast SNF2, which is a part of 
the SWI/SNF complex (Debernardi et al., 2002). SWI/SNF is a 
conserved multi-protein complex, which plays a role in chromatin 
remodeling in an ATP dependent manner. Among the other 
interactors of AF10, FLRG is interesting from the point of view of the 
hematopoiesis. FLRG is a secreted glycoprotein, which participates 
in erythrocyte commitment. AF10 interacts with FLRG via its PHD 
domain and this interaction enhances AF10 mediated transcription 
(Forissier et al., 2007; Maguer-Satta and Rimokh, 2004). In a 
recent publication, AF10 was shown to play a key role in the 
survival of undifferentiated hematopoietic cells (Chamorro-Garcia et 
al., 2012). 
1.9 Mechanism of CALM/AF10 mediated leukemogenesis 
Very little is known about the molecular mechanism of how the 
CALM/AF10 fusion leads to leukemia (Caudell and Aplan, 2008). It 
is known that the interaction of AF10 with H3K79 methyltransferase 
hDOT1L is critical for the pathogenesis of MLL-AF10 mediated 
leukemia. Mistargeting of hDOT1L to the Hoxa9 locus potentially 
plays a key role in the leukemogenesis of MLL-AF10 (Okada et al., 
2005). Recently, our group reported that the expression the 
CALM/AF10 fusion gene results in the global reduction of H3K79 
methylation in human and murine leukemic cells (Lin et al., 2009). 
This reduction of H3K79 methylation leads to global genomic 
instability (Lin et al., 2009). It has also been shown by several 
groups that overexpression of Hoxa cluster genes is a molecular 
signature of CALM/AF10 driven leukemias (Caudell et al., 2007; Dik 
et al., 2005; Okada et al., 2006). Together with the Hoxa cluster 
genes, the Hox cofactor MEIS1 and the polycomb group gene BMI1 
were also found to be upregulated in CALM/AF10 positive T-ALL 
patients (Dik et al., 2005; Mulaw et al., 2012). Our group also 
reported recently, that CALM/AF10-positive leukemias show a global 
upregulation of genes involved in DNA repair and chromatin 
assembly (Mulaw et al., 2012). 
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1.10 Mouse models of CALM/AF10 leukemia 
In a bone marrow transplantation model, overexpression of 
CALM/AF10 fusion resulted in the development of an aggressive 
AML with a median latency of 10 weeks. A proportion of the 
leukemic cells showed co-expression of the lymphoid marker B220 
with the myeloid markers Gr1 and Mac1 (MM) (Deshpande et al., 
2006). B220 is the murine homolog of human CD45R, a pan B 
lymphocyte specific marker, which is expressed on early and 
mature B cells. For the identification of the ‘leukemia propagating 
cell’, the leukemic cells were subdivided into 3 groups on the basis 
of  their surface marker expression:  B220+/MM-; B220+/MM+ and 
B220-/MM+. Using a limiting dilution transplantation approach, 
Deshpande and colleagues were able to show that the frequency of 
the ‘leukemia propagating cell’ was highest in the B220+/MM- cell 
population with about 1 in 34 cells (Deshpande et al., 2006). This 
intriguing finding led to the hypothesis that the CALM/AF10 fusion 
gene induces an aberrant myeloid development of B220+ early 
lymphoid progenitors (Deshpande et al., 2006). 
However, when CALM/AF10 was expressed as a transgene in all 
hematpoietic cells under the control of the Vav promoter in mice, 
only 40% of the animals developed acute myeloid leukemia with a 
long latency of 12 months (Caudell et al., 2007). In the leukemic 
cells the Hoxa cluster genes were overexpressed and an impaired 
thymus development was noted. The results from this CALM/AF10 
transgenic model are quite different from the bone marrow 
transplantation model where all mice developed leukemia after a 
very short latency. 
A former member of our group, Alexander Krause, generated two 
transgenic CALM/AF10 mouse lines, in which the CALM/AF10 fusion 
is expressed from B cell specific IgH enhancer/promoter or from the 
proximal Lck promoter. None of the transgenic mouse lines 
developed leukemia even after a long observation period of up to 1 
½ years (Krause, 2006).The results from the different CALM/AF10 
models strongly sugggest that it is critical for the CALM/AF10 fusion 
to be expressed in the correct hematopoietic cell type for leukemia 
development.  
Aim 1: Analysing the requirement for tissue-specific 
expression of CALM/AF10 in leukemogenesis using a murine 
knock-in model 
To investigate at which stage of the hematopoietic development the 
expression of the CALM/AF10 fusion would be leukemogenic, we 
generated a knock-in mouse model of the CALM/AF10 fusion. In the 
Rosa26 loxP-stop-loxP-CALM/AF10 (R26LSLCA) mouse line, the 
CALM/AF10 cDNA is preceded by a loxP flanked transcriptional stop 
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cassette and integrated into the Rosa26 locus. Using tissue-specific 
expression of the Cre recombinase or a Tamoxifen controllable 
version of the Cre recombinase (Cre/Estrogen receptor fusion), the 
stop cassette can be removed, enabling the expression of the 
CALM/AF10 fusion from the Rosa26 promoter. By crossing 
R26LSLCA mouse line with lines that express Cre in a tissue-specific 
manner, we were able to achieve cell type-specific expression of the 
CALM/AF10 fusion protein.  
Aim 2: Testing BMI1 as a potential collaborator in 
CALM/AF10-mediated leukemogensis using a murine 
retroviral bone marrow transplantation model 
BMI1, a polycomb group gene, was reported to be specifically 
upregulated in both human and murine CALM/AF10-positive 
leukemias (Dik et al., 2005; Mulaw et al., 2012). BMI1 was 
originally identified at a retroviral integration site that led to 
leukemia development in an Eµ-Myc transgenic mouse model (van 
Lohuizen et al., 1991).  BMI1 has been shown to be important for 
the self-renewal capacity of hematopoietic stem cells and to play a 
role in leukemogenesis (Lessard and Sauvageau, 2003; Park et al., 
2003; Rizo et al., 2010).  
To determine the role of BMI1 in CALM/AF10 leukemia, we 
expressed BMI1 retrovirally together with CALM/AF10. We used two 
approaches. In the first approach, BMI1 was retrovirally over-
epressed in IgH-CALM/AF10 transgenic bone marrow cells and the 
retrovirally-modified cells were transplanted into wild type mice. In 
the second approach, we retrovirally co-expressed both BMI1 and 
CALM/AF10 in a murine bone marrow transplantation model. 
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2. Materials and Methods 
 
2.1 Materials 
2.1.1 Chemicals  
Table 2.1 List of chemicals 
 
Name  IUPAC Name Molecular 
Formula  
Molar 
mass 
(g/mol) 
Company 
Agarose (14)-3,6-anhydro-α-
L-galactopyranosyl-
(13)-β-D-
galactopyranan 
 
 167.6 ± 
7.8 x 
103 
Carl Roth 
® GmbH, 
Germany 
Acetic Acid  C2H4O2 60.05 Carl Roth 
® GmbH, 
Germany 
Acrylamid 
Rotiphorese ® Gel 
30(37.5:1) 
Prop-2-enamid C3H5NO 71.08 Carl Roth 
® GmbH, 
Germany 
Aprotinin  C284H432N84O7
9S7 
6511.5
1 
Sigma 
Aldrich  
USA 
Ammonium Chloride 
Solution 
 NH4Cl 53.49 Stemcell 
  
Technologi
es, USA 
Ammonium 
Persulfate 
 (NH4)2S2O8 228.18 Sigma 
Aldrich  
USA 
Bromophenol Blue 2,6-dibromo-4-[3-
(3,5-dibromo-4-
hydroxyphenyl)-1,1-
dioxo-3-
benzo[c]oxathiolyl]p
henol 
 
C19H10BR4O5
S 
669.96 NEB, 
USA 
Bovine Serum 
Albumin (BSA) 
   Sigma-
Aldrich, 
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USA 
Bradford Reagent 
(BioRad Protein 
Assay reagent) 
   BioRad 
Laboratory 
GmbH, 
Munich.Ge
rmany. 
β-Mercaptoethanol 2-hydroxy-1-
ethanethiol 
C2H6SO 78.13 Sigma 
Aldrich  
USA 
Chloroform  CHCl3 119.38 Carl Roth 
® GmbH, 
Germany 
Ciprobay    Bayer 
Schering 
Pharma 
AG 
DEPC Diethylpyrocarbona
te 
C6H10O5 162.14 Invitrogen 
DMSO Dimethyl Sulfoxide C2H6OS 78.13 Carl Roth 
® GmbH, 
Germany 
DNazol    Invitrogen, 
Germany 
dNTP mix (10mM 
mix of dATP, dGTP, 
dCTP, dTTP) 
   Invitrogen, 
USA 
 
DPBS    Pan 
Biotech, 
Germany 
DTT (Dithiothreitol) 2S,3S-1,4-Bis-
sulfanylbutane-2,3-
diol 
C4H10O2S2 154.26 Invitrogen, 
USA 
ECL Plus Western 
Blotting Detection 
reagent 
   Amersham
,Germany 
EDTA 
(Ethylenediaminetetr
aacetic acid) 
2[2(bis(carboxymet
hyl)amino)ethyl(car
boxymethyl)amino]
acetic acid 
 
C10H16N2O8 292.25 Carl Roth 
® GmbH, 
Germany 
Ethanol - CH3CH2OH 46.068 Carl Roth 
® GmbH, 
Germany 
5-FU 5-Fluorouracil C4H3FN2O2  Medac 
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FBS (Fetal Bovine 
Serum) 
   Biochrome 
AG, Berli,. 
Germany 
Formaldehyde 
(37%) 
 CH2O 30.03 Carl Roth 
® GmbH, 
Germany 
Giemsa Solution    Merck 
Darmstadt, 
Germany 
Glycerol  C3H8O3 92.09 Carl Roth 
® GmbH, 
Germany 
Heparin (Heparin 
Sodium injectable 
solution) 
   B.Braun 
Melsungen 
AG 
Hydrochloric Acid  HCl 36.46 Merck, 
Darmstadt,
Germany 
Hydrogen Peroxide  H2O2 34.014
7 
Merck, 
Darmstadt,
Germany 
Isopropanol Propan-2-ol C3H8O 60.10 Merck, 
Darmstadt,
Germany 
Leupeptin Ac-Leu-Leu-Arg-H; 
N-acetyl-L-leucyl-L-
leucyl-D,L-
argininaldehyde 
 
 426.6 Sigma 
Aldrich  
USA 
May-Grünwald’s  
eosine methylene 
blue solution 
   Merck, 
Darmstadt, 
Germany 
Methanol  CH4O 32.04 Carl Roth 
® GmbH, 
Germany 
Milk powder    Carl Roth 
® GmbH, 
Germany 
Phenol/Chlorform/is
oamylalcohol(25:24:
1) 
   Invitrogen. 
Pefabloc 4-(2-Aminoethyl) 
benzenesulfonyl 
fluoride 
hydrochloride 
C8H10FNO2S 
 
203.23
5 
Sigma-
Aldrich, 
USA 
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Penicilin/Streptomyci
n 
   Pan 
Biotech, 
Germany 
 
Pepstatin 3-hydroxy-4-[2-[3-
hydroxy-6-methyl-
4-[3-methyl-2-[3-
methyl-2-(3-
methylbutanoylami
no)butanoyl]amino-
butanoyl]amino-
heptanoyl]- 
aminopropanoylami
no]-6-methyl-
heptanoic acid 
 
C34H63N5O9 
 
685.89 Sigma-
Aldrich 
USA 
Potassium Chloride  KCl 74.55 Carl Roth 
® GmbH, 
Germany 
Propidium Iodide  C27H34I2N4 668.39 Sigma-
Aldrich, 
USA 
Protamine Sulfate    Sigma-
Aldrich, 
USA 
Proteinase Inhibitor 
cocktail 
   Sigma-
Aldrich, 
USA 
Sodium Acetate  C2H3NaO2 82.03 Carl Roth 
® GmbH, 
Germany 
Sodium Chloride  NaCl 58.44 Carl Roth 
® GmbH, 
Germany 
SDS Sodium dodecyl 
sulfate 
NaC12H25SO4 288.38 Carl Roth 
® GmbH, 
Germany 
Sodium Hydroxide  NaOH 39.99 Carl Roth 
® GmbH, 
Germany 
di-Sodium Hydrogen 
Phosphate 
 Na2HPO4 141.96 Carl Roth 
® GmbH, 
Germany 
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Monosodium 
phosphate 
 NaH2PO4 119.98 Carl Roth 
® GmbH, 
Germany 
TEMED Tetramethylthylendi
amin 
C6H16N2 116.2 Sigma-
Aldrich 
USA 
Tris 2.Amino-2-
hydroxymethyl-
propane-1,3-diol 
C4H11NO3 121.14 Carl Roth 
® GmbH, 
Germany 
Trizol®    Invitrogen, 
Germany 
Trypsin EDTA    PAN 
Biotech 
Trypan Blue    Invitrogen,
Germany 
Tween 20 Polyoxyethelene(20
) sorbitan 
monolaurate 
C58H114O26 1227.5
4 
Sigma-
Aldrich 
USA 
Xylene Cyanol  C25H27N2O6S2
Na 
538.61 Carl Roth 
® GmbH, 
Germany 
 
 
2.1.2 Enzymes  
Table 2.2: List of Enzymes 
 
Name Function Unit Definition Company Assay Condition 
Benzonase Degrades all 
forms of DNA 
and RNA. Used 
to remove nucleic 
acid from protein 
samples 
Amount of enzyme 
required to digest 37µg 
of DNA completely under 
standard reaction 
condition 
Sigma-
Aldrich®, 
USA 
Mg2+ Conc:1-
2mM, pH              
8.0-9.0 
Temperature: 
37°C 
β-ME       0-
100mM 
Monovalent 
Cation 
Conc:     0-20mM 
DNase I Eliminates DNA 
from RNA 
preparations. 
One unit increases the 
absorbance of a high 
molecular weight DNA 
solution at a rate 
Invitrogen M NaAc(pH 5.0) 
5mM MgCl2 
50µg/ml calf 
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0.001A260units/min/ml of 
reaction mixture at 25°C 
thymus DNA 
Proteinase K Proteinase K is a 
non-specific, 
subtilisin-related 
serine protease 
with a very high 
specific activity. 
Used to remove 
protein from DNA 
preparation  
 
One unit is defined as 
the amount of enzyme 
required to liberate folin-
positive amino acids and 
peptides corresponding 
to 1 µmol of tyrosine in 1 
minute at 37°C in a total 
reaction volume of 250 
µl  
 
NEB 30 mM Tris HCl,  
  pH 8.0  
 
RNaseH Specifically 
degrades RNA 
strands in a DNA-
RNA hybrid 
One unit is defined as 
the amount of RNase H 
that solubilizes 1 nmol 
poly(A) in 20 minutes at 
+37°C 
Invitrogen 220 mM Tris-HCl, 
0.1 M KCl, 10mM 
MgCl2, 
0.1 mM DTT, 
5%(W/V) 
Sucrose, 0.5nmol 
3H labelled 
Poly(A)poly(dT) 
Temperature: 
37°C 
Thermoscript 
Reverse 
Transcriptase 
Synthesizes DNA 
from RNA 
template 
One unit incorporates 1 
nmol of dTTP into acid-
precipitable material in 
10 min at 37°C using 
poly(A)ïoligo(dT)25 
as template-primer . 
Invitrogen 250 mM Tris 
acetate(pH 8.4), 
 375mM potassiun 
acetate,40mM 
magnesium 
acetate  
Taq DNA 
Polymerase 
The enzyme has 
a template 
independent 
terminal 
transferase that 
adds 3' 
deoxyadenosine 
to the product 
end and has a 5'-
3' exonuclease 
activity (but no 3'-
5' exonuclease 
activity)  
One unit of Taq DNA 
polymerase incorporates 
10 nmol of 
deoxyribonucleotide into 
DNA in 30 minutes at 
74°C. 
Invitrogen  
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2.1.3 Primers and Probes 
Table 2.3 List of Primers: 
Name Sequence Purpose 
pMIG F 5'CCCTTGAACCTCCTCGTTCGACC Amplification of 
the insert in the 
MSCV vector. 
pMIG R 5' CGTCGCCGTCCAGCTCGACCA Amplification of 
the insert in the 
MSCV vector. 
C/A brkpnt F 5' GCAATCTTGGCATCGGAAAT Amplification of 
the breapoint 
region of the 
CALM/AF10 
fusion. 
C/A brkpnt R 5'GCCTGTCGACATCCATGTTT Amplification of 
the breapoint 
region of the 
CALM/AF10 
fusion. 
Vav Cre F 5' GACAGGCAGGCCTTCTCTGAA Genotyping Vav 
cre transgenic 
mice. 
Vav Cre R 5'CTTCTCCACACCAGCTGTGGA Genotyping Vav 
cre transgenic 
mice. 
Mb1 Cre F 5'ACCTCTGATGAAGTCAGGAAGAAC Genotyping Mb1 
Cre transgenic 
mice. 
Mb1 Cre R 5'GGAGATGTCCTTCACTCTGATTCT Genotyping Mb1 
Cre transgenic 
mice. 
CD19 Cre F 5'AACCAGTCAACACCCTTC Genotyping CD19 
Cre transgenic 
mice. 
CD19 Cre R  5'CCAGACTAGATACAGACCAG Genotyping CD19 
Cre transgenic 
mice 
Cre 7 5' TCAGCTACACCAGAGACG Genotyping CD19 
Cre transgenic 
mice 
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Cre-ER F 5' AATCGCCATCTTCCAGCAGG Genotyping 
Rosa26 Cre ER 
mice 
CRE-ER R 5' GATCGCTGCCAGGATATACG Genotyping 
Rosa26 Cre ER 
mice 
Beta act F 5' TGGGAATGGGTCAGAAGGAC Amplification of 
beta actin from 
cDNA 
Beta act R 5' CGGTCAGGATCTTCATGAGG Amplification of 
beta actin from 
cDNA 
ROSA CALM fu 
F 
5'CGGTTGAGGACAAACTCTTCG Detection of the 
recombination 
efficiency in 
Rosa26LSLCA 
mice 
ROSA CALM fu 
R 
5'TGCCAACTGTGGGATGTTCAC Detection of the 
recombination 
efficiency in 
Rosa26LSLCA 
mice 
 
 
Table 2.4: Primers and Probes used in Real-time PCR 
 
Name Sequence 
5’ to 3’ 
Purpose 
CA brkpnt 
Probe 
(MGB Probe) 
6-FAM-GGAGCACAGAGATGTGAA  
 
Detection of 
CALM/AF10 
fusion transcript 
along the break-
point 
RTCAFWD AAACCCCTTTGGCCCTGTA Detection of 
CALM/AF10 
fusion transcript 
along the break-
point 
RTCAREV AAGCTCCATCCTTATGGGGAC Detection of 
CALM/AF10 
fusion transcript 
along the break-
point 
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along the break-
point 
Bmi Probe 
(MGB Probe) 
6-FAM-TGTGATTCCAGGTTCA 
 
Detection of 
mouse Bmi1 
transcript 
Bmi1 FWD TGGAGACCAGCAAGTATTGTCCTA Detection of 
mouse Bmi1 
transcript 
Bmi1 REV TTATGTTCAGGAGTGGTCTGGTTTT Detection of 
mouse Bmi1 
transcript 
HoxA5 Probe 
(MGB Probe) 
6-FAM AGGCTCATGATTAAAAG Detection of 
mouse HoxA5 
transcript 
HoxA5 FWD 
 
ACAGGCGCTATAATGGCAATAAA Detection of 
mouse HoxA5 
transcript 
HoxA5 Rev 
 
CCCTGTTCTCGTTGCCCTAA Detection of 
mouse HoxA5 
transcript 
HoxA7 Probe 
(MGB Probe) 
6-FAM CCATTGGCTTCAGCC Detection of 
mouse HoxA7 
transcript 
HoxA7 FWD 
 
TGTGACTTTCCCACCCTCTGT Detection of 
mouse HoxA7 
transcript 
HoxA7 Rev 
 
CCAGAGGCCATTTCCAGAAC Detection of 
mouse HoxA7 
transcript 
HoxA9 Probe 
(MGB Probe) 
6-FAM ATCCTGCGGTTCTGG Detection of 
mouse HoxA9 
transcript 
HoxA9 FWD 
 
CGGTCCTTGTTGATTTTCTTCAT Detection of 
mouse HoxA9 
transcript 
HoxA9 Rev CGAAAGGCAGGTCAAGATCTG Detection of 
mouse HoxA9 
transcript 
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HoxA10 Probe 
(MGB Probe) 
6-FAM CAGTAGGAGCTCTCTTC Detection of 
mouse HoxA10 
transcript 
HoxA10 FWD 
 
TTGTCCGCAGCATCGTAGAG Detection of 
mouse HoxA10 
transcript 
HoxA10 Rev 
 
TCGTGTTCTTTTGCGCAGAA Detection of 
mouse HoxA10 
transcript 
Meis1 Probe 
(MGB Probe) 
6-FAM CATTGTTGGTGACTGCAG Detection of 
mouse Meis1 
transcript 
Meis1 FWD 
 
ACTGCCTGCAACAGCTGATTAA Detection of 
mouse Meis1 
transcript 
Meis1 Rev 
 
AATCGGGAAGGATGGGAAAA Detection of 
mouse Meis1 
transcript 
 
 
2.1.4 Antibodies and Cytokines 
Table  2.5 : Antibodies 
 
Name Company Dilution 
PE-Rat Anti-Mouse CD19 BD Pharmingen 1:200 
APC Hamster Anti-
MouseCD3e 
BD Pharmingen 1:200 
APC Rat Anti-Mouse CD43 BD Pharmingen  
PE-Rat Anti-Mouse 
CD45R/B220 
BD Pharmingen 1:200 
PE Rat Anti-Mouse Ly-6G 
and Ly-6C/Gr1 
BD Pharmingen 1:200 
PE Rat Anti-Mouse 
CD11b/Mac1 
BD Pharmingen 1:200 
APC Rat Anti-Mouse 
CD11b/Mac1 
BD Pharmingen 1:200 
APC Rat Anti-Mouse Ly-6G 
and Ly-6C/Gr1 
BD Pharmingen 1:200 
  
 
20 
and Ly-6C/Gr1 
PE Rat Anti-Mouse TER-119 BD Pharmingen 1:200 
APC Rat Anti-Mouse 
CD45R/B220 
BD Pharmingen 1:200 
PE Rat Anti-Mouse Ly-
6A/E/Sca1 
BD Pharmingen 1:200 
APC Rat Anti-Mouse 
CD117/c-Kit 
BD Pharmingen 1:200 
PE Rat Anti-Mouse CD4 BD Pharmingen 1:200 
APC Rat Anti-Mouse CD8a BD Pharmingen 1:200 
Mouse Anti Bmi1 Abcam 1:2000 
Mouse Anti FLAG Sigma 1:5000 
Goat Anti-Mouse-IgG-HRP Santa Cruz Biotechnology 1:3000 
F4/80 (BM8)-FITC Santa Cruz Biotechnology 1 µg per 1X106 
cells 
PE Rat anti mouse IgM BD Pharmingen 1:200 
PE Rat Anti Mouse CD24 BD Pharmingen 1:200 
FITC Rat Anti-Mouse CD23 BD Pharmingen 1:500 
CD 45R Micro-beads, Mouse  Miltenyibiotec 10 µl beads for 107 
cells 
CD43 Microbeads, Mouse  Miltenyibiotec 10 µl beads for 107 
cells 
 
 
Table 2.6: Murine Cytokines 
 
Name Company 
murine Interleukin 3 (mIL3) Tebu-bio, Offenbach, Germany 
murine Interleukin 6 (mIL6) Tebu-bio, Offenbach, Germany 
murine SCF  Tebu-bio, Offenbach, Germany 
mM CS Tebu-bio, Offenbach, Germany 
mGM-CSF (Lyophilized) Tebu-bio, Offenbach, Germany 
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2.1.5 Buffers and Solutions: 
Table: 2.7 Buffers and Solutions used in Molecular Biology 
 
Name Component 
Lysis Buffer for mouse tails: 
 
5 mM EDTA pH 8.0 
200 mM NaCl 
100 mM Tris HCl pH 8.5 
100µg/ml Proteinase K (added freshly) 
Storage: RT 
FACs Buffer: PBS 
1% FCS 
1 mg/l propidium iodide 
Storage: Light protected, at 4°C 
 
MACs Buffer: 
 
PBS pH 7.2 
0.5% BSA 
2mM EDTA 
0.09% Azide 
Storage: Light protected, at 4°C 
 
Cell Freezing Buffer: 
 
10% DMSO in FBS (V/V) 
Made freshly, can be stored at 4°C for a 
month 
 
50X TAE Buffer  
 
242 gm Tris base 
57.1 mL Acetic Acid 
100mL 0.5M EDTA 
Volume adjusted to 1 L, pH 8.5 
(Adjusted using KOH) 
Storage: at 4°C 
 
TE Buffer: 
 
10 mM Tris-HCl, pH 8.0 
1 mM EDTA, pH 8.0 
Storage: at 4°C 
 
P1 Buffer for miniprep 50 mM Tris.Cl pH 8.0 
10 mM EDTA 
100 µg/ml Rnase A 
P2 Buffer for miniprep 200 mM NaOH 
1% SDS (W/V), always prepared fresh 
P3 Buffer for miniprep 3 M potassium acetate pH 5.5 
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Table:2.8  Buffers Used in Protein Chemistry 
 
Name  Component 
Freeze- thaw Lysis Buffer (Protein 
Extraction) 
 
600 mM KCl 
20 mM Tris-Cl (pH 7.8) 
20% Glycerol 
Storage: at 4°C 
 
Added freshly: 
0.4 mg/ml Pefabloc 
10 µg/ml Leupeptin 
10 µg/mL Pepstatin 
5 µg/mL Aprotinin 
Tris-HCl 1.5 M, pH 8.8 Tris powder in d2H2O, 
adjusted pH with HCL 
 
1 M, pH 6.8 Tris powder in d2H2O, 
adjusted pH with HCL 
 
1 M, pH 8.0 Tris powder in d2H2O, 
adjusted pH with HCL 
 
1 M, pH 7.5 Tris powder in d2H2O, 
adjusted pH with HCL 
 
Storage at 4°C 
EDTA 0.5M EDTA in d2H2O, pH 8 adjusted by 
KOH 
Storage at 4°C 
 
10% SDS Sodium Dedocyl Sulfate in d2 H2 O  
(W /V) 
Storage at 4°C 
 
10%APS Ammonium persulfate in d2H2O, (W/V) 
(Aliquots stored at -20°C) 
 
2X Laemmli Sample Loading Buffer 10% β -mercaptoethanol 
6% SDS 
20% Glycerol 
0.2 mg/ml Bromophenol blue 
0.025x Laemmli stacking buffer (optional) 
Storage: RT, up to 2 months 
 
1X TBS 10 mM Tris/HCl pH 8.0 
150 mM NaCl 
Storage: RT 
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10x Tris-Glycine 
Electrophoresis Buffer 
250 mM Tris 
1.92 M Glycine 
1% SDS 
Storage: RT 
 
Gel Transfer Buffer (Western Blotting) 25 mM Tris 
192 mM Glycine 
20% Methanol 
Storage: 4°C 
 
1X TBST 1X TBS 
0.1% Tween 20 
Storage RT 
 
Blocking Solution 5% dried milk powder (W/V) in TBST 
Stripping Solution 62.5 mM Tris/HCl pH 6.8 
0.1 M β -mercaptoethanol 
2% SDS 
Storage: RT  
1.6   Culture Media 
2.1.6.1 Media for Animal Cell Culture: 
 
The following media were used under sterile conditions for culturing 
animal cells and were stored at 4°C  
Name Company 
Dulbecco's Modified Eagle Medium 
(DMEM) 
 
PAN Biotech GmbH, Germany 
Roswell Park Memorial Institute Culture 
Medium (RPMI 1640) 
PAN Biotech GmbH, Germany 
Methocult 3434 (For Colony Forming Cell 
Assay) 
Stem Cell Technologies, Vancouver, 
Canada. 
 
2.1.6.2 Media for Bacterial Culture 
LB media (Luria-Bertani Media) 
1% Tryptone 
0.5% yeast Extract 
1% NaCl 
pH 7.0 
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LB Agar 
1.5% Agar in LB media 
A ready to use powder of LB media and LB agar from Carl Roth 
GmbH was used to prepare bacterial culture media. The required 
amount of powder was dissolved in distilled water, autoclaved and 
stored at room temperature. 
2.1.7 Antibodies: 
 
Name Concentration Company 
Penicillin-
Streptomycin(100X) 
10,000 unit Pen/mL 
10 mg Strep/ mL 
PAN Biotech GmbH, 
Germany 
Kanamycin Sulphate 
(1000X) 
50mg/mL PAN Biotech GmbH, 
Germany 
 
2.1.8 Mammalian Cell Line: 
 
Name Description Source 
GP+E86 Mouse fibroblast cell line American Type Culture 
Collection (ATCC) 
NIH3T3 Contact inhibited NIH 
swiss mouse embryonic 
fibroblast cell line 
DSMZ (Deutsche 
Sammlung von 
Mikroorganismen und 
Zellkulturen GmbH) 
U937 Established from the 
pleural fusion of a 37 year 
old man with Histiocytic 
lymphoma 
DSMZ (Deutsche 
Sammlung von 
Mikroorganismen und 
Zellkulturen GmbH) 
 
2.1.9  Transgenic Mouse Lines: 
 
Mouse line Backgound 
Rosa26-Cre-ERT2 C57BL/6 
Mb1-Cre C57Bl/6 
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CD19-Cre C57Bl/6 
Vav-Cre C57Bl/6 
Wild type C57Bl/6 C57Bl/6 
Wild type FVB FVB 
IghCALM/AF10 Transgenic 
line 
FVB 
Rosa26-loxP-stop-loxP-
CALM/AF10 knock-in line 
C57Bl/6 
2.1.10 Kits and Consumable Materials 
 
Name Company 
Blotting Paper Schleicher & Schuell 
Cell strainer  40µm Nylon BD Falcon 
Cover slips Menzel Gläser 
Cryotubes Carl Roth GmbH, Karlsruhe, Germany 
Electroporation cuvettes 2 mm EquiBio, Kent, UK 
Microcentrifuge tubes Eppendorf, Hamburg, Germany 
FACS Polystrene round-bottom tubes Becton Dickinson, Meylan, France 
Freezing container (Cry0 1° C) Nalgene TM, USA 
Glassware Schott, Jena, Germany 
Hybond Nitrocellulose membrane Amersham, Freiburg, Germany 
Hypercassete™ 18x24 cm Amersham, 
Freiburg 
Amersham, Freiburg, Germany 
Hyperfilm ECL high performance Amersham, Freiburg, Germany 
LS columns Miltenyi Biotech,  Germany 
Microscope slides Menzel-Gläser® 
Morter and Pestle Sigma-Aldrich labware. 
MiniMACS Seperator Miltenyi Biotech, Germany 
Nuclease free tubes , 1.5 ml Ambion® Life technologies. 
PCR tubes,0.2ml Biozym GmbH 
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Pipette tips Carl Roth, Karlsruhe, Germany 
Plastic cuvettes for photometer Carl Roth, Karlsruhe, Germany 
Plastic ware for cell culture Sarstedt, Nümbrecht, Germany 
Plastic ware for cell culture Corning, USA 
Polypropylene conical tubes Becton Dickinson, Meylan, France 
QIAquick Gel extraction kit Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
Syringes and needles Braun, Melsungen, Germany 
Surgical instruments Medicon Instrument 
 
2.1.11 Instruments  
Name Company 
Axiophot Widefield Flourescence 
Microscope 
Carl-Zeiss, Jena, Germany 
Axiovert 135 Microscope Carl-Zeiss, Jena, Germany 
BD FACSCalibur BD Biosciences 
BioPhotometer 6131 Eppendorf Humburg Germanyc 
Centrifuge 5424 R Eppendorf Humburg Germany 
Centrifuge Rotanta 46 RC Hettich zentrifugen, Germany 
Cytospin-2-Shandon Block Scientific,Inc 
Electroporator (Easyject Prima) EquiBio Peqlab, Germany 
E-Box- gel documentation system Vilber Lourmat Deutschland GmbH 
Film developing machine  
M35X-OMAT Processor 
 
Kodak AG, Stuttgart, Germany 
Gel electrophoresis systems Bio-rad, Munich, Germany 
Incubator (For mammalian cell culture: 
CO2 
control) 
Heraeus Instruments, Langenselbold, 
Germany 
Innova™  4400 Incubator Shaker New Brunswick Scientific, Nürtingen, 
Germany 
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Mini Trans-Blot Electrophoretic Transfer 
Cell 
Bio-Rad Laboratories, Hercules, CA 
NanoDrop ND 1000 spectrophotometer Thermo scientific, Delaware, USA 
TaqMan 7900HT- Real-Time PCR 
system 
Applied Biosystems/ Life Technologies 
Thermocycler: Cyclone 25 PeQlab, Erlangen, Germany 
Thermomixer Compact Eppendorf, Hamburg, Germany 
Vortex T Ginie 2 Scientific Industries,Inc 
 
2.1.11 Software 
 
Name Company Usage 
MS office Microsoft Corporation, 
USA 
For text editing, data 
analysis 
Sigma Plot Systat Software Inc For generating graphs and 
data analysis 
SDS 2.3 Applied Biosystems For analysis of real-time 
PCR data 
Macvector™12.0 Oxford Molecular Group Sequence annotation, 
restriction site mapping. 
Primer Express Ver 3 Applied Biosystems Designing primers and 
probes for real-time PCR 
Endnote X4 Thomson Reuters Bibliography management 
WinMDI 2.9  Flow cytometry data 
analysis 
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2.2 Methods 
2.2.1 Methods related to animal cell culture 
2.2.1.1 Cultivation of mammalian cells 
All the mammalian cell lines used in the study were cultivated in 
incubators at 37°C in the presence of 95% relative air humidity and 
5% CO2. All the cell culture media used in the study were 
supplemented with 10% Fetal Calf Serum (FCS) and penicillin-
streptomycin (final concentration: penicillin: 100 U/ml and 
streptomycin: 100 µg/ml). 
2.2.1.2 Cultivation of adherent cells 
All the adherent cell lines were grown in complete Dulbecco’s 
Minimum Essential medium (DMEM) under above mentioned 
conditions. For harvesting, the confluent cultures were washed once 
with pre-warmed (37°C) phosphate buffered saline (PBS) and 
treated with trypsin-EDTA at 37°C for 3-5 minutes for the 
detachment of the cells from the surface of the culture flask and 
separation of the cells from each other. Adding complete DMEM 
stopped the activity of the trypsin and the cell suspension was 
either used for subculturing or for the preparation of frozen stocks. 
The cell lines were propagated and maintained by dividing the 
confluent cultures at a ratio of 1:3, 1:5 or 1:10 every 3-5 days 
depending on the growth characteristics of the cell lines. 
2.2.1.3 Freezing and thawing of the cells 
Mammalian cells can remain viable for years if they are stored 
properly in liquid nitrogen. After re-dissolving the cell pellet in FBS 
containing 10% vol DMSO, 1X107 cells were frozen in 1.5 ml 
cryotubes. DMSO serves as a cryoprotective agent and is used to 
minimize the cellular injury induced by the freezing and thawing 
procedures. The cryotubes were then placed in a cryo freezing 
container inside a -80° C freezer to gently freeze cells at a cooling 
rate of about 1° C/min. While short-term preservation of cell lines 
at -80°C is possible, storage in liquid nitrogen (-196°C) or its vapor 
(-120°C) is preferred for longer preservation of cell viability. 
For optimal recovery and viability of the cells, rapid thawing is 
essential. 
Therefore, the cells were thawed quickly in a 37°C water bath and, 
as DMSO in the freezing medium is toxic to the cells, the cells were 
subsequently washed with 10-20 ml of DPBS or culture medium and 
centrifugation at 1000 rpm (~300 x g) for 5 min. The supernatant 
was discarded and the pellet resuspended in fresh culture medium. 
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All the thawed cell lines were cultured for 3 days before being used. 
2.2.1.4 Determination of cell viability: Trypan Blue exclusion method 
Determination of the number of viable cells is an essential step in 
cell culture before seeding the cells for culturing further or for 
simply determining the cell number. Trypan Blue is the most 
commonly used dye to determine cell viability. The dye is mixed 
with the cells, as essential characteristic, viable cells actively 
exclude the dye but dead cells stain with the dye. When seen under 
microscope, dead cells appear blue. On the basis of this staining, 
living cells can be separated and the number of viable cells can be 
determined. 
For the determination of the number of viable cells, the cell 
suspension was diluted with trypan blue at a ratio of 1:2 to 1:5 (cell 
suspension: trypan blue) and the numbers of viable (unstained) 
cells in a 4 x 1 mm2 area were counted with the help of a Neubauer 
haemocytometer under a phase contrast microscope. The total 
number of viable cells per ml of the cell suspension (non-diluted) 
was calculated using the following formula: 
           
2.2.1.5 Preparation of high titre virus producing stable cell line: 
To transduce murine bone marrow cells with retrovirus, high titre 
virus producing cell lines are required. E86 is a mouse fibroblast cell 
line, which was genetically engineered for stable retrovirus 
production. MSCV 2.1 (Murine Stem Cell virus) is a vector, which 
allows delivery and stable expression of the gene of interest along 
with a flourescent protein into dividing cells. The gene of interest is 
cloned into the Multiple Cloning Site (MCS), which is located 
upstream of the Internal Ribosome Entry Site (IRES). An enhanced 
Yellow Fluorescent Protein (YFP) (MSCV 2.1 with YFP: pMIY) or 
Green fluorescent Protein (GFP) (MSCV 2.1 with GFP: pMIG) gene is 
present downstream of the IRES so that the gene of interest and 
YFP or GFP will  be co-expressed (Fig 2.1). The viral LTR promoter 
drives the expression of the gene of interest and the fluorescent 
marker gene. The vector is transfected into the E86 cells to obtain 
stably virus producing cell lines. 
   
Figure 2.1: A map of the pMIY vector 
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The E86-BMI1-FLAG-YFP (B lymphoma Mo-MLV insertion region 1 
homolog) cell line was kindly provided by Dr Keith Humphries (Terry 
Fox Laboratory, British Columbia Cancer Agency, Vancouver, British 
Columbia, Canada). The E86 cell line contains a MSCV vector in 
which the human BMI1 cDNA is cloned in the MCS along with a C 
terminal FLAG tag (Fig 2.2). A frozen vial with cells was thawed and 
expanded for two days in a 10 cm dish. After the cells started 
growing healthily, Yellow Flourescence marker (YFP) positive cells 
were sorted using Fluorescence Activated Cell Sorting (FACs). After 
three rounds of sorting, a 99% YFP positive cell line was 
established, which was used to transduce murine bone marrow 
cells. 
 
 
Figure 2.2: A map of pMIY vector with BMI1.  
 
Determining the viral titre of the producer cell line 
To determine the viral titre produced by the packaging cell line 
(E86), we employd the following method: 
1x105 NIH-3T3 cells were plated in each well of a 12 well adherent 
cell plate in three replicates and cultured for 24 hours. After 24 
hours, Virus Containing Medium (VCM) was collected from a 70-
80% confluent plate of virus producing E86 cell line.  500 µl VCM + 
20 µl Protamin Sulfate (PS) were mixed in an Eppendorf tube and in 
another tube, 50 µl VCM and 450 µl DMEM medium were mixed with 
20 µl PS. The medium from the NIH-3T3 cells was removed and 
VCM in different dilutions was carefully overlaid on the NIH-3T3 
cells and incubated for 4-5 hrs at 37 °C. Cells in the third well were 
allowed to grow as untransduced controls. After 4-5 hours, 3 mL 
DMEM supplemented with 10% FBS were added to each well and 
incubated for 48 hours at 37 °C. After 48 hours, the NIH-3T3 cells 
were harvested and GFP or YFP positivity was analyzed using flow 
cytometry. Using the following formula, the viral titre can be 
calculated in transducing unit per ml (TU/ml): 
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2.2.1.6 Syngeneic bone marrow transplantation in mice 
To investigate the effect of a gene of interest in the hematopoietic 
system, a murine syngeneic bone marrow transplantation model 
can be used.  In this model system, bone marrow cells from donor 
mice are extracted and manipulated to introduce the gene of 
interest and then transplanted into sub-lethally irradiated recipient 
syngeneic mice.  To analyse the effect of BMI1 over-expression in 
Igh-E/P-CALM/AF10 transgenic FVB mice, a retroviral bone marrow 
transplantation model was used. The experimental strategy and 
plan are shown in Figure 2.3. 
 
 
Figure 2.3: A flow chart of the retroviral bone marrow transplantation method. 
  
5FU injection of the donor mice 
To kill the cycling cells and subsequently to enrich the 
hematopoietic progenitor population in the bone marrow, donor 
mice were injected with 5-flourouracil (5FU). The dose of 5FU varies 
for different mouse strains. For the FVB strain, 90 mg 5FU per kg 
was administered via tail vein injection. 8-12 week-old animals 
were used as donors. 
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Preparation of murine bone marrow cells 
Four days after the 5FU injections, the donor mice were sacrificed, 
and their femur, tibia and the pelvic bones were dissected with 
sterile surgical scissors and forceps. The muscles and tissues were 
carefully removed as much as possible with a sterile scalpel without 
breaking the bones at the joints. The bones were then crushed with 
the help of a mortar and pestle in 3% FBS supplemented PBS 
(sterile). While crushing, the bones break and the bone marrow 
cells are released into the PBS. The marrow cell containing PBS-FBS 
suspension was then carefully collected with pipettes and filtered 
through 45 µm sterile Millipore filters. The bone marrow cells will 
pass through the filter but some tissue debris will be retained. The 
crushed bones were repeatedly washed with PBS-FBS until the 
effluent PBS becomes colorless to ensure collection of as many bone 
marrow cells as possible. The harvested bone marrow cells were 
pelleted at 1070 RPM for 10 mins at 4°C. The pellet was carefully 
resuspended in ammonium chloride (NH4Cl) and incubated for 10 
mins on ice to lyse the RBC. After 10 mins, the cells were 
centrifuged at 1070 RPM for 10 mins at 4°C again. The pellet was 
washed with PBS to remove remaining NH4Cl and finally the bone 
marrow cells were cultured in DMEM media supplemented with 15% 
FBS and cytokines (10 ng/mL mIL-6, 6 ng/ml mIL-3 and 100 ng/mL 
murine stem cell factor).  
Irradiation of E86 viral producer cell lines: 
E86 cells carrying the gene of interest were harvested from ≈80% 
confluent plates in 15% DMEM media (10 ml final volume from one 
confluent plate). If a double transduction was planned then the two 
E86 producer cell lines were mixed according to their retroviral titre. 
Then the cells were ready for irradiation. 10 ml of each sample was 
taken in a 15 ml Falcon tube and the caps were sealed with parafilm 
(optional). The cells were irradiated with 40 Gy. Irradiated cells 
were plated in new plates for adherent cells 
Retroviral transduction of bone marrow cells 
On day 6, two days after the bone marrow extraction, the bone 
marrow cells were retrovirally transduced by co-culturing with the 
virus producing E86 cell line carrying the gene of interest. This was 
done as follows: 
The bone marrow cells were harvested and transferred to a Falcon 
tube. Before transfer, cells were filtered again using a 45 µm filter 
to remove clumps. Adherent cells were collected with a scraper. 
Bone marrow cells were centrifuged at 1070 RPM at 4°C for 10 
mins. The pellet was resuspended in 15% FBS DMEM media. Then 
  
 
33 
the volume was adjusted so that for each plate to be transduced 10 
ml of media would be available. Cytokine and protamine sulfate 
(PS) was added accordingly. The cells were suspended in media 
with cytokine and PS. Irradiated plates of E86 cells were handled 
carefully and kept in the incubator as long as possible. (The cells 
tend to dislodge from the monolayer at this step). The medium was 
carefully removed from the E86 cells, and the bone marrow cells 
were overlaid on the E86 cells without disturbing the E86 cell layer. 
Then the plates were incubated at 37°C for 25 to 36 hours. After 
this incubation, the bone marrow cells were carefully removed from 
the E86 cells, washed and replated with fresh media supplemented 
with cytokines. 
 
Transplantation  
Four days after the transduction (the 10th day after 5FU injection), 
successfully transduced bone marrow cells were sorted for YFP 
positivity. Non-transduced cells were also collected to aid 
hematopoietic reconstitution of the recipient mice.  
Recipient mice were from the same inbred strain (syngeneic) as the 
donor (in our experiment the FVB strain) and 8-12 weeks old. 
Before the transplantation, recipients were lethally irradiated (Cs137 
gamma radiation). The dosage of the irradiation depended on the 
mouse strain. FVB mice were irradiated with 800 cGy.  After 
irradiation, each recipient received 0.5 million transduced and 0.5 
million non-transduced bone marrow cells via tail vein injection. 
Transplanted animals were kept in Individually Ventilated Cages 
(IVC) for four weeks after transplant. Their drinking water was 
supplemented with ciprofloxacin and acetic acid to prevent 
infection. 
Follow-Up 
Following transplantation, mice were regularly examined and closely 
monitored for any signs of leukemia or other diseases. The 
engraftment of the bone marrow was assessed in blood collected 
from the tail veins. We also performed WBC and RBC counts.  
When high WBC counts accompanied by ruffled fur, fatigue, heavy 
breathing and lethargy were observed, the animals were sacrificed, 
since these symptoms were usually followed by the rapid demise of 
the animals. Peripheral blood, spleen and bones from the pelvis and 
legs were collected and the rest of the body was fixed in buffered 
formalin. The cells from peripheral blood, spleen and bone marrow 
were analyzed with FACS. Smears and cytospins of the cells were 
also prepared and stained with Giemsa-May-Grünwald for 
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morphology studies. Formalin-fixed organs were processed for 
histology and immunohistochemistry (for details see “Post mortem 
analysis” in the next paragraph). 
2.2.1.7 Post mortem analysis of mice 
Collection of the peripheral blood and its processing 
After the mouse was sacrificed by CO2 asphyxiation, it was sterilized 
with 70% ethyl alcohol and the body was dissected with sterile 
forceps and scissors. The thoracic cage was opened, and blood from 
the heart was carefully collected with a sterile needle and a heparin-
coated syringe.  
After the collection of the peripheral blood, the following procedures 
were performed: 
Blood smear preparation: 
2-3 µl freshly collected peripheral blood was placed on a glass slide 
and spread across the glass slide with the help of another clean 
slide. 
Determination of WBC count: 
2 µl blood was mixed with 48 µl NH4Cl and incubated on ice for 10 
mins. WBCs were counted using a hemocytometer. Depending on 
the number of cells, additional dilutions were made with trypan 
blue. 
The final formula to determine the number of WBC in the peripheral 
blood/mL is 
(Number of total living cells counted in all 4 squares of the 
Neubauer chamber)/4 X 25 X dilution (if any) X 104 = WBCs per mL 
 
Determination of RBC count: 
1 µl of blood was mixed in 10 mL PBS and the RBCs were counted 
using a Neubauer hemocytometer. The number of RBCs in the 
peripheral blood/mL was calculated with the following formula: 
(Number of total cells counted in 4 squares of the Neubauer 
chamber)/4 X dilution (if any) X 108 = RBCs per mL 
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Preparing peripheral blood mononuclear cells (PBMC): 
Total blood was treated with NH4Cl to lyse the RBCs on ice for 20 
mins. After 20 mins the cells were spun down and was washed with 
PBS to obtain the PBMCs. 
Preparation of splenocytes: 
The spleen was dissected from the sacrificed mouse and preserved 
in PBS with 3% FBS. The size and weight of the spleen was 
documented. A small part of the organ was transferred to buffered 
formalin for histology. 
The rest of the spleen was crushed in PBS using a plunger from a 
sterile syringe and passed through 0.45 µm filter. A single cell 
suspension was obtained by gently pipetting up and down. The cells 
were centrifuged at 1070 RPM, 4°C for 10 min. The pellet was 
treated with NH4Cl for 10 mins on ice followed by a wash with PBS. 
Flowcytometric analysis of the murine cells 
To analyze the surface markers on the cells from different organs of 
the animal, flow cytometry was used. 
After sacrificing the animals single cell suspensions from peripheral 
blood and different organs were prepared. The cells were 
immunostained with different murine antibodies. For each staining, 
1X106 cells were used. Antibodies in specific dilutions were added to 
the cells suspended in PBS and incubated on ice for 20 min. The 
cells were washed and resuspended in FACs buffer and analyzed 
using FACS Calibur. 
Cytospin preparation 
For studying the morphology of the cells in peripheral blood and in 
different hematopoietic organs, the cells were permanently fixed on 
glass slides using a cytospin centrifuge and stained with Giemsa and 
May-Grünwald. 
The cell suspensions were prepared (PB cell, slides were air-dried. 
May-Grünwald staining: 
Blood smear and the cytospin slides were arranged in racks and 
immersed in fresh May-Grünwald solution (undiluted) for 3 mins, 
followed by a 5 min rinse in distilled water. Then the slides were 
immersed in 1:50 diluted Giemsa stain for 1 hour, followed by 
another 5 min wash by immersing the slide rack in distilled water. 
Finally, the stained slides were air dried overnight and then 
examined under the microscope. 
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2.2.1.8 Colony Forming Cell (CFC) assay 
 CFC assays were performed to evaluate the clonogenic potential of 
the hematopoietic progenitors. For this assay, transduced bone 
marrow or bone marrow cells from sacrificed animals were cultured 
in a semi solid agar called MethCult. For our experiments, 
MethoCult 3434 was used, which is supplemented with cytokines 
supporting the growth of myeloid progenitors. For this procedure 
the following protocol given by Stem Cell Technologies was used:  
A MethCult 3434 bottle was thawed and the medium was dispensed 
in 3 mL aliquots and stored at -20°C. 500 bone marrow cells were 
suspended in 300 µl of DMEM media. The 3 mL aliquot of MethoCult 
was thawed at room temperature and the 300 µl cell suspension 
was added to it and vortexed thoroughly. Then the aliquot was set 
aside so that the bubbles could escape. 35 mm diameter culture 
dishes were labeled appropriately. Each experiment was performed 
at least in duplicate. 
After 10-20 mins the bubbles had dissipated, and the MethoCult 
was taken up with a 16 gauge blunt end needle attached to a 3 mL 
sterile syringe. 
To expel most of the air from the syringe, approximately 1 mL 
medium was drawn into the syringe. Then by gently depressing the 
plunger the medium was expelled completely. This process was 
repeated until no air space was visible in the syringe anymore. 
Finally, after removing all air bubbles, the MethoCult medium with 
the cell was taken into the syringe and 1.1 mL were dispensed per 
35 mm plate. The culture dishes for the CFC assays had been tested 
for minimal cell adherence. Adherence of cells during the CFC assay 
can cause inhibition of colony growth and obscure visualization of 
colonies. By gently tilting and rotating each plate, the 
methylcellulose medium was evenly distributed. Two 35 mm plates 
were placed into a 100 mm petri dish. A third, open 35 mm plate 
containing 3 mL of sterile water was also placed in the bigger Petri 
dish. The use of a 100 mm petri dish and an open 35 mm plate with 
water helps to maintain humidity and minimizes contamination 
during culture and handling. 
The Petri dishes with the three smaller plates were placed in an 
incubator maintained at 37°C, 5% CO2 and ≥ 95% humidity. After 
7-10 days, the plates were analysed for colony growth. When 
colonies appeared, they were counted and from the morphology of 
the cells the origin of the colonies was determined. After the 
colonies were counted, the plates were ready for re-plating. The 
cells were collected by dissolving the methylcellulose in warm PBS 
and were then used for replating and flow cytometry analysis. 
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2.2.1.9 B cell harvesting from mouse spleens using magnetic 
cell separation  
To isolate B cells from mouse spleen, a magnetic cell separation 
technique was used. Magnetically labeled B220 antibody-beads 
were used for a positive selection of B cells and magnetically 
labeled CD43 beads were used for negative selection of B cells from 
spleen. We followed the protocol from Miltenyi Biotec, the suppliers 
of the magnetic bead separation kits. The procedure was performed 
as follows: 
A single cell suspension was made from the spleen in PBS or MACs 
buffer. 
Cells were counted. For 107 cells, 10 µl magnetically labeled 
antibody beads and 90µl MACs buffer was used. After counting, the 
cells were pelleted. The supernatant was discarded and equal 
amount of beads were added directly to the pellet. After 20 mins of 
incbation at 4°C, the tubes were filled with 10 ml of MACs buffer. 
The tubes were centrifuged, and the pellet was resuspended in 500 
µl MACs buffer. The LS columns were placed in the MACS separator 
and washed once with 3 ml of MACs buffer. The matrix of the LS 
Columns is composed of ferromagnetic spheres, which are covered 
with a cell-friendly coating allowing fast and gentle separation of 
cells. When placed in the magnetic field of a MACS® Separator, the 
spheres amplify the magnetic field by 10,000-fold, thus inducing a 
high magnetic field gradient within the column. This is crucial for 
isolation of cells which are only minimally labeled with 
MACS® MicroBeads, leaving enough epitopes free for concurrent 
antibody staining. The space between the spheres is several times 
larger than primary and most cultured cells. This allows the cells to 
freely flow through the column. Magnetically labeled cells are held 
in suspension within the column and do not actually “bind” the 
column matrix. This suspension minimizes stress on the cells and 
allows for efficient sterile washing by avoiding cell aggregation. LS 
Columns can be used to separate material less than 30 µm in size. 
The collection tubes were placed on ice underneath the column. 
The cells (500µl) were loaded to the column. The column was 
washed 3 times with 3ml PBS/Ba. The flow through contained 
unlabelled cells (CD43 negative cells, resting B cells) 
To collect the labelled cells, which adhered to the column, the 
column was removed from the separator, placed on the collection 
tube and filled with 5 ml MACs buffer. Then quickly flushed with a 
pestle. The eluent contained the positive fraction (B220 positive B 
cells). 
Cells were counted in a 1 in 10 dilution. 
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2.2.2. Microbiology Methods 
2.2.2.1 Culturing bacteria 
For routine bacterial cultures, frozen cells from glycerol stocks were 
streaked out on LB-agar plates containing appropriate antibiotics 
and incubated O/N (over-night) at 37°C to obtain single colonies. A 
single colony was then inoculated in the desired volume of LB 
medium containing the appropriate antibiotic and incubated O/N at 
37°C in a shaking incubator at 190 rpm. To prepare competent 
bacterial cells, LB agar and medium without antibiotics were used. 
2.2.2.2 Preparation of bacterial stocks 
850 µl of an overnight bacterial culture was mixed with 150 µl of 
glycerol and stored at -20°C or at -80°C for long-term storage 
2.2.2.3 Preparation of electrocompetent cells: 
Electrocompetent cells are specially prepared bacterial cells, which 
can take up naked extracellular DNA upon electropermeabilization 
of the cellular membrane by an externally applied electrical field. 
This process of delivering DNA into the bacterial cells is called 
electroporation. For making bacterial cells competent for 
electropration (electrocompetent), bacterial cells are washed 
several times in water to remove salt from the cell solutions. This 
leads to a high resistance and very low conductivity of the bacterial 
cell suspension, which is required for the electroporation to be 
successful. 
For making electrocompetent cells a single bacterial colony was 
inoculated in 10 ml LB medium and grown overnight at 37°C. On 
the next day, the overnight pre-culture was inoculated into 400 ml 
of fresh LB and grown till an OD600 of 0.5-0.6 was reached (around 
2 hrs). The culture was cooled on ice, and the cells were pelleted in 
a cooling centrifuge at 4500 RPM for 5 mins. The cell pellet was 
washed twice using 40 ml ice-cold water. Cells were washed several 
times using 20 ml 10% glycerol (cold). The pellet was finally 
resuspended in 800 µl 10% glycerol and 50 µl aliquots were stored 
in microcentrifuge tubes at -80°C. 
2.2.2.4 Transformation/ Electroporation 
Electrocompetent cells were thawed on ice. 1-5 µl plasmid DNA 
(0.1-2 ng) was mixed with the competent cells. The mix was 
incubated exactly for 1 min on ice. Then it was transferred to a pre-
cooled cuvette. The cuvette was placed in an electroporation device 
and electroporation was performed at 2500 V. One ml LB was added 
to the cuvette and mixed gently by pipetting up and down. The mix 
was transferred to a new microfuge tube, incubated for 1 hour at 
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37°C shaking at 210 rpm. Finally, the cells were spun down at 3100 
rpm at room temperature. Almost all the medium, except for 70 µl 
was removed and discarded. The cell pellet was resuspended in the 
remaining 70 µl of supernatant. Cells were spread on LB agar plates 
with or without antibiotics. Each transformation reaction was plated 
on two plates, 10 µl on one plate and 60µl on a second plate. This 
allowed us to pick single colony of transformed bacteria in case of 
very efficient transformation. Both plates were incubated overnight 
at 37°C.  
2.2.3 Methods in molecular biology 
2.2.3.1. Isolation of Plasmid DNA (Mini prep) 
Approximately 1.5 ml of a bacterial overnight culture was 
centrifuged at 11,000 rpm for approximately 1 minute. The 
supernatant was discarded and the pellet was resuspended in 300 
µl Buffer P1. 300 µl freshly prepared P2 was immediately added and 
the mix was left at room temperature for 5 minutes. Following the 
5-minute incubation, 300 µl P3 was added and the sample was 
centrifuged at 14,000 rpm for 10 minutes. 900 µl of the 
supernatant was taken and transferred to a fresh tube. Plasmid 
DNA was precipitated by adding 0.7 volume of isopropanol. Tubes 
were kept at -20°C for 10 minutes and were later centrifuged for 30 
minutes at 4°C. The supernatant was discarded and the pellet was 
washed with 70% ethanol by centrifuging at 14,000 rpm for 15 
minutes. The supernatant was discarded and the pellet was dried at 
room temperature for 10 minutes. The pellet was resuspended in 20 
µl of 1x TE buffer and kept at -20°C for future use. 
2.2.3.2 Isolation of genomic DNA from mouse tails 
This protocol was adopted from Laird (Laird, 1991). The tail DNA 
from mice was extracted for genotyping. Small pieces of tail tips 
were clipped from 5-8 week old mice and the following protocol was 
used to extract the DNA. 
Lysis: Tail pieces were immersed in lysis buffer containing 
proteinase K (0.5 ml) and shaken overnight in a thermo-mixer at 
55°C. 
Precipitation: The next day, the tubes containing the digested 
samples were centrifuged at room temperature for 10 mins at 
14000 RPM. The supernatant containing the DNA was transferred to 
fresh tubes avoiding the cellular debris. One volume of ispropanol 
was added to the lysate and the tubes were vortexed until the 
precipitation was complete. 
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Recovery of the DNA: After the precipitation was complete the 
tubes were centrifuged for 10 min at 14,000 RPM. The pellet 
containing the DNA was washed using 70% ethanol, air dried and 
finally dissolved in 30-100 µl of TE buffer depending on the size of 
the pellet. 
2.2.3.3 DNA extraction from mouse tissue using DNAzol 
For the extraction of DNA from mouse tissues (peripheral blood, 
bone marrow spleen, kidney etc), we used the DNAzol reagent from 
Life Technologies according to the manufacturer’s protocol. 
1 mL DNAzol can be used to isolate DNA from 25-50 mg of tissue, 
0.1mL whole blood or 1-3x107 cells. A single cell suspension of the 
cells from the tissue was prepared using the homogenizer and the 
cell number was determined. According to the cell numbers, DNAzol 
was added to the cell pellet and by gently pipetting up and down, 
the cells were lysed homogeneously. To precipitate DNA from the 
homogenate, 100% ethanol was added, 100 µl for every 1 mL of 
DNazol. Inverting the tubes a couple of times mixed samples. The 
tubes were incubated for 3 mins at room temperature until a visible 
precipitate had formed. The DNA precipitate was taken up with a 
pipette tip and attached to the side of the tube, the supernatant 
was carefully decanted. The DNA was washed with cold 70% 
ethanol two to three times and air-dried briefly. The pellet was 
finally dissolved in 8 mM NaOH 
2.2.3.4 Extraction of RNA from animal cells/tissue using TRIzol®  
First, a single cell suspension was prepared from the mouse tissue. 
To isolate total RNA from these cells, the following method was 
used, which is adapted from the protocol provided with the TRIzol 
reagent. 
The cells were lysed in TRIzol® Reagent by repetitive pipetting. 1 
ml of TRIzol® reagent was used for 5-10 x106 of cells. Washing the 
cells before addition of TRIzol® was avoided as this increases the 
likelihood of mRNA degradation. Insoluble material was removed 
from the homogenate by centrifugation at 12,000 g for 10 minutes 
at 2-8°C. The resulting pellet contains cell membranes, 
polysaccharides, and high molecular weight DNA, while the 
supernatant contains RNA. The clear supernatant was transferred to 
a fresh tube. The homogenized samples were incubated for 5 
minutes at 15 to 30°C to permit the complete dissociation of 
nucleoprotein complexes. 0.2 ml chloroform per 1 ml of TRIzol® 
reagent was added. The tubes were shaken vigorously by hand for 
15 seconds and incubated at 15 to 30°C for 2 to 3 minutes. The 
samples were centrifuged at no more than 12,000 g for 15 minutes 
at 2-8°C. After the centrifugation, the mixture separates into a 
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lower red, phenol-chloroform phase, an interphase, and a colorless 
upper aqueous phase. RNA remains exclusively in the aqueous 
phase. The volume of the aqueous phase is about 60% of the 
volume of TRIzol® reagent used for homogenization. RNA was 
precipitated from the aqueous phase by mixing with 0.5 mL 
isopropanol per 1 mL of TRIzol®. Samples were incubated for 10 
minutes at 15-30°C and then centrifuged at 12,000 RPM for 10 
minutes at 2-8°C. The RNA forms a gel like pellet. The supernatant 
was discarded. Pellets were washed with 75% ethanol, 1mL for 
every 1ml of TRIZOL. Samples were mixed by vortexing and then 
centrifuged at 7500g for 10 minutes at 2-8°C. The supernatant was 
removed, and pellets were air-dried. Finally, the pellet was 
dissolved in DEPC water by pipetting up and down and incubating 
the sample at 60 °C for 10 minutes. 
2.2.3.5 Isolation of RNA using the RNeasy Mini Kit 
RNA from the fresh mouse organs was extracted using the RNeasy 
Mini kit. The kit was also used for additional purification of some 
already extracted RNA sample. The following protocol was adapted 
from the RNeasy Mini handbook provided by Qiagen. 
A single cell suspension was prepared from the organs. To 1 ml RTL 
buffer 10 µl β-mercaptoethanol were added. For 0.5-1 x 107 cells, 
600 µl RTL buffer was used. Cells were lysed in RTL buffer by 
pipetting up and down several times. If adherent cells grown in 
monolayer were used, they were directly lysed on the plate. 1 
volume of 70% ethanol was added to the cell lysate, mixed 
thoroughly, and then the lysate was transferred to the RNeasy spin 
column along with the precipitate if formed. Up to 700 µl can be 
transferred to the spin column at one time. Then the columns were 
centrifuged ≥ 8000 rpm for 15-30 sec. The flow-through was 
collected in the 2 mL collection tubes supplied with the columns. 
The RNA bound to the membrane in the column. The columns were 
then washed with wash buffer RW1. The flow through was 
discarded. 500 µl RPE buffer was added to the columns and columns 
were centrifuged at ≥ 8000 RPM for 15-30 sec. The RPE buffer 
concentrate, which comes with the kit, was dissolved in ethanol 
before the process was started. The wash step with RPE was 
repeated twice. Finally the RNA was eluted with 30-50 µl nuclease 
free water. 
2.2.3.6 Agarose gel electrophoresis: 
Electrophoresis was used to separate DNA/RNA molecules on the 
basis of their mobility through a gel matrix in an electric field. The 
mobility depends on the molecular weight of the DNA or RNA 
molecules and their secondary structure. Non-denaturing gel 
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electrophoresis was used for DNA/RNA separation and for both the 
analysis and isolation of DNA fragments. The agarose concentration 
of the gels was determined according to the desired range of 
separation of linear DNA according to the following table: 
 
For RNA samples, 2% agarose gels were used. 
The gel was prepared by dissolving agarose powder in warm 0.5X 
TAE with 1X SYBR Safe (Invitrogen). The gel was poured onto a 
horizontal gel tray. After the gel was completely cool, it was 
transferred into appropriate gel-running chambers. The DNA 
samples were loaded in the gel pockets with loading dye added to 
1x final concentration. By applying an electric field of approximately 
700 V/m, the DNA fragments were separated. Under these 
conditions, the negatively charged DNA molecules migrate through 
the gel matrix to the anode at speeds inversely proportional to the 
length of the individual DNA fragments. The gels would typically be 
run for 1 to 2 hours. 
2.2.3.7 Gel Purification of DNA fragments: 
This protocol is adapted from Qiagen® gel extraction kit QIAquick. 
It is designed to extract and purify DNA fragments from agarose 
gels in TAE or TBE buffer. 
The DNA fragment was excised with a clean and sharp scalpel from 
the agarose gel. The gel slice was weighed, 3 volumes of buffer QG 
were added to 1 volume of the gel (100 mg corresponds to 100 µl). 
For gels with more than 2% agarose content, 6 volumes of QG 
buffer were added. The mix was incubated at 50°C for 10 minutes 
(or till the gel slice was dissolved completely). Then 1 volume of 
isopropanol was added to the samples. The whole mixture was 
transferred to a QIAquick spin column, which was placed on the 2 
ml collection tube. Spin columns were centrifuged for 1 minute and 
the flow-through was discarded. The columns were again washed 
with 0.5 ml of QG buffer. 0.75 ml Buffer PE was added to the 
columns to wash, centrifuged for 1 minute and the flow-through 
was discarded. The spin columns were spun for an additional 2 
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minutes to remove the remaining Buffer PE. QIAquick columns were 
placed on clean microcentrifuge tube. The DNA was eluted using 50 
µl Buffer EB (10 mM Tris.Cl, pH 8.5). Buffer EB was added at the 
centre of the QIAquick membrane, incubated for 4 min and finally 
the column was centrifuged for 1 min at top speed to collect the 
DNA. 
2.2.3.8 Estimation of the DNA or RNA concentration 
DNA and RNA concentrations were determined using a Nanodrop 
spectrophotometer. 1.5 µl samples were used for each 
measurement. The purity of the samples was determined by 
OD260/OD280 ratio. SYBR Safe stained agarose gels were also used 
for the estimation of DNA concentration by comparing the strength 
of the DNA band to be assessed with standard DNA markers. 
2.2.3.9 Digestion of DNA with restriction enzymes 
Restriction enzymes are site-specific endonucleases purified from 
different bacteria. These enzymes can recognize specific sequences 
in double stranded DNA and hydrolyze the phosphodiester bond. 
These enzymes are frequently used in molecular biology to cut DNA 
at specific locations. These enzymes are active only at certain salt 
concentration, which vary from enzyme to enzyme. The correct salt 
concentrations are supplied with specific buffers that are provided 
with the enzymes. A specific amount of DNA (genomic or plasmid, 
usually between 100 and 1000 ng) was incubated with required 
quantity of enzyme and specific buffer at the optimal temperature. 
Multiple enzymes can also be used at the same time using the 
correct buffers. 
A typical restriction digestion reaction is presented below. The 
ingredients reagents are mixed in the following order for a 20 µl 
reaction. 
Component Volume 
Nuclease free water 16 µl 
10X buffer (recommended) 2 µl 
DNA 1 µl (∼1 µg) 
Restriction enzyme 1 µl (5-10U) 
 
2.2.3.10 Polymerase Chain Reaction (PCR): 
The PCR technique is used to amplify DNA fragments of interest in 
an exponential fashion. The amplification is achieved using synthetic 
oligonucleotides called primers that flank the sequence to be 
amplified. These primers, under appropriate conditions, anneal to 
the denatured target sequence and, in the presence of a heat stable 
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DNA polymerase enzyme and dNTPs, the synthesis of a 
complementary strand of the target sequence takes place. As 
template 1 µl cDNA (about 10 to 200 ng), 1 µl genomic DNA (0.1 to 
1 µg) or 0.5 ng plasmid DNA was used. The PCR reactions were 
prepared as follows: 
 
Reagents Amount 
(for one 25 µl 
reaction) 
10X PCR Buffer 2.5 µl 
50 mM MgCl2 0.75 µl 
10 mM dNTP mix 0.5 µl 
100 pmol/µl Primer F 0.5 µl 
100 pmol/µl Primer R 0.5 µl 
Taq Polymerase 0.2 µl 
DNA (0.5ng/µl-
1µg/µl) 
1-5 µl 
Water to a total of  25 µl 
 
The total reaction volume was adjusted depending on the specific 
requirements. 
The reaction was cycled through a specific temperature profile; a 
standard PCR program is given below  
 
Steps Temperature Time No of Cycles 
Initial 
denaturation 
95°C 5-10 min 1 
Subsequent 
denaturation 
95°C 30 sec 
Primer 
annealing 
55-60°C 30 sec 
Elongation 72°C 1-3 min 
20-35 
Final 
Elongation 
72°C 5-10 min 1 
 
 
The annealing temperature can vary depending on the primers; the 
elongation time varied depending on the size of the amplicon. For 
every 1000 bp, 1 min elongation time is required. 
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2.2.3.11 Reverse Transcriptase Polymerase Chain Reaction (RT 
PCR) 
RT PCR is a very sensitive and reproducible method to detect 
specific RNA molecules. The process involves two steps: 
cDNA synthesis: 
cDNA synthsis is the process in which a completary DNA copy 
of mRNA is prepared by the reverse transcriptase enzyme.  
Amplification: 
Amplification of specific regions of cDNA using specific primers 
by PCR. 
The following protocol is for cDNA synthesis using 
ThermoScript system: 
 
Primer and RNA master mix (for 1 reaction) 
Components Volume 
RNA (10 pg - 5 µg) – x µl 
10 mM DNTP mix 2 µl 
Random primer mix (50 
ng/µl) 
1 µl 
DEPC treated water to 12 µl 
 
The above master mix was heated at 65°C for 5 mins and then 
placed on ice. 
Reaction mix (for 1 reaction): 
5x cDNA synthesis buffer was vortexed for 5 secs and placed 
on ice just before use. The master mix was pipetted on ice 
and gently vortexed 
 
Component Volume 
5X buffer 4 µl 
0.1 M DTT 1 µl 
Rnase OUT  40 U/µl 1 µl 
DEPC treated water 1 µl 
Thermoscript RT 15U/µlt 1 µl 
 
8 µl of the master mix was aliquoted into each of the tubes 
containing primer and RNA. 
The tubes were transferred to the thermal cycler and the following 
program was used: 
25°C  for 30 min 
50°C for 50 min 
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85°C for 5 min 
        After that, 1 µl RNase H was added to each reaction and 
incubated at 37°C for 20 mins. The cDNA was stored at -20°C or 
used directly for PCR. 
PCR was carried out using Platinum® Taq DNA Polymerase High 
Fidelity. 10% of the cDNA synthesis reaction (2 µl) was used for 
one PCR reaction. The following components were mixed in a 0.2 
or 0.5 ml, thin-walled PCR tube. Below is a pipetting scheme for a 
50 µl reaction: 
 
Components Volume 
10X High Fidelity buffer 5 µl 
50 mM MgSO4 2 µl 
10 mM dNTP mix 1 µl 
10 µM sense primer 1 µl 
10 µM antisense primer 1 µl 
Platinum Taq 0.2 µl 
DEPC treated water 37.8 µl 
cDNA from the synthesis 
reaction 
2 µl 
 
The PCR reactions were cycled through the following temperature 
profile on a thermal cycler: 
 
94°C for 2 min 
94°C for 30 sec 
55°C for 30 sec (temperature depends on primer) 
68°C for 1 min/kb extension time 
4°C hold 
10 µl of the amplification product was analyzed on an agarose gel. 
 
Below is a flow chart of the process adapted from Invitrogen: 
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Fig 2.3: Schematic plan of cDNA RT-PCR process (adapted from Invitrogen) 
2.2.3.12 Real-time PCR  
Real-time PCR is a very sensitive and reliable technique to measure 
the products generated during the exponential phase of the PCR 
reaction. These measurements allow a very accurate estimate of 
the initial template amount. In the TaqMan real-time assay, a 
''TaqMan probe'' is used which is non-extendable and homologous 
to the amplicon. The probe has a fluorescent reporter dye attached 
to its 5' end and a quencher dye at its 3' end. The probe binds to 
the target sequence. As long as the probe is intact, the fluorescent 
dye and the quencher are in close proximity so the quencher 
significantly decreases the fluorescence emitted by the dye through 
a process called FRET (Fluorescence Resonance Energy Transfer). 
But as soon as the primers bind the target sequence and the 
polymerization begins, the 5' nuclease activity of the Taq 
polymerase cleaves the 5' end of the probe and the quencher dye is 
released. Once the quencher dye is released, the close proximity 
between the quencher and the fluorescent dye is lost. This leads to 
an increase in fluorescence from the free dye. In addition, the 
cleavage removes the probe from the target strand and the 
amplification continues. With each cycle of amplification, additional 
reporter dye molecules are cleaved leading to an increased intensity 
of the fluorescence proportional to the number of specific PCR 
products. 
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Fig 2.4:Schematic presentation of the basic principle of TaqMan assay 
(Adapted from Arya et.al, Expert Rev. Mol. Diagn.2005) 
 
Below is the basic protocol for real-time PCR: 
Good quality cDNA samples were prepared from total mRNA, and 
the concentrations of the samples were determined accurately. A 
master mix was prepared with the reverse and forward primers, 
probe and the universal PCR mix from Applied Biosystems. A 
standard example of real-time PCR master mix is given in the 
following table: 
 
 
Component Volume 
cDNA ∼ 100-200 ng 
Probe (concentration?) 0.05 µl 
Forward Primer (molarity?) 0.2 µl 
Reverse Primer (molarity?) 0.2 µl 
2x Taqman universal PCR mix 10 µl 
Water to make the final volume 20 µl 
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The master mix was then dispensed into the designated wells of the 
96 well PCR plates. Known amounts of cDNA samples were 
appropriately added to the wells. Both technical and biological 
replicates were performed for a robust statistical analysis of the 
results. The plate was then placed into the ABI real-time thermal 
cycler programmed for the following cycles: 
50°C, 2 min 
95°C, 10 mins 
40 cycles of the following steps: 
95°C, 15 secs 
60°C, 1 min 
 
Following amplification, the CT values (CT values: the cycle number 
at which the fluorescence exceeds a threshold value) of the target 
gene and internal standards were recorded and the data was 
analyzed using the SDS 2.1 software. 
2.2.3.13 Protein extraction by the freeze-thaw lysis method 
Cells were harvested using ice cold PBS and the samples were 
transferred to a 1.5 mL microfuge tube. The cells were pelleted in a 
cold centrifuge at top speed. The pellet was resuspended in FT Lysis 
buffer. 80 µl buffer was used per 10 cm confluent dish. After 
dissolving the pellet completely, the tubes were emersed in liquid 
nitrogen for snap-freezing. Frozen tubes were taken out of liquid 
nitrogen and placed on ice for thawing. After the samples were 
thawed, they were briefly mixed by vortexing. This process of 
freeze-thawing was repeated for 2 more times. Finally 250 U 
Benzonase was added to each sample to digest DNA in 10 min room 
temperature incubation. The protein concentration was measured 
using the Bradford method. Before proceeding for SDS-PAGE, the 
samples were mixed with an equal volume of 2x Laemmli buffer, 
heated at 95°C for denaturation and loaded on the gel. 
2.2.3.14 Estimation of protein concentration 
To determine the protein concentration in cell lysates, the Bradford 
Assay was performed (Bradford, 1976). This is a colorimetric assay.  
The principle of this assay is based on an absorbance shift in the 
Coomassie dye, when the red form of the dye changes and 
stabilizes into a blue form, Coomassie blue, after binding to protein. 
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Thus, the concentration of the total protein in the lysate can be 
measured by reading the absorbance at 595 nm with a 
spectrophotometer. The assay is performed in the following steps: 
The Bradford protein assay reagent (BIO-RAD) was diluted 1:5 with 
water. For the standard curve, 200 µg/ml, 400 µg/ml, 600 µg/ml, 
800 µg/ml and 1000 µg/ml protein standards were used. The 
protein standards were all made from a  10 mg/mL stock solutions. 
20 µl of each dilution was mixed with 980 µl of diluted Bio-Rad 
protein assay reagent. The mixture was then added to a cuvette 
and the absorbance of these protein solutions was measured at 595 
nm using a photometer. For the unknown sample, 2 µl were diluted 
in 18 µl water and mixed with 980 µl Bio-Rad protein Assay reagent 
and the absorbance was measured at 959 nm. Measurements of the 
unknown samples were performed two or three times as technical 
replicates. From the readings of the known standards, a standard 
curve was calculated and the concentrations of the unknown 
samples were determined. 
2.2.3.15 Polyacrylamide gel electrophoresis (PAGE) 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to their molecular weight under 
denaturing conditions. SDS-PA gels of appropriate concentrations 
were prepared depending on the size of the proteins to be 
separated. For SDS-PAGE, the gels are prepared in two layers with 
different acrylamide concentration. These layers are known as 
stacking gels and separating or resolving gel. As the name implies, 
the stacking gel concentrates the proteins in a thin band before 
they enter the separating gel, which separates the proteins 
according to size. This results in sharper protein bands in the 
separating gel. The separating gel is poured first and then the 
stacking gel is poured on top of the separating gel. The 
polyacrylamide concentration of the stacking gel is always the same 
(5%), whereas the acrylamide concentration of the separating gel 
varies according to the size of the proteins that need to be 
separated. For the preparation of a 12% separating gel (as an 
example) and 5% stacking gel the following reagents were mixed: 
 For 10 ml 12% resolving gel:  
Component Volume 
Water 5.3 ml 
30% acrylamide mix 2.0 ml 
1.5 M Tris (pH 8.8) 2.5 ml 
10% SDS 0.1 ml 
10% ammonium persulfate 
(APS) 
0.1 ml 
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TEMED 8 µl 
 
For 3 ml 5% stacking gel:      
 
Component Volume 
Water 2.1 ml 
30% acrylamide mix 0.5 ml 
1.0 M Tris (pH 6.8) 0.38 ml 
10% SDS 30 µl 
10% APS 30 µl 
TEMED 3 µl 
 
TEMED and APS were always added last to the gel mixtures, just 
before the gel was poured. The separating gel mix was poured first 
into the gel cassette and was allowed to polymerize at RT. After the 
polymerization of the separating gel, the stacking gel mix was 
prepared and poured on top of the polymerized separating gel. Then 
the comb was positioned in the upper portion of the stacking gel to 
form the loading wells. Samples to be loaded onto the gel were 
denatured by boiling at 95°C for 5 minutes in SDS Laemmli buffer. 
The SDS-Laemmli buffer confers a negative charge to each protein 
in proportion to its mass, resulting in the movement of the protein 
towards the anode (+) through the gel matrix at a speed that is 
roughly proportional to the molecular weight of the protein in a 
specific weight range. The proteins were resolved by applying 60-
120 V (1 kV/m) for 4-8 hours at 4°C in 1x Tris-Glycine 
electrophoresis buffer. 10-50 µg of each protein sample were 
loaded in each well. A commercial protein size marker was also 
loaded so that the molecular weight of the proteins could be 
estimated. 
2.2.3.16 Western blot analysis 
Western blot analysis is a widely used technique to detect the 
presence of a specific protein in a given sample. This technique is 
also used for quantitative estimation of a protein in a sample. The 
method involves the separation of proteins according to their 
molecular weight using electrophoresis through an SDS-PAGE gel, 
transfer of the proteins on a membrane and detection of the 
proteins with antibodies specific for the target protein. Below is a 
step-by-step description of the process: 
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Gel Transfer 
Protein in a sample were separated on a SDS-PAGE gel according to 
size and then transferred to a nitrocellulose membrane using a wet 
transfer system (Mini Trans-Blot Electrophoretic Transfer Cell, Bio-
Rad). The transfer assembly was prepared according to the 
instructions of the manufacturer. For this, the gel, filter papers, 
sponges were all equilibrated in cold transfer buffer for 5 mins. 
Then the transfer sandwich was prepared in the following order: 
Negative electrode, sponge, two sheets of blotting paper, gel, 
membrane, two sheets of blotting paper, sponge, positive electrode.  
The sandwich was locked in place inside the designated cassette 
and placed into the transfer chamber. To keep the chamber cold, 
special ice packs provided with the transfer system were used. The 
chamber was filled with the transfer buffer. A small magnetic stir 
bar was placed inside the chamber. The whole assembly was placed 
on a magnetic stirrer in the cold room and the transfer was 
performed overnight at 100 V, which was ramped up to 200 V in the 
last 1 hour. 
Blocking and Hybridization 
After disassembling the transfer system, the membrane was 
removed carefully from the gel, and the lanes were marked with 
pencil. The membrane was then incubated in blocking solution and 
placed on a rocking platform in the cold room for overnight or at 
room temperature for 2 hours. The primary antibody was diluted in 
the blocking solution (5% milk powder in TBST), and the membrane 
was transferred to the antibody solution and allowed to shake on 
the rocking platform for 1 hour at room temperature or overnight in 
the cold room. The dilution of the primary antibody varied from 
antibody to antibody. After the incubation with the primary 
antidbody, the membrane was washed 3 times with TBST for 5 
minutes each on the rocking platform. The secondary antibody was 
also diluted in the blocking solution. The membrane was incubated 
with the secondary antibody for 30-45 mins at room temperature. 
Finally, the membrane was washed 3 times with TBST as described 
before.  
Detection 
The secondary antibodies, which had the enyzme horseradish 
peroxidase covalently linked to them, were detected by incubating 
the membrane with enhanced chemiluminescence reagent for 3- 5 
min at RT (ECL, Amersham Pharmacia biotech). The membranes 
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were then placed in an X-ray film cassette and autoradiography 
films were exposed for 5 sec to 10 min. 
Stripping 
In order to probe the same membrane with a different antibody, the 
immunoblots were stripped. Immunoblots were stripped by 
incubating in stripping solution at 56° C for 30 min, followed by two 
washes in TBST buffer for 10 min at RT. The membranes were then 
blocked again and probed with a different primary antibody. 
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3. Results 
3.1 Rosa26 knock-in mouse model for CALM/AF10 leukemia 
In order to achieve expression of the CALM/AF10 fusion in a tissue 
inducible manner, a knock-in mouse line was generated by 
Alexandre Krause, a previous member of our group, in collaboration 
with Dr Marlon Schneider and Prof Eckhard Wolf from the Gene 
Center, Munich. In this mouse line, the cDNA of the human 
CALM/AF10 fusion gene is knocked into the murine Rosa26 locus. In 
the next paragraphs, I will give an overview of how this mouse line 
was generated by Alexandre Krause. 
In order to generate the above-mentioned line, two vectors were 
used pBigT and pROSA26 PA. These vectors were kindly provided 
by Frank Constantini from Columbia University, USA. These two 
vectors are commonly used to target the ubiquitously expressed 
Rosa26 locus in the mouse genome with a cassette that allows 
expression of a gene of interest from the ROSA26 locus.  
3.1.1 Genaration of Rosa26-loxPstoploxP-CALM/AF10 mouse 
line 
3.1.1.1 Cloning of the knock-in construct 
First, the CALM/AF10 fusion was excised from the pIGCASV-40 
construct, which is described in Alexandre Krause's thesis. Below is 
a schematic diagram of this construct: 
 
Fig 3.1: Schematic representation of pIGCASV-40 construct (Taken from the 
doctoral thesis of Dr Alexandre Krause) 
 
CALM/AF10 along with the SV40 splice/polyA cassette was released 
from this construct using SacI and NotI and subcloned into the MCS 
(multiple cloning site) of the pBigT vector (Srinivas et al., 2001). In 
the pBigT vector, the MCS is preceded by a loxP flanked 
transcriptional stop cassette, which blocks expression of the 
transgene but can be excised via Cre-mediated recombination. This 
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vector allows conditional expression of the transgene. Below is the 
map of the pBigT vector: 
 
Fig 3.2: Vector map of pBigT (Source http://www.srinivas.org) 
 
The entire inducible cassette along with the CALM/AF10 cDNA was 
then excised from pBigT with PacI and AscI and cloned into the 
Rosa26PA vector. This vector contains the genomic sequence to 
target the murine Rosa26 locus. Below is the map of pRosa26PA 
vector: 
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Fig 3.3 Vector map of Rosa26PA (Source: Addgene;Originally generated by 
Philipp M Soriano) 
In the final construct, CALM/AF10 is preceded by a strong 
transcriptional stop sequence flanked by loxP sites. The 
transcriptional stop cassette prematurely terminates the 
transcription from the Rosa26 promoter. So the knocked-in 
CALM/AF10 fusion gene is not expressed in Rosa26 loxP-Stop-loxP 
CALM/AF10 (R26LSLCA) mice. However, when these mice are 
crossed with Cre-producing transgenic mice, the Cre-mediated 
  
 
57 
excision of the floxed termination sequence leads to the expression 
of the CALM/AF10 gene from the Rosa26 promoter. By crossing 
R26LSLCA mice with different strains of Cre-transgenic mice, which 
express the Cre recombinase in different tissues, tissue specific and 
conditional expression of the fusion can be achieved. 
Below is the diagram of the final construct: 
 
Fig 3.4: The final construct Rosa26 loxP-stop-loxP CALM/AF10 (R26LSLCA) 
 
3.1.1.2 Generating ES cell lines with the Rosa26 Knock-in and 
generation of the chimeric mouse 
The R26LSLCA construct was sequenced to confirm its correctness. 
The vector was then linearized with KpnI and electroporated into 
mouse embryonic stem (ES) cells derived from the 129X1/SvJ 
strain. The ES cells were grown under Neomycin selection. Only 
stably transfected ES cells would grow in the selection medium. A 
total of 49 ES cell clones were amplified. The DNA was prepared 
from the clones and site-specific integration of the vector was 
confirmed by Southern blot analysis. A 387 bp region from the 
Rosa26 promoter was used as probe. The genomic DNA of ES cell 
clones were digested with EcoRV. The Rosa 26 locus specific 
insertion of the construct leads to the appearance of a new band of 
∼ 4.2 Kb size in addition to the 11 kb wild type band. The schematic 
presentation of the Southern strategy and the Southern blot 
performed by Alexandre Krause is shown below:  
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Fig 3.5: Southern strategy: The Southern probe (red) is located outside of the 
targeting construct in the region of the Rosa26 promoter. The genomic DNA was 
digested by EcoRV. If the Rosa 26 locus was successfully targeted, a recombinant 
band will appear because of the introduction of a new EcoRV site. ( original figure is 
adapted and modified from Srinivas S et al. BMC developmental Biology 2001) 
 
 
Figure 3.6: Southern blot for screening ES cell clones positive for targeted 
recombination. Genomic DNA of 7 ES cell clones digested with EcoRV and probed 
with the Rosa26 promoter probe. Clone 1 and 2 are wild type but clone 3, 4, 5, 6, 7 
are heterozygous for the targeted allele. (Performed by Alexandre Krause) 
 
  
 
59 
 
 
7 positive ES clones confirmed by Southern blot were selected for 
further functional analysis. These clones were transiently 
transfected with Cre expressing vectors (experiment done by Dr PD 
Marlon Schneider at the Gene Center) and then cDNA was extracted 
from those cells. The successful excision of the transcriptional stop-
cassette from the Rosa26 locus and the expression of the 
CALM/AF10 fusion were confirmed by RT PCR. 
 
 
Figure 3.7: RT PCR from the cDNA of 3 recombinant ES cell clones. ES cells 
were transiently transfected with Cre protein expressing plasmids, RNA was 
extracted and a RT-PCR using CALM/AF10 specific primer pair was performed. 
(Lane1: Clone A10 cDNA with reverse transcriptase (RT); Lane 2: Clone A11 cDNA 
with RT; Lane 3: Clone B2 cDNA with RT; Lane 4: Clone A11 cDNA without RT; 
Lane 5: clone A11 cDNA without RT; Lane 5: B2 cDNA without RT; Lane 6: Positive 
control; Lane 7: water control. (Experiment done by Alexandre Krause) 
 
In the previous experiment, the expression of the CALM/AF10 fusion 
is clearly visible in clone A10 and B2. Clone A10 was used for the 
blastocyst injection. ES cells were injected into the C57BL/6J 
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blastocyst and then the injected blastocyst was transferred to a 
surrogate mother. Chimeric mice were born and one of them 
showed germline transmission of the knock-in allele and the 
Rosa26LSL-CALM/AF10 (R26LSLCA) line was established. The work 
in my thesis project was performed with this mouse line. 
3.1.1.3 R26LSLCA mice do not express CALM/AF10 fusion without 
Cre protein activity 
R26LSLCA mice were genotyped by a PCR-based genotyping assay 
using the CA brkpnt F and CA brkpnt R primer pair.  R26LSLCA mice 
carrying the CALM/AF10 transgene are also called “CA+/Cre-“ in 
this thesis. In Figure 3.8 an agarose gel picture shows the PCR 
genotyping assay from 7 R26LSLCA mice: 
 
Fig 3.8: Example of the PCR genotyping assay for the R26SLSCA allele. 
Genomic DNA (gDNA) was extracted from the tail tips of seven 8-10 week old F1 
mice from the R26LSLCA X C57BL/6 cross. The gDNA was assayed for the 
presence of the R26SLSCA allele by PCR. Using the C/Abrkpnt F and C/Abrkpnt R 
primer pair (table 2.1.3), the ∼525 bp band in lanes 1, 2, and 6 indicates the 
presence of the R26LSLCA allele. 
Bone marrow cells were isolated from 3 CA+/Cre- mice and cDNA 
was prepared from the bone marrow cells. Real time RT PCR was 
performed on those cDNA samples using realtime probe (CA brkpnt 
probe) and the primer pairs RTCAFWD and RTCAREV (Table 2.4) 
specific for the CALM/AF10 breakpoint. No detectable level of 
CALM/AF10 fusion transcript was identified in the bone marrow of 
these mice. This result indicates that in R26LSLCA mice, CALM/AF10 
transcript is not produced without the activity of Cre protein. 
3.1.1.4 Hematopoietic cells of CA+/Cre- mice and syngeneic wild 
type mice (CA-/Cre-) have a similar immunophenotype  
A flow cytometry based immunophenotyping assay was performed 
on the peripheral blood, bone marrow and spleen cells of CA+/Cre- 
mice and syngenic wild type mice of similar age. These wildtype 
1 2 3 4 5 6 7 
+ 
Control 
1Kb+
DNA 
ladde
r 
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mice are called “CA-/Cre-’’. The standard anibodies used for this 
assay are listed in the following table:Table 3.1: Standard panel of 
antibodies used for immunophenotype analysis by flow cytometry 
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Name of the 
Antibody 
Specificity Target 
compartment 
PE-rat anti-mouse 
Gr1  
Reacts with a common 
epitope Ly-6G and Ly-
6C present on 
granulocytes and 
monocytes but not on 
erythrocytes. 
Myeloid 
APC rat anti-mouse 
CD11b or Mac1 alpha 
Reacts with the 170 kDa 
α chain of Mac1 or 
CD11b which is 
expressed at varying 
levels on granulocytes, 
macrophages, myeloid 
derived dendritic cells, 
natural killer cells, 
microglia and B-1 cells 
Myeloid 
PE-rat anti-mouse 
Ly-6A/E or Sca1 
Reacts with the 18kDa 
phosphatidylinositol-
anchored protein Sca1 
which is expressed on 
the multipotent 
hematopoietic stem 
cells in the bone 
marrow of mice 
Stem cell, progenitor 
cell 
APC rat anti-mouse 
CD117 or c-Kit 
Reacts with CD117, a 
transmembrane 
tyrosine kinase receptor 
encoded by Kit gene. 
CD117 is expressed on 
hematopoietic 
progenitor cells 
committed to myeloid, 
erythroid lineages also 
on the precursors of B 
and T cells. 
stem cell, progenitor 
cell 
APC rat anti-mouse 
CD45R or B220 
Reacts with an epitope 
of the extracellular 
domain of 
transmembrane CD45 
glycoprotein. CD45 is 
expressed on B 
lymphocytes at all 
stages from pro-B 
through mature and 
activated B cells 
Lymphoid 
APC rat anti-mouse 
CD43 or Ly-48 
Reacts with 115 kDa 
glycoform of CD43 
which is expressed on 
pro-B cells,plasma 
Lymphoid/myeloid 
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cells,granulocytes, 
monocytes,macrophage, 
platelets, natural kille 
cells,peritoneal and 
splenic CD5+ B cells 
and most T helper cells. 
The resting peripheral B 
cells do not express this 
protein. 
APC hamster anti-
mouse CD3e 
Reacts with 25kDa ε 
chain of the T cell 
receptor-associated CD3 
complex, which is 
expressed on 
thymocytes, mature T 
lymphocytes and NK 
cells. 
Lymphoid 
PE rat anti-mouse 
CD4 
Reacts with the CD4 
differentiation antigen 
expressed on most 
thymocytes, 
subpopulation of mature 
T cells (T helper cells) 
and a subset of NK-T 
cells. 
Lymphoid 
APC-rat anti-mouse 
CD8a 
Reacts with the 38 kDa 
α chain of CD8 
differentiation antigen 
expressed by cytotoxic 
T cells 
Lymphoid 
PE rat anti-mouse 
CD19 
Reacts with CD19, a 
95kDa transmembrane 
glycoprotein, which is a 
B cell lineage 
differentiation antigen. 
Lymphoid 
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Aliquots of peripheral blood (PB), bone marrow (BM) and spleen 
cells (Spl) were stained with two antibodies at the same time 
conjugated either to PE (phycoerithrin) or APC (Allophycocyanin). 
Antibodies were used in the following combinations: Gr1-PE/Mac1-
APC; Sca1-PE/cKit-APC; B220-PE/CD43-APC; CD4-PE/CD3-APC; 
CD4-PE/CD8-APC; CD19-PE/B220-APC. The antibody-stained cells 
were analyzed on a flow cytometer. 
PB cells from 3 CA+/Cre- mice and BM and Spl cells from 6 
CA+/Cre- mice were isolated and immunophenotyping analysis was 
performed. As wild type control, PB, BM and Spl cells from 5 CA-
/Cre- mice were isolated and their immunophenotype was analyzed 
using flow cytometry. The results are summarized in the following 
figures: 
 
Fig 3.9: Immunophenotype of the peripheral blood cells from wild type mice (CA-/Cre-) 
and CA+/Cre- mice The bar graphs represent the average percentage of surface markers 
and their combinations. The error bars represent the standard deviation. There was no 
significant difference in the expression of surface markers between the two groups of 
animals. 
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Fig 3.10: Immunophenotype of the bone marrow cells from wild type mice (CA-/Cre-) 
and CA+/Cre- mice The bar graphs represent the average percentage of surface markers 
and their combinations. The error bars represent the standard deviation. Expression of the 
myeloid surface markers Gr1, Mac1 was higher in the CA+/Cre- mice in comparison to the 
wild type mice but  (p value for Gr1 is 0.002, Mac1 is 0.003 and GM++ is 0.006. All other 
markers show similar distributions between two groups. 
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Fig 3.11: Immunophenotype of the spleen cells from wild type mice (CA-/Cre-) 
and CA+/Cre- mice The bar graphs represent the average percentage of surface 
markers and their combinations. The error bars represent the standard deviation. 
Mac1 positive cells were more in CA+/Cre-mice (p value 0.03) but other surface 
markers showed similar distribution between two groups of animals. 
Hematopoietic cells from CA+/Cre- mice and the wild type CA-/Cre-
mice by and large show similar immunophenotype. The variation 
that was observed in the expression of myeloid markers on the 
bone marrow and spleen cells could be considered as normal 
variation. 
Since the hematopoietic compartments of these two groups of 
animals are quite similar, we combined them into one group for a 
larger cohort of control mice. For the comparative 
immunophenotypic analysis in the remainder of this thesis, we have 
used this combined group of mice (data from 5 CA-/Cre- and 6 
CA+/Cre- animals) as controls. 
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3.1.2 Ubiquitous expression of CALM/AF10 using CreERT2  
To achieve ubiquitous expression of the CALM/AF10 (CA) fusion, the 
R26LSLCA mouse line was crossed with the Rosa26 Cre-ERT2 line 
(kindly provided by Eckhardt Wolf's group, Gene center). These 
mice have a Cre recombinase/estrogen receptor fusion gene 
integrated in the ubiquitously expressed Rosa26 locus (Soriano, 
1999). The offspring of this cross, which had both knock-in Rosa26 
alleles, was called CA+/CreER+. The estrogen receptor T2 part of 
the fusion portein is responsible for a cytosolic location of the Cre-
ERT2 fusion protein. In the presence of Tamoxifen, the Cre-ERT2 
fusion protein translocates into the nucleus, where the Cre moiety 
of the fusion protein mediates loxP-specific recombination and 
removal of the transcriptional stop cassette of the R26LSLCA allele 
(Soriano, 1999). This results in the ubiquitous expression of the 
CALM/AF10 fusion protein.  
The F1 generation animals were genotyped at the age of 5-8 weeks 
using the primer pair CA brkpnt F and R and Cre-Er F and R (Table 
2.3).  
The double positive (CA+/Cre-ER+) animals were injected intra-
peritonially with 1 mg of Tamoxifen for 5 consecutive days. The 
Tamoxifen dose was not adjusted to the body weight of the 
individual animals, although all the injected animals were of same 
age (12 weeks old) and had very similar body weight.  As control, 
R26LSLCA mice that did not have the Cre-ERT2 allele (CA+/Cre-Er-) 
were treated with Tamoxifen in the similar way. After 5 days of 
induction, one CA+/Cre-ER+ and one CA+/Cre-ER- control mouse 
were sacrificed and cDNA from the spleen and the bone marrow was 
prepared to analyze the expression of CALM/AF10 using RT-PCR. In 
this PCR a primer pair specific for the breakpoint in the CALM/AF10 
cDNA was used. 
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Fig 3.12: Expression of the CALM/AF10 fusion in CA+/Cre-ER+ mice after 
Tamoxifen treatment. Lane 1: Negative control, water; Lane 3: cDNA from 
CA+/Cre-ER+ bone marrow (BM) without reverse transcriptase (RT); Lane 5: cDNA 
from CA+/Cre-ER- BM without RT; Lane 7: cDNA from CA+/Cre-ER+ spleen (Spl) 
without RT; Lane 8: cDNA from CA+/Cre-ER- Spl without RT; Lane 10: Fermentas 
1kb plus DNA ladder; Lane 11: Genomic DNA from CA+/Cre-ER+ as positive control 
for the CALM/AF10 amplicon; Lane 13: cDNA from CA+/Cre-ER+ BM with RT; Lane 
15: cDNA from CA+/Cre-ER- BM with RT; Lane 17: cDNA from CA+/Cre-ER+ Spl 
with RT; Lane 19: cDNA from CA+/Cre-ER- Spl with RT. Primer pair specific for 
CALM/AF10 breakpoint (C/A brkpnt F and CA brkpnt R) was used for the assay,  
In the bone marrow of the Tamoxifen treated mouse (CA+/Cre-
ER+), expression of the CALM/AF10 fusion gene was detected (band 
size ∼ 500bp; lane 13 in Fig 3.12). In the spleen from the same 
mouse very low levels of CALM/AF10 mRNA could also be detected 
(lane 17 in Fig 3.12). In the negative controls without RT no 
amplification was found. These controls were especially important 
since any small carry-over of mouse genomic DNA would also lead 
to a PCR product of the same size with these primers. There was 
also no expression of CALM/AF10 in the bone marrow and spleen of 
the Tamoxifen treated CA+/Cre-ER- mouse (lanes 15 and 19). 
The expression of the CALM/AF10 fusion gene was also detected in 
a second group of Tamoxifen treated CA+/Cre-ER+ mice. 3 animals 
were sacrificed (12 weeks old): one Tamoxifen-treated CA+/Cre-
Er+ mouse, one CA+/Cre-ER+ mouse without Tamoxifen treatment 
and a Tamoxifen-treated CA+/Cre-ER-. From all the mice cDNA was 
prepared from the bone marrow and spleen, and an RT PCR was 
performed using the primer pair CA brkpnt F and R (Table 2.3). To 
  
 
69 
assay the quality of the cDNA, beta-actin was used as control 
(Figure 3.13). 
 
  
Fig 3.13: Amplification of beta-actin house-keeping gene and CALM/AF10 
fusion gene from the cDNA of the mouse tissue. DP Spln (In): CA+/Cre-ER+ 
spleen cDNA, Tamoxifen treatment; DP BM (In): CA+/Cre-ER+ bone marrow cDNA, 
Tamoxifen treatment; CA+Spln (In): CA+/Cre-ER- spleen cDNA, Tamoxifen 
treatment; CA+ BM (In): CA+/Cre-ER- bone marrow cDNA, Tamoxifen treatment; DP 
Spln (Unin): CA+/Cre-ER+ spleen cDNA without Tamoxifen treatment; DP BM 
(Unin): CA+/Cre-ER+ bone marrow cDNA without Tamoxifen treatment. Size of the 
beta actin amplicon ∼ 250 bp, size of CALM/AF10 ∼ 550 bp -RT: Control samples 
without reverse transcriptase; +RT: Samples with reverse transcriptase. In: induced 
or Tamoxifen treated; Unin: not induced, no Tamoxifen treatment 
Beta-actin expression was detected in all the cDNA samples except 
for the cDNA from CA+/Cre-ER- bone marrow (Figure 3.13). 
CALM/AF10 expression was detected in the bone marrow and spleen 
of the two Tamoxifen-induced CA+/Cre-ER+ mice (Figure 3.13). But 
CALM/AF10 expression was also detected in the spleen cDNA of the 
uninduced CA+/Cre-ER+ mouse. Since the -RT control did not show 
amplification, genomic DNA contamination can be ruled out. This 
result suggests Tamoxifen-independent (leaky) activity of the Cre-
ERT2 recombinase. 
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3.1.2.1 Analyzing the efficiency of Cre recombination of the 
R26LSLCA allele:  
 
 
Fig 3.14: PCR based strategy for analyzing the recombination efficiency of the 
Cre protein. Schematic representation of R26SLSCA allele showing the position of 
the fusion primer F and R.  These two primers amplify a 411 bp region between the 
5’ loxP and the start of the CALM/AF10 cDNA after Cre- mediated recombination. 
 
To assay the recombination efficiency of the Cre recombinase at the 
R26SLSCA allele, a PCR based strategy was developed. In figure 
3.14, the position of the forward primer is indicated as “Fusion 
primer F” This primer binds to the splice acceptor region, 5' of the 
first loxP site (bp 1167-1188). The reverse primer (“Fusion primer 
R”) binds to the region between the second LoxP site and the start 
codon of the CALM/AF10 gene (bp 4258-4278). This primer pair will 
amplify a 411 bp region after the stop cassette has been removed 
by Cre-mediated recombination at the loxP sites. In the non-
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recombined state, the distance between these two primers is 3.1 
kb, too large to be amplified in a normal PCR experiment.    
The recombination efficiency of the Cre-ERT2 protein was assayed 
by performing the above PCR assay on the genomic DNA of 
Tamoxifen treated CA+/Cre-ER+ mice. Genomic DNA from 
untreated and treated CA+/Cre-ER+ mice and Tamoxifen treated 
CA+/Cre-ER- mice were included as controls in the assay. 
 
Fig 3.15: PCR from genomic DNA of bone marrow and spleen to detect 
CreERT2-mediated genomic recombination. Lane 1: water control; Lane 2: 1 Kb 
DNA ladder; Lane 3: Bone marrow DNA from a Tamoxifen treated CA+/Cre-ER- 
mouse; Lane 4: Spleen DNA from a Tamoxifen treated CA+/Cre-ER- mouse; Lane 5: 
Bone marrow DNA from a CA+/Cre-ER+ mouse without Tamoxifen treatment; Lane 
6: Spleen DNA from a CA+/Cre-ER+ mouse without Tamoxifen treatment; Lane 8: 
Bone marrow DNA from a Tamoxifen-treated CA+/Cre-ER+ mouse; Lane 9: Spleen 
DNA from a Tamoxifen-treated CA+/Cre-ER+ mouse; 
In the above PCR assay, the expected band of 400-500 bp, which 
indicated successful excision of the transcriptional stop-cassette, 
was only detected in the organs of Tamoxifen treated CA+/Cre-ER+ 
mice (Lane 8 and 9; figure 3.15). No amplification was seen from 
the DNA of the untreated CA+/Cre-ER+ mice or from the Tamoxifen 
treated CA+/Cre-ER- mice. These results clearly showed that the 
Cre enzyme functioned as expected in the CA+/Cre-ER+ mice, 
excising the loxP site-flanked transcriptional stop cassette 5’ of the 
CA fusion gene in the RS26SLSCA allele.  
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3.1.2.2 Ubiquitous expression of CALM/AF10 after Cre-ERT2-
mediated recombinatoin does not cause leukemia 
A total of 19 CA+/Cre-ER+ mice were treated with Tamoxifen when 
they were 8-10 weeks old. Along with the CA+/Cre-ER+ 
experimental animals, 8 CA+/Cre-ER- and 8 CA-/Cre-ER+ control 
mice were treated with Tamoxifen in the same fashion and 
observed. The details of the tamoxifen treated mouse cohort are 
summarised in Tables A1, A2 and A3 in the appendix.  
Tamoxifen-treated CA+/Cre-ER+ mice, which expressed CALM/AF10 
ubiquitously, did not develop any leukemia or hematopoietic 
phenotype even after a long observation period of 24 months.  
3.1.2.3 Analysis of CA+/Cre-ER+ Tamoxifen-treated mice 
Flow cytometry 
To analyze the bone marrow compartment and splenocytes, 3 
clinically healthy CA+/Cre-ER+ mice that had undergone Tamoxifen 
treatment at 8 to 10 weeks of age were sacrificed at the age of 12 
months. Their bone marrow and spleen cells were stained with 
antibodies from our standard antibody panel (table 3.1). The 
immunophenotype of the hematopoietic cells from these mice are 
compared with that of our control mouse group as described earlier.  
 
The results from the experiment are shown in figure 3.16 and 3.17. 
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Fig 3.16: Immunophenotype of the bone marrow cells from tamoxifen treated 
CA+/Cre-ER+ mice (N=3) and control mice (N=11). Average percentages of 
epitope positive cells for each epitope are shown as bar graphs. The error bars 
represent the standard deviations. The number of myeloid cells were slightly higher 
in the bone marrow of Tamoxifen treated CA+/Cre-ER+ mice. P value for the Gr1+ 
cells is 0.04, for Mac1+ cells is 0.03. Other markers show more or less equal 
distribution between two groups of animals 
The number of Mac1 positive and Gr1 positive cells was higher in 
Tamoxifen treated CA+/Cre-ER+ mice. Apart from that there were 
no significant differences in the distribution of the various surface 
markers on the bone marrow cells from the Tamoxifen-treated 
CA+/Cre-ER+ mice compared to the bone marrow cells from control 
mice. 
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Fig 3.17: Immunophenotype of the spleen cells from Tamoxifen-treated 
CA+/Cre-ER+ mice (N=3) and the control mice (N=11). Average percentages of 
epitope positive cells for each epitope are shown as bar graphs. The error bar 
represents the standard deviation. Number of Mac1+ cells is very high in Tamoxifen 
treated CA+/Cre-ER+ mice (p value 1.69E-5).  
The spleen cells from CA+/Cre-ER+ and the control mice showed a 
by and large similar immunophenotype. However, the percentage of 
Mac1 positive cells was higher in the spleen cells derived from 
CA+/Cre-ER+ mice than in spleen cells from control mice (p value 
1.69E-5). The other markers showed a similar distribution between 
the two groups. 
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3.1.3 Expression of the CALM/AF10 fusion gene in the entire 
hematopoietic compartment after Vav-Cre mediated 
recombination 
To achieve expression of the CALM/AF10 fusion gene in the entire 
hematopoietic compartment, Rosa26LSLCA mice were crossed with 
the Vav-Cre mouse line. (Kindly provided by Dr Mathias Kieslinger, 
Helmholtz Zentrum Munich). In this mouse line, the Cre protein is 
expressed under the murine Vav gene regulatory elements 
(Georgiades et al., 2002). The Vav gene is expressed almost 
exclusively in hematopoietic cells starting from early fetal liver 
hematopoiesis onwards (Ogilvy et al., 1999). 
Rosa26LSLCA mice were crossed with Vav-Cre mice and the 
offsprings were genotyped using a PCR-based assay when they 
were 8-10 weeks old. The CALM/AF10 fusion breakpoint-specific 
primers (CA brkpntF and CA brkpnt R) and Vav-Cre-specific primers 
(Vav Cre F and Vav Cre R) were used in the assay. Double positive 
mice showing amplification with the CALM/AF10 fusion breakpoint 
primers and the Vav-Cre primers were monitored for the 
development of leukemia. The double positive mice are called 
CA+/Vav-Cre+. 
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Fig 3.18: Example of the PCR-based genotyping assay for Vav-Cre. Genomic 
DNA extracted from the tail tips of nine 8-10 week old F1 mice from the initial 
R26LSLCA x Vav-Cre cross was used for the assay. The ∼ 550 bp band using 
CALM/AF10 breakpoint specific primers (CA brkpnt F, CA brkpnt R) indicates the 
presence of the CALM/AF10 transgene. A ∼ 500 bp band with the Vav Cre F and Vav 
Cre R primers shows the presence of the Vav-Cre transgene. On the above gel mice 
number 29, 31, and 32 are positive in both the CALM/AF10 and Vav-Cre assay.  
The expression of CALM/AF10 fusion transcript was detected in the 
bone marrow of CA+/Vav-Cre+ mice by RT-PCR and realtime RT-
PCR. cDNA was prepared from the bone marrow cells of one 
CA+/Vav-Cre+ mouse. As a CALM/AF10 positive control, cDNA from 
the U937 cell line was used. U937 is a human monocytic cell line 
containing CALM/AF10 translocation, from which the CALM/AF10 
fusion was cloned originally. Realtime RT PCR was performed on 
these two cDNA samples using the CALM/AF10 breakpoint specific 
primer pair and probe. Amplification of the beta actin gene was 
used as the endogenous control. This experiment showed that the 
expression of the CALM/AF10 fusion transcript is slightly higher in 
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the bone marrow of the CA+/Vav-Cre+ mouse than in the U937 cell 
line. As mentioned in the introduction, the CALM/AF10 fusion was 
originally cloned from the U937 cell line. The results of this 
experiment are shown in figure 3.19 
  
Fig 3.19: Detection of CALM/AF10 transcript in the bone marrow cells of a 
CA+/Vav-Cre+ mouse. cDNA was prepared from the bone marrow cells of one 
CA+/Vav-Cre+ mouse and U937 cells. Realtime PCR was performed using 
CALM/AF10 fusion breakpoint specific primer pair and probe. Amplfiication of the 
ACTB (beta actin) was used as endogenous control. For CALM/AF10 and beta-actin, 
three replicates were assayed. The bar graphs represent the normalized CT value of 
the CALM/AF10 transcript. The error bars represent the standard deviation between 
the technical replicates. In both samples, the expression of the CALM/AF10 fusion 
was detected. Since the CTvalue for CALM/AF10 transcript is slightly lower in 
CA+/Vav-Cre+ bone marrow cells than in U937,the level of CALM/AF10 transcript is 
slightly higher in the bone marrow of CA+/Vav-Cre+ mouse. 
A total of 23 CA+/Vav-Cre+ mice along with 12 CA-/Vav-Cre+ 
controls and 15 R26LSLCA mice (CA+/Vav-Cre-) mice (common 
control arm for all Cre lines) were observed for leukemia 
development for a period of up to 600 days. 
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3.1.3.1 Expression of the CALM/AF10 fuson gene in Vav 
expressing cells leads to the development of an acute myeloid 
leukemia 
The R26LSLCA mice expressing the CALM/AF10 fusion gene after 
Vav-Cre mediated recombination developed an acute myeloid 
leukemia with a median latency of 354 days and a 100% 
penetrance. A total of 23 CA+/Vav-Cre+ animals were observed. A 
post mortem analysis was possible in only 15 leukemic animals. 8 
animals were found dead in their cages and could not be analyzed 
in detail. 6 out of 8 dead mice had splenomegaly, which strongly 
suggests that they died of leukemia. In 2 dead animals we could not 
do any analysis due to severe autolysis of the organs. The days of 
survival for each leukemic animal are listed in table A4 in the 
appendix. 
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Fig 3.20: Kaplan-Meier survival plot of CA+/Vav-Cre+, CA+/Vav-Cre- and CA-
/Vav-Cre+ mice. All the mice expressing the CALM/AF10 fusion gene (CA+/Vav-
Cre+)(N=15) developed an acute myeloid leukemia with a median latency of 354 
days (ranging from 261 to 497 days). In contrast, the mice from both control groups: 
CA+/Vav-Cre- (N=12) and CA-/Vav-Cre+ mice (N=12) remained healthy. Each step 
on the survival graph indicates one event (death of an animal). The dots indicate the 
censored animals, which could not be analyzed. 
 
Shortly before their death, leukemic animals showed the typical 
symptoms associated with leukemia like ruffled fur, hunched back, 
reduced movement, weight loss and tachypnea. Animals were 
thoroughly monitored for the development of these signs and 
symptoms. Peripheral blood was regularly collected from the tail 
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vein of the animals under observation for routine WBC and RBC 
count.  
3.1.3.2 Leukocytosis and anemia in the leukemic mice: 
In all the analysed leukemic mice, a several fold expansion of the 
white blood cell (WBC) was observed. The RBC count was relatively 
reduced, indicating anemia. 
 
Fig 3.21: Distribution of the WBC counts in the peripheral blood of leukemic 
CA+/Vav-Cre+ n= 8 and healthy control mice (CA+/Cre- and CA-/Cre-), n=8. 
WBC counts in the leukemic mice were significantly higher compared to the healthy 
controls. (p value 0.026) 
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Fig 3.22: Distribution of RBC counts in the peripheral blood of leukemic 
CA+/Vav-Cre+ mice and the healthy controls (CA+/Cre- and CA-/Cre-). The 
number of RBC in the peripheral blood of leukemic mice was significantly reduced 
(p= 0.0001) 
3.1.3.3 Splenomegaly  
The spleens of the leukemic animals were enlarged. We dissected 6 
out of 8 mice that were found dead in the cage and found their 
spleens to be enlarged. 
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Fig 3.23: Distribution of spleen weight of leukemic CA+/Vav-Cre+ mice and 
healthy control mice (CA+/Cre-and CA-/Cre-). The weight of the spleen from the 
analyzed leukemic animals was significantly higher (p value 0.0042) than in the 
healthy controls. 
 
 
Fig 3.24: Picture of two spleens from leukemic mice (CA+/vav-Cre+) and one 
spleen from a non-leukemic mouse (CA+/Cre-). 
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Fig 3.25: Picture of a post mortem dissection of a leukemic mouse (Id: vav 81) 
with splenomegaly and pale organs.  
3.1.3.4 Blast-like cells in the peripheral blood, bone marrow and 
spleen of the leukemic mice 
To study the morphology of the cells from leukemic mice, 
cytological slides were prepared with the peripheral blood smear 
and cytospin preparations with cells from bone marrow and spleen. 
In the PB smears, lymphocytes were almost absent. Most of the 
cells were of myeloid origin. Many large cells with immature 
appearance, prominent chromatin and bluish cytoplasm were found 
in the PB smears and cytospins from bone marrow and spleen from 
leukemic mice. 
 
Fig 3.26: Giemsa-May-Grünwald staining of the peripheral blood (PB) smear 
and the cytospins from PB, bone marrow (BM) and spleen cells from a 
leukemic mouse (Id:Vav57). Abnormal blast like cells (arrows) was observed in all 
preparations. (Magnification 63X) 
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3.1.3.5 Infiltration of multiple organs by the blast cells in leukemic 
mice 
Histopathological sections were prepared from formalin fixed organs 
of the leukemic mice. Infiltrating leukemic blasts were identified 
using immunohistochemistry. A diffuse infiltration of leukemic blasts 
in most organs examined was detected attesting to the severity and 
aggressiveness of the disease. Infiltrated organs included spleen, 
kidney, liver, lung, pancreas, salivary gland, thymus and the gastro 
intestinal tract. 
 
Fig 3.27: Section of organs from a leukemic CA+/Vav-Cre+ mice (Mouse Id  vav 
32). Different organs were infiltrated by the leukemic blast cells. The figure shows  
hematoxylin and eosin (H&E) stained organ sections at different magnifications. A. 
The infiltration in the sleepn involved predominantly the red pulp; B. infiltration in the 
lung; C. In the kidney section glomerular infiltration is visible; D. Extensive infiltration 
in the sinusoidal and the periportal space of the liver; E and F. Infiltrates were found 
in the salivary gland and the pancreas. Arrows indicate areas of infiltrating blast cells. 
(Histology was performed by Priv Doz Dr Leticia Quintanilla-Fend in the Institute for 
Pathology, University of Tübingen) 
 
3.1.3.6 Myeloid origin of the leukemic blasts 
To characterize the type and the differentiation stage of the 
infiltrating blasts in these leukemias, several immunohistochemical 
stainings were performed on the fixed tissue sections. 
Myeloperoxidase (MPO) is an enzyme present from the early 
granulocyte precursor stage onwards. A positive myeloperoxidase 
staining indicates a myeloid origin of the blasts and it distinguishes 
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them from immature lymphoid blasts. Chloracetate-esterase 
(ASDCL) is the stain used to identify cells of the granulocytic 
lineage from an early promyelocytic stage onwards. To identify the 
B and T lymphocytic blasts, B220 and CD3 stainings were 
performed, respectively. A positive TdT (terminal desoxynucleotide 
transferase) will identify cells of lymphoid origin. To confirm the 
nature of the infiltrating blasts, all the above-mentioned stainings 
were performed on the tissue sections from leukemic mice.  
The infiltrating blasts were positive for MPO and ASDCL confirming 
their myeloid nature. Tissue sections were negative for TdT 
staining. CD3 and B220 staining showed a few residual lymphocytes 
present in the spleen of the leukemic mouse. Some mature 
granulocytes were also observed in the tissue sections. These 
analyses revealed that the CALM/AF10 fusion gene in the CA+/Vav-
Cre+ mice led to the development of an acute myeloid leukemia 
with maturation.  
 
Fig 3.28: Immunohistochemistry on the tissue sections from CA+/Vav-Cre+ 
leukemic mice. Spleen, liver, lung and kidney sections show the presence of 
myeloid marker positive infiltrating blasts. Black arrows indicate areas of infiltrating 
blasts. 
3.1.3.7 The leukemic blasts in 40% of the CA+/Vav-Cre+ leukemic 
mice co-express myeloid and lymphoid markers 
Using flow cytometric analysis the immunophenotype of the 
leukemic cells from several hematopoietic organs was analyzed in 
detail. Single cell suspensions for flow cytometry were prepared 
from the peripheral blood, bone marrow and the spleen of the 
leukemic mice and stained with several antibodies detecting 
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epitopes specific for the myeloid, B and T lymphocytic 
compartment. Antibodies from our standard panel described in table 
3.1 were used. In all the CA+/Vav-Cre+ leukemic mice, the cells 
were positive for the myeloid markers Mac1 and Gr1 reconfirming 
the myeloid nature of the leukemia. But in 6 out of 15 leukemias, 
the leukemic cells were also positive for lymphoid markers. As 
graphically represented in figure 3.29, the leukemic animals could 
be divided into two groups on the basis of the immunophenotype of 
their leukemic cells. In 6 out of 15 leukemic animals, 40±6% cells in 
the peripheral blood, 35±12.09% cells in the bone marrow and 
44±4.58% of spleen cells were positive for both the myeloid marker 
Mac1 and the B lymphoid marker B220. We will call these leukemias 
“biphenotypic”. In this group, the number of cells staining positive 
only for B220 was 51±15% in the peripheral blood, 45.3±17.4% in 
bone marrow and 57.5±6.4% in the spleen. These percentages of 
B220+ cells are significantly higher than in the control mice (p 
values for PB, BM, spleen are 2.7E-5, 1.26E-5 and 0.0001, 
respectively).  
In contrast, in the other group of leukemias (9 mice out of total 15 
animals), the number of cells staining positive for B220 was very 
low: 14.6±8.61% in the peripheral blood, 6.83±3.25% in the bone 
marrow and 23.66±12.8% in the spleen. In this group of leukemias, 
the majority of cells (on an average, 60% cells) stained positive for 
the myeloid maker Mac1. We will call the leukemias in this group 
“myeloid”. A population of cells staining positive for both the 
lymphoid marker B220 and the myeloid marker Mac1 
(B220+/Mac1+) was virtually absent in this myeloid group. In both 
groups, the number of Mac1 positive cells was very high in the 
blood, bone marrow and spleen. However, in the biphenotypic 
group the number of Gr1+ cells was not significantly different from 
the control mice whereas in the myeloid group there was 
significantly high number of Gr1+ cells present in all the 
hematopoietic organs. In summary, the leukemic bulk in the 
myeloid group was Mac1high Gr1high B220- where as in the 
biphenotypic group, leukemic cells were Mac1high Gr1low B220high. 
The number of cells positive for the T cell markers CD3, CD4, and 
CD8 was greatly reduced in all cases. For the detailed values of 
surface markers of control and leukemic animals please refer to the 
appendix table A5, A6 and A7. 
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Fig 3.29: Summary of the immunophenotype of the leukemias in the CA+/Vav-
Cre+ mice. Based on the phenotype of the leukemic cells, two groups of leukemias 
(myeloid and biphenotypic) can be distinguished. The upper panels A, B, C 
summarize the surface marker distribution in the peripheral blood, bone marow and 
on the splenocytes in the myeloid group (data from 6 of 9 animals). The majority of 
cells are Mac1 positive in all the organs. Only very few cells are positive for the 
lymphoid marker B220. The lower panels D, E, F show the surface markers on the 
peripheral blood, bone marrow and spleen cells from the biphenotypic group of 
leukemias (data from 5 of 6 animals). In this group, a high percentage of B220 
positive cells are found in all three organs. And there is a very prominent population 
of cells co-expressing the myeloid marker Mac1 and the lymphoid marker B220  
(green circles). The difference in the percentage of B220 positive cells between the 
two groups is significant. In peripheral blood the p value is 0.0002, in bone marrow 
the p value is 0.0001, in spleen the p value is 0.0001 
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Fig 3.30: Immunostaining analysis of hematopoietic cells from the two groups 
of leukemia using flowcytometry.  Immunostaining of the hematopoietic cells from 
mouse VCA 72 and VCA 57 using Gr1-PE and B220-PE in combination with Mac1-
APC antibodies are shown. Mouse VCA72 developed a myeloid leukemia. Majority of 
the cells in the hematopoietic organs are Gr1-Mac1 positive. Immunostaining using 
Mac1 and B220 reveals that B220 positive cells are almost absent in all the 
hematopoietic organs of this mouse. In the lower panel immunostaining of the 
peripheral blood, bone marrow and spleen cells from the mouse VCA57, which 
developed biphenotypic leukemia is shown. In this case B220-PE and Mac1-APC 
antibody staining reveals the presence of Mac1+/B220+ biphenotypic population in 
all the hematopoietic organs  
 
Immunophenotype of 2 leukemic CA+/Vav-Cre+ mice from each 
group of leukemia are shown in figure 3.30. The upper two rows of 
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the figure show hematopoietic organs from mouse VCA 72 which 
developed a myeloid leukemia. Gr1+/Mac1+ myeloid cells infiltrated 
all the organs. There were no B220 positive cells in PB and BM, very 
few in the spleen, the Mac1+/B220+ population is absent. The 
lower two rows show immunostaining of the cells of mouse VCA 57, 
which developed biphenotypic leukemia. High number of Mac1+ 
cells are present in all the organs of this mouse, number of Gr1+ 
cells is fewer than the VCA 72 mouse with myeloid leukemia and 
when we look at the B220, Mac1 staining we see the presence of 
biphenotypic Mac1+/B220+ cells in all the organs. 
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3.1.3.8 Most leukemic cells stain positive for monocytic markers 
Bone marrow cells extracted from both myeloid and biphenotypic 
leukemias were further characterized using a few more antibodies 
specific for surface markers like CD23, IgM, F4/80 and CD24 
antibodies. The details of the antibodies used are given in the 
following table: 
Table 3.2 List of antibodies for characterization of the leukemic cells 
Name of the antibody Specificity 
F4/80, rat monoclonal antibody, 
FITC conjugate 
Recognizes the F4/80, which is a 
member of the epidermal growth 
factor EGF-TM7 family. This 
family includes class B G protein 
coupled receptors. Mostly 
present on macrophage and 
monocytes. 
PE rat anti-mouse IgM Recognizes specifically mouse 
IgM of Igh-C(a) and Igh-C(b) 
haplotypes. 
FITC rat anti-mouse CD23 Reacts with CD23, an 
immunoglobulin receptor 
expressed on mature 
conventional B lymphocytes but 
not on T cells. 
PE rat anti-mouse CD24 Reacts with CD24, a membrane 
associated glycoprotein present 
on B lymphocytes, granulocytes 
and monocytes. 
 
.  
In figure 3.31, Mac1 positive bone marrow cells from leukemic 
mouse VCA 57 are co-stained with antibodies specific for CD23, 
CD24, F4/80 and IgM antibodies. This mouse had biphenotypic 
leukemia. The bone marrow cells from another mouse VCA 74 with 
myeloid leukemia were also stained using same antibodies and the 
results are summarized in figure 3.32. On an average in both 
groups, 47.6± 11.39 % of the bone marrow cells co-stained for 
Mac1 and CD24 and 48.1±9.19 % cells stained positive for Mac1 
and F4/80 indicating the monocytic nature of these cells. The 
staining pattern of these markers was not obviously different 
between the two leukemic groups. Staining for CD23 and IgM 
markers were negative in both cases. 
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Fig 3.31: Immunostaining of the bone marrow cells from a biphenotypic 
leukemia sample using monocytic markers. Mac1 positive bone marrow cells 
from mouse VCA 57 were co-stained with Mac1 and F4/80 (A), Mac1 and IgM (B), 
Mac1 and CD23 (C) and Mac1 and CD24 (D). 38% cells stained positive for F4/80 
marker (A) and 46% cells were positive for CD24 (D). There were no CD23 and IgM 
positive cells as indicated in B and C. 
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Fig 3.32: Immunostaining of the bone marrow cells from a myeloid leukemia 
sample using monocytic markers. Leukemic bone marrow cells from mouse VCA 
74 were co-stained with Mac1 and F4/80 (A), Mac1 and IgM (B), Mac1 and CD23 (C) 
and Mac1 and CD24 (D). 38% cells stained positive for F4/80 marker (A) and 60% 
cells were positive for CD24 (D). There were no CD23 and IgM positive cells as 
indicated in B and C. 
3.1.3.9 Flow cytometric analysis of the peripheral blood, bone 
marrow and spleen shows significant alterations in leukemic 
CA+/Vav-Cre+ mice 
The immunophenotype of cells from the peripheral blood, bone 
marrow and spleen of leukemic CA+/Vav-Cre+ mice was compared 
with those of our control mouse group, as described earlier. 
Samples from both 7 myeloid and 6 biphenotypic leukemias are 
used in this analysis. In this comparison, as expected, significant 
differences were observed. The expansion of the myeloid 
compartment is visible in the blood, bone marrow and also in spleen 
in both groups of leukemias. The number of CD3, CD4 and CD8 
positive cells (T cells) is significantly reduced in the spleen and the 
peripheral blood indicating a myeloid bias in hematopoiesis. The 
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results are summarized in the following figures (Figures 3.33, 3.34 
and 3.35). 
 
Fig 3.33: Immunophenotype of the peripheral blood cells from leukemic mice 
(CA+/Vav-Cre+) and the control mice. The average percentage of cells staining 
positive for each marker is shown as a bar graph. The error bars represent the 
standard deviation. A significant expansion of the myeloid compartment (Gr1+, 
Mac1+, Gr1+/Mac1+) in the leukemic samples from both groups is seen. In the 
biphenotypic leukemia number of B220 positive cells is significantly higher than the 
control (p value 2.07E-5) and the myeloid group of leukemia (p value 0.0002). 
Number of CD4, CD3, CD8 positive lymphoid cells are reduced in both groups of 
leukemias, in comparison to the control mice. 
 
  
 
94 
 
 
Fig 3.34: Immunophenotype of the bone marrow cells from leukemic mice 
(CA+/Vav-Cre+) and the control mice. The average percentage of cells staining 
positive for each marker is shown as a bar graph. The error bars represent the 
standard deviation. A significant expansion of the Mac1+ cells in the leukemic 
samples is seen. There is a very high proportion of Gr1+ cells in the myeloid 
leukemias in comparison to the controls, (p value: 3.77x10-5). The biphenotypic 
leukemias have a lower proportion of Gr1+ cells in comparison to the myeloid 
leukemias (p value: 0.0001). The proportion of B220+ cells is very high in the 
biphenotypic leukemic samples in comparison to control (p value: 1.26x10-5) and the 
myeloid leukemia (p value: 0.0001).  
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Fig 3.35: Immunophenotype of the spleen cells from leukemic mice (CA+/Vav-
Cre+) and the control mice. The average percentage of cells staining positive for 
each marker is shown as a bar graph. The error bars represent the standard 
deviation. The proportion of Mac1+ cells is very high in both groups of leukemias in 
comparison to the controls. The percentage of Gr1+ cells is higher in the myeloid 
leukemias in comparison to the control (p value: 0.002). However, in the biphenotypic 
leukemias there are fewer Gr1+ cells and there is no significant difference from the 
controls (p value 0.0105). The proportion of B220 positive cells is very high in 
biphenotypic leukemia in comparison to the control (p value: 0.0001) or the myeloid 
leukemias (p value: 0.0001). 
The individual values of different surface markers on the cells of the 
hematopoietic organs from the leukemic and the control mice are 
shown in tables A5, A6, A7 in the Appendix. 
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3.1.4 B cell-specific expression of CALM/AF10 using CD19-
Cre and Mb1-Cre transgenic mice  
To achieve expression of the CALM/AF10 fusion protein in the B cell 
compartment, the CD19-Cre and Mb1-Cre transgenic mouse lines 
were crossed with R26LSLCA mice. Dr Ursula Zimber-Strobl’s group 
kindly provided both Cre lines.  
Robert C. Rickert et al generated the CD19-Cre transgenic mice 
(Rickert et al., 1997). In this mouse line, the Cre gene is under the 
transcriptional control of the CD19 locus. The CD19 gene is 
expressed specifically in B cells from an early stage throughout B 
cell development and differentiation. In the CD19-Cre mice, a Cre 
expression cassette was inserted into the second exon of the CD19 
gene by homologous recombination. Due to this insertion, the 
coding region of CD19 gene is disrupted but all the regulatory 
elements of the CD19 locus are left intact. Mice with one CD19-Cre 
allele have a normal phenotype and can be used for B cell-specific 
deletion of loxP flanked (floxed) target regions. 
The Mb1-Cre mice were generated by Hobeika and colleagues 
(Hobeika et al., 2006). In this mouse line, the Cre expression 
cassette is integrated into the Mb1 locus. The Mb1 gene encodes 
the Igα signalling subunit of the B cell antigen receptor. Mb1 is 
highly expressed in B cells from the very early pro-B cell stage in 
the bone marrow and also in the later stages of B cell development 
but not in plasma cells. Different stages of B cell development are 
outlined in the following figure, stages expressing the CD19 and 
Mb1 genes are indicated. 
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Fig 3.36: An outline of the B cell development showing the stages where Mb1 
and CD19 markers express. (Original figure adapted from Nature Reviews 
Inmmunity, December 2001 and modified) 
R26LSLCA mice were crossed with both the Mb1-Cre and CD19-Cre 
lines. Tail DNA from 8-10 week old F1 offspring was used for a PCR-
based genotyping assay. Animals positive for both CALM/AF10 and 
Cre should express CALM/AF10 in the B cells where CD19 or Mb1 
expression occurs. These double positive mice were called 
CA+/CD19-Cre+ and CA+/Mb1-Cre+, respectively. 
 
Fig 3.37: Example of the PCR genotyping assay for the CALM/AF10 breakpoint. 
Genomic DNA extracted from the tail tips of ten 8-10 week old F1 mice from the 
R26LSLCA X Mb1-Cre cross was assayed for the presence of the R26SLSCA allele. 
Using the C/Abrkpnt F and C/Abrkpnt R primer pair (table 2.1.3), the ∼525 bp band in 
lanes 2, 4, 5, 7, and 10 indicates the presence of the R26LSLCA allele. 
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Fig 3.38: Example of the PCR genotyping assay for the Mb1-Cre allele. Genomic 
DNA extracted from the tail tips of seven 8-10 week old F1 mice from the R26LSLCA 
X Mb1-Cre cross was used for the assay. Using the Mb1 Cre F and Mb1 Cre R 
primer pair (Table 2.3.1) the appearance of a band of about 510 bp in lanes 1, 6 and 
7 indicates the presence of the Mb1-Cre allele. 
 
 
 
Fig 3.39: Example of the PCR genotyping assay for the CD19-Cre allele. 
Genomic DNA extracted from the tail tips of nine 8-10 week old F1 mice from the 
R26LSLCA X CD19-Cre cross was used for the assay. The ∼750 bp band seen in 
lanes 1, 3, 4, 6 and 8 originates from the disrupted CD19 locus where the Cre coding 
cassette has been integrated; the 500 bp band corresponds to the wild type CD19 
locus. The CD19 Cre F and CD19 Cre R primer pair Cre (Table 2.3.1) was used for 
the genotyping. 
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3.1.4.1 CALM/AF10 fusion transcript is expressed in the B cells of 
CA+/Mb1-Cre+ and CA+/CD19-Cre+ mice 
To analyze the expression of the CALM/AF10 fusion gene in the B 
cells of CA+/Mb1-Cre+ and CA+/CD19-Cre+ mice, CD43 negative 
resting B cells were isolated from the spleens of one CA+/Mb1-Cre+ 
mouse and one CA+/CD19-Cre+ mouse by magnetic cell isolation 
(MACs), cDNA was prepared from these cells and RT PCR was 
performed. 
CD43 is a marker for granulocyte, monocyte, macrophage, CD5+ 
splenic B cells, T lymphocytes. Only peripheral resting B cells are 
negative for CD43. Single cell suspension of spleen cells were 
prepared and incubated with magnetically labeled CD43 antibody. 
Then the cells were passed through a column placed in a strong 
magnetic field. CD43+ Cells were labeled with the magnetic 
antibodies and hence were retained in the column because of the 
magnetic field. Unlabelled CD43- cells were collected in the flow 
through. cDNA was isolated from the B cells of these two mice and 
RT PCR and realtime RT PCR was performed. The expression of the 
CALM/AF10 fusion transcript was detected in the B cells from both 
the CA+/Mb1-Cre+ and the CA+/CD19-Cre+ mouse. 
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Fig 3.40: Agarose gel of the RT-PCR assay performed on the cDNA of B cells 
isolated from a CA+/Mb1-Cre+ mouse and a CA+/CD19-Cre+ mouse. 
Amplification of the internal control gene beta-actin (ACTB) from the B cell cDNA of 
both mice are shown in the upper-left panel. In the lower left panel is the negative 
control reaction (without reverse transcriptase) to detect the presence of any carry 
over genomic DNA. The upper right panel shows the expression of CALM/AF10 
fusion in both cDNA samples. The lower right hand panel has the corresponding 
control without reverse transcriptase (RT). 
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The expression of the CALM/AF10 fusion gene was detected in the 
cDNA sample from the B cells of the CA+/Mb1-Cre+ mouse as well 
as from the CA+/CD19-Cre+ mouse. The expression level of the 
fusion gene was higher in CA+/Mb1-Cre+ mouse. 
Realtime RT PCR was performed with the same cDNA samples from 
murine B cells to analyze the expression of the CALM/AF10 fusion 
transcript in a quantitative way. CALM/AF10 breakpoint specific 
probes and primers were used for the assay. cDNA from U937 cell 
line was used as a positive control for CALM/AF10 in the realtime RT 
PCR assay and to compare expression levels. U937 is a human cell 
line, which harbors the CALM/AF10 fusion and was originally used 
for the cloning of this fusion. We could detect the expression of 
CALM/AF10 fusion transcript in all samples. As previously seen in 
the RT-PCR results, we saw higher expression levels of CALM/AF10 
in the B cells from CA+/Mb1-Cre+ mice. It should be noted that the 
expression levels both in the B cells from the CA+/Mb1-Cre+ and 
the CA+/CD19-Cre+ mouse are higher than in the U937 cell line. 
The results are summarized in the following figure. 
 
Fig 3.41: Detection of the CALM/AF10 fusion transcript in the B cells from 
CA+/Mb1-Cre+ mice and CA+/CD19-Cre+ mice using realtime RT- PCR. Realtime 
RT PCR was performed on the cDNA samples of B cells from one CA+/Mb1-Cre+ 
mouse and one CA+/CD19-Cre+ mouse using CALM/AF10 fusion breakpoint specific 
probe and primer pair (Table 2.4). cDNA of U937 cells was used as CALM/AF10 
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positive control. For each reaction 3 technical replicates were performed. The error 
bars represent the standard deviation of the technical replicates. For all the samples, 
beta-actin gene was used as the endogenous control for cDNA quality and amount. 
The CT values of the CALM/AF10 transcripts were normalized using the endogenous 
control beta actin. The bar graphs represent the normalized CTvalue of CALM/AF10 
transcript in each sample. The CT value of a transcript in realtime PCR correlates 
inversely with its expression. Higher CT values of a transcript indicate lower 
expression levels. 
3.1.4.2 The expression of the CALM/AF10 fusion gene in the B cells 
from the early pro-B cell stage onwards does not lead to the 
development of leukemia 
A total of 20 CA+/CD19-Cre+ mice were observed for 12-18 
months for the development of leukemia. As a control 15 CA-
/CD19-Cre+ mice were also observed. These mice were all healthy 
during the period of observation and did not show any phenotypic 
abnormality. 
25 CA+/Mb1-Cre+ and 16 CA-/Mb1-Cre+ mice were observed for 
12-18 months. These mice also remained all clinically healthy and 
did not develop any signs of leukemia during the observation 
period. 
3.1.4.3 Flow cytometric analysis shows normal immunophenotype 
of bone marrow and spleen cells in CA+/Mb1-Cre+ mice. 
Four clinically healthy CA+/Mb1-Cre+ mice were sacrificed at the 
age of 13 months and immunophenotyping of the bone marrow and 
splenocytes was performed with our standard antibody panel (Table 
3.1) and the data were compared with the immunophenotype of 
mice from the control group as described before.   
The distribution of surface markers on the hematopoietic cells 
showed a similar pattern between the CA+/Mb1-Cre+ mice and the 
control mice. However, slightly higher number of Mac1+ cells was 
found in CA+/Mb1-Cre+ spleens and bone marrows. But the other 
myeloid markers, like Gr1, CD43 did not show any significant 
difference between the two groups. The expression of B lymphocytic 
markers, like B220, CD19 and T lymphocytic markers like CD4, 
CD3, CD8 was also quite similar between the groups. The results 
are summarized in figure 3.42 and 3.43. 
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Fig 3.42: Immunophenotype of the bone marrow cells from mice expressing 
CALM/AF10 in the B cells by Mb1-Cre mediated recombination (CA+/Mb1-Cre+) 
and bone marrow cells from the controls. The average percentage of individual 
surface markers and their combinations as described before is represented as bar 
graphs. The error bars represent the standard deviations. Different surface markers 
show similar distribution between the two groups except for the Mac1 expression, 
which is slighty higher in the CA+/Mb1-Cre+ mice but difference is not statistically 
significant. 
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Fig 3.43: Immunophenotype of the splenocytes from CA+/Mb1-Cre+ mice and 
the control mice. The average percentage of individual surface markers and their 
combinations, as described before, is represented as bar graphs. The error bars 
represent the standard deviation. The number of Mac1+ cells is significantly higher in 
the CA+/Mb1-Cre+ mice in comparison to the control group (p value 0.08) but the 
other markers show a similar distribution between the two groups. 
3.1.4.4 Immunophenotypic analysis of peripheral blood, bone 
marrow and spleen cells from CA+/CD19-Cre+ mice shows a 
normal pattern 
6 healthy CA+/CD19-Cre+ mice were sacrificed at the age of 16 
months, and their peripheral blood, bone marrow and spleen cells 
were extracted for immunophenotype analysis. These mice express 
the CALM/AF10 fusion gene in the B-lymphocytes from the early 
pre-B to mature B cell stage after Cre-mediated recombination. For 
the comparison data from our standard control group was used. 
The results are summarised in figure 3.44, 3.45 and 3.46.  
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Fig 3.44: Immunophenotype of peripheral blood cells extracted from 
CA+/CD19-Cre+ mice and the controls. The average percentage of individual 
surface markers and their combinations is represented as columns. Error bars 
represent +/- standard deviation. The number of Sca1+ cells was significantly higher 
in CA+/CD19-Cre+ mice (p value 0.0009) the number of B220+ and CD19+ B cells 
was also significantly higher in CA+/CD19-Cre+ mice (p value for B220: 1.56E-6 and 
for CD19: 2.43E-6).  
 
In the peripheral blood of CA+/CD19-Cre+ mice, the number of 
Sca1+ cells was significantly higher than in the control mice. The 
number B220+ and CD19+ cells were also significantly higher in the 
CA+/CD19-Cre+ mice. This difference was not so marked on the 
cells from the bone marrow and spleen. All the other markers 
showed no significantly different distribution between the two 
groups in PB, BM and spleen. 
 
  
 
106 
 
Fig 3.45: Immunophenotype of bone marrow cells extracted from CA+/CD19-
Cre+ mice and the control mice. The average percentage of individual surface 
markers and their combinations is represented as columns. The error bars represent 
the standard deviation. Bone marrow cells from both groups show a similar 
phenotype. 
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Fig 3.46: Immunophenotype of spleen cells extracted from CA+/CD19-Cre+ 
mice and the control mice. The average percentage of individual surface markers 
and their combinations is represented as columns. The error bars represent the 
standard deviation. Bone marrow cells from both groups show a similar phenotype. 
The number of B220 positive B cells is higher in the spleen from CA+/CD19-Cre+ 
mice (p value 0.001). There is no other significant difference in the distribution of 
surface markers between two groups. 
 
3.1.5 Comparative analysis of CA+/Vav-Cre+,CA+/Mb1-Cre+ 
and CA+/CD19-Cre+ mice 
The expression of CALM/AF10 in cells expressing the Cre 
recombinase under the control of the Vav locus leads to the 
development of myeloid leukemia in all the mice but when 
CALM/AF10 is expressed in the B-lymphoid compartment in the 
CD19-Cre and Mb1-Cre crosses, all the mice remain healthy. For an 
overall picture, we are going to compare the leukemic and non-
leukemic mice that express CALM/AF10 in different hematopoietic 
compartments. In the following figure, I shall give the survival plot 
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of the number of mice we have observed from each cross of the 
R26SLSCA mice with the three Cre-transgenic lines. 
 
Fig 3.47: Kaplan-Meier survival plot of CA+/vav-Cre+ mice (n=23), CA+/mb1-Cre+ mice 
(n=25) and CA+/CD19-Cre+ mice (n=20). All CA+/vav-Cre+ mice developed leukemia with a 
median latency of 352 days. Post mortem analysis was possible for 15 mice. The dots 
indicate 8 censored mice that could not be analyzed. None of the CA+/Mb1-Cre+ or 
CA+/CD19-Cre+ mice developed leukemia. 
 
3.1.5.1 Comparative immunophenotype of the leukemic CA+/Vav-
Cre+ mice and non -leukemic CA+/Mb1-Cre+ mice and CA+/CD19-
Cre+ mice 
The immunophenotype of the leukemic CA+/Vav-Cre+ mice and 
non-leukemic CA+/Mb1-Cre+ and CA+/CD19-Cre+ mice has been 
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compared with our control group of mice (CA+/Cre- and CA-/Cre-) 
previously and discussed in detail. The leukemic mice, as expected, 
showed significant alterations in their hematopoietic compartment. 
The hematopoietic cells from the CA+/Mb1-Cre+ and CA+/CD19-
Cre+ mice that expressed CALM/AF10 in B cells and did not develop 
leukemia showed quite a normal immunophenotype with very few 
exceptions. 
For an overall picture, we compared the hematopoietic 
compartments of leukemic and non-leukemic mice expressing 
CALM/AF10. In the following figures, we show the 
immunophenotype of the hematopoietic cells from the leukemic 
CA+/Vav-Cre+ mice and the non-leukemic CA+/Mb1-Cre+, 
CA+/CD19-Cre+ mice together with our control group. 
Fig 3.48: Comparative immunophenotype of the peripheral blood cells from the 
control mice, CA+/Mb1-Cre+ mice, CA+/CD19-Cre+ mice and the leukemic 
CA+/Vav-Cre+ mice. The bar graphs represent the average number of positive cells 
for each surface marker or their combination. Error bars represent the standard 
deviation. In the leukemic mice there is a massive expansion of the myeloid 
compartment shown here by high number of Gr1+, Mac1+ and Gr1+/Mac1+ cells. In 
the peripheral blood of CA+/CD19-Cre+ mice, the number of B220+ and CD19+ B 
cells is very high. But in these non-leukemic mice the number of myeloid cells and T 
lymphocytes appear normal according to our assay. 
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Fig 3.49: Immunophenotypes of the bone marrow cells from the control mice, 
CA+/Mb1-Cre+ mice, CA+/CD19-Cre+ mice and the leukemic CA+/Vav-Cre+ 
mice. The bar graphs represent the average number of cells positive for each 
surface marker or their combination. Error bars represent the standard deviation. In 
the bone marrow of the leukemic mice there is an expansion of the myeloid 
compartment with high numbers of Gr1+, Mac1+, Gr1+/Mac1+ cells and CD43+ 
cells.  
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Fig 3.50 Comparative immunophenotype of the spleen cells from the control 
mice, CA+/Mb1-Cre+ mice, CA+/CD19-Cre+ mice and the leukemic CA+/Vav-
Cre+ mice. The bar graphs represent the average number of cells positive for each 
surface marker or their combination. Error bars represent the standard deviation. 
Leukemic spleen cells show very high expression of myeloid markers like Gr1, Mac1 
as expected. Surprisingly, the number of Mac1 positive cells is very high in the 
spleen of CA+/Mb1-Cre+, even comparable to the spleen cells from the CA+/Vav-
Cre+ mice with leukemia. We can also see low number of Sca1+ cells in the 
leukemic spleen. The number of CD4+, CD3+ and CD8+ T cells is also reduced. The 
spleen cells of the other groups do not share these features. Spleen cells from 
CA+/CD19-Cre+ mice show a normal immunophenotype. 
3.1.5.2 Comparable levels of the CALM/AF10 fusion transcript were 
detected in the leukemic bone marrow cells and non-leukemic 
cells of CA+/Mb1-Cre+ mice 
To determine the level of the CALM/AF10 fusion transcript in the 
bone marrow and spleen of the leukemic CA+/Vav-Cre+ mice and 
in the bone marrow and the B cells of non-leukemic CA+/Mb1-Cre+ 
mice, we performed a real time RT-PCR assay. 
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cDNA was isolated from the unsorted bone marrow cells of 3 
leukemic CA+/Vav-Cre+ mice, the unsorted spleen cells of 4 
leukemic CA+/Vav-Cre+ mice, unsorted bone marrow cells of 3 
non-leukemic CA+/Mb1-Cre+ mice and B220 marker positive MACs-
sorted B cells of 6 CA+/Mb1-Cre+ mice (age 12 months) and 3 
CA+/CD19-Cre+ mice (age 18 months). cDNA from the U937 cell 
line was used as a positive control for the CALM/AF10 transcript. As 
mentioned earlier, the CALM/AF10 fusion was originally cloned from 
the U937 cell line. Realtime RT PCR was performed to analyze the 
expression of CALM/AF10 transcript using primers detecting the 
CALM/AF10 breakpoint. Both the 18s rRNA gene and the beta actin 
gene transcripts were used as controls for cDNA quantity and 
integrity in this assay. 
The CALM/AF10 transcript had the highest expression in the 
leukemic spleen and was expressed at comparable levels in the 
leukemic bone marrow of CA+/Vav-Cre+ mice and in the B cells of 
CA+/Mb1-Cre+ and CA+/CD19-Cre+ mice. The CALM/AF10 
transcript was detected at slightly lower levels in the bone marrow 
of the CA+/Mb1-Cre+ mice. This observation is probably due to the 
fact that the expression of CALM/AF10 is restricted to B cells in 
CA+/Mb1-Cre+ mice and that the B cells constitute only a smaller 
percentage of the bone marrow cells. The CT values of the 
CALM/AF10 transcript in the different tissues, normalized to the 
beta-actin expression are shown in figure 3.51. 
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Fig 3.51: Detection of the CALM/AF10 transcript in the bone marrow and spleen cells of 
the leukemic CA+/Vav-Cre+ mice and in the B cells of non-leukemic CA+/Mb1-Cre+, 
CA+/CD19-Cre+ mice and U937 cell line.. Bar graphs represent the CTvalue of CALM/AF10 
transcript normalized to the expression of the endogenous control beta-actin. Bone marrow 
cells from 3 leukemic mice, spleen cells from 4 leukemic mice, B220+ B cells from 6 
CA+/Mb1-Cre+ mice and 3 CA+/CD19-Cre+ mice are assayed. The error bars represent the 
standard deviations among the biological replicates. As a positive control, the U937 cell line 
was used. Three technical replicates were assayed for all samples. For U937, error bars 
represent the standard deviation between the technical replicates. 
 
3.1.5.3 The HoxA cluster genes and the Hox co-factor Meis1 are 
overexpressed in leukemic cells from CA+/Vav-Cre+ mice 
Hox genes play important roles in hematopoietic differentiation and 
changes in their expression levels are found in several 
hematological malignancies. Several HoxA cluster genes are 
overexpressed in CALM/AF10 positive T-ALL patients (Dik et al., 
2005). The expression of Hoxa5, Hoxa7, Hoxa9, Hoxa10, Hoxb4, 
Bmi1 and the Hox co-factor Meis1 was assayed using real time RT-
PCR in leukemic and normal bone marrow and spleen cells from 
CA+/Vav-Cre+ and wild type control mice (CA-/Cre-).  
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cDNA was isolated from the unsorted bone marrow cells of 4 
leukemic CA+/Vav-Cre+ mice. In 3 cases there were more than 
80% blasts cells present in the bone marrow. One of the samples 
had 50% blast in the bone marrow. Among these mice two mice 
had myeloid leukemia and two mice had the biphenotypic type of 
AML. As controls, we have used unsorted bone marrow cells from 3 
wildtype mice (CA-/Cre-). From the immunophenotype we know 
that the bone marrow of the leukemic mice contains very different 
cell populations compared to the wild type bone marrow. We used 
the control bone marrow cells just to set a normal base line for the 
expression of the genes we tested. As internal control both the 18s 
rRNA gene and beta actin were used. 
All the tested genes from the Hoxa cluster and Meis1 showed higher 
expression levels in the leukemic bone marrow. The expression 
level of the tested genes did not vary among the leukemic samples. 
The sample with 50% blasts also had very high levels of Hoxa 
cluster gene and Meis1 expression. 
Bmi1, a polycomb group gene, was also overexpressed in the 
CALM/AF10 positive T-ALL patient samples reported by Dik and 
colleagues (Dik et al., 2005). The Bmi1 transcript showed just 
slightly higher (2 to 3 fold) expression levels in the leukemic bone 
marrow. Hoxb4 was taken as a control outside the HoxA cluster and 
as a Hox gene that is not usually over-expressed in leukemic cells. 
The results are summarized in figure 3.52 A and B. 
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Fig 3.52: Quantification of the Hoxa gene and Meis1 transcript levels in the 
leukemic bone marrow of CA+/Vav-Cre+ mice (N=4) relative to transcript levels 
in bone marrow from wild type mice (N=3). RNA transript analysis for Hoxa5, 
Hoxa7, Hoxa9, Hoxa10, Meis1 was performed using real time RT-PCR from bone 
marrow samples from 4 leukemic CA+/Vav-Cre+ and 3 wild type mice. For each 
sample, 3-6 technical replications were assayed. As endogenous control, both beta-
actin and 18srRNA were used. In the chart, the ΔCT values were calculated using 
beta actin. The expression of Hoxa5, Hoxa7, Hoxa9, Hoxa10, Meis1, Bmi1 and 
Hoxb4 was normalized to beta actin. Chart A shows the normalized expression level 
of each transcript in leukemic and wild type bone marrow. The error bars show 
standard deviation among biological replicates. All the Hoxa cluster genes have 
lower CT value in leukemic samples. Chart B shows the fold change in the 
expression level of each transcript compared to wild type bone marrow. The Hoxb4 
gene is from the HoxB cluster and does not show higher expression levels in the 
leukemic cells. The Bmi1 transcript is expressed at slightly higher levels in the 
leukemic cells (1.33 fold) and all the HoxA genes are expressed from 13 to 27 fold 
higher in the leukemic bone marrow. 
 
cDNA was isolated from the unsorted spleen cells of 4 leukemic 
CA+/Vav-Cre+ mice. Among the 4 chosen leukemias, all of them 
had more than 80% blasts in the bone marrow. Out of the 4 
leukemias, 2 were myeloid and the other two biphenotypic. As 
controls we used cDNA from spleens of 3 wildtype mice. We 
assayed the level of Hoxa5, Hoxa7, Hoxa9, Meis1 and Hoxb4 
transcripts in the leukemic spleen and compared it with their 
expression levels in the spleen cells from wild type mice (CA-/Cre-). 
18s rRNA gene and beta-actin gene were used as endogenous 
controls. The results are summarized in figure 3.53 A and B. We 
could not detect Hoxa7 and Hoxa9 in wild type spleen cells but in 
leukemic samples these transcripts were present at a reasonably 
high level. Hoxa5 and Hox co-factor Meis1 showed very high levels 
  
 
116 
of expression in the leukemic spleen. Hoxb4 expression was 
unchanged. The expression of Hoxa10 transcript was detectable 
neither in wild type nor in leukemic spleen cells. We did not perform 
qRT-PCR for Bmi1 transcript on spleen samples. 
 
Fig 3.53: Relative quantification of the Hoxa gene and Meis1 transcripts in the 
leukemic spleen of CA+/Vav-Cre+ mice compared to transcript levels in normal 
spleen. RNA transcript analysis for Hoxa5, Hoxa7, Hoxa9, Meis1 and Hoxb4 was 
performed using realtime RT-PCR on 4 leukemic and 3 wildtype spleen samples. For 
each sample, 3-6 technical replications were performed. Chart A shows the 
normalized expression level of each transcript (ΔCT) in leukemic and wildtype spleen. 
The ΔCT calculations in this chart were preformed using beta actin as endogenous 
control. We could not detect Hoxa7 and Hoxa9 transcripts in wildtype spleen cells, 
which are marked with red stars. The chart B shows the fold expression changes of 
Hoxa5, Hoxb4 and Meis1 transcripts, compared to wild type spleen cells. The Hoxb4 
gene is from the HoxB cluster and does not show higher expression levels in the 
leukemic cells. Meis1 shows 58 fold higher expression in the spleen cells from the 
leukemic CA+/Vav-Cre+ mice compared to spleen cells from wild type mice. We 
could not calculate the fold change for Hoxa7 and Hoxa9 as they were not detectable 
in wild type spleen cells. 
.  
3.1.5.4 The Hoxa cluster and Meis1 overexpression is only found in 
the leukemic cells from CA+/Vav-Cre+ mice and not in non-
leukemic cells of CA+/Mb1-Cre+ mice  
Real time RT-PCR was performed to measure the expression of the 
HoxA cluster genes and Meis1 transcripts in the B cells from 3 
healthy CA+/Mb1-Cre+ and 4 wildtype (CA-/Cre-) mice. B220+ 
cells were isolated from the spleen cells of three 1 year old 
CA+/Mb1-Cre+ mice using MACs seperation. In these B cells, the 
CALM/AF10 fusion gene is expressed after Mb1-Cre-mediated 
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recombination. We already showed the expression of the 
CALM/AF10 fusion transcript in these cells (Fig 3.51). As controls, 
cDNA from isolated B220+ B cells from the spleen of 4 wild type 
(CA-/Cre-) mice was used. We measured the expression of Hoxa5, 
Hoxa7, Hoxa9, Meis1, Bmi1 and Hoxb4 transcripts. 18s rRNA and 
beta actin were used as endogenous controls. We wanted to 
compare the expression level of these tested genes between 
CALM/AF10 expressing B cells and the wild type B cells. We were 
not able to detect Hoxa7, Hoxa9 and Hoxa10 transcripts in any of 
the samples. 
Hoxa5 gene or Meis1 expression levels were not significantly 
different between B cells from CA+/Mb1-Cre+ and wild type mice. 
The results are summarized in figure 3.54 
  
Fig 3.54:  Relative quantification of the Hoxa genes and Meis1 transcript levels 
in B cells from CA+/Mb1-Cre+ and wild type mice. Real time PCR assays for 
Hoxa5, Hoxa7, Hoxa9, Meis1, Bmi1 and Hoxb4 were performed on RNA from 
CA+/Mb1-Cre+ and wild type mice. B cells from 3 CA+/Mb1 Cre+ mice and from 4 
wild type mice were used for this assay. For each samples 3-6 technical replicates 
were performed.  We could not detect Hoxa7, Hoxa9 or Hoxa10 in any of the 
samples. The chart A shows the normalized levels of transcripts (ΔCT ) in the B cells 
from wild type and CA+/Mb1-Cre+mice. For the normalization and calculation of ΔCT, 
beta actin was used as endogenous control. Note that all the detected transcripts 
show similar ΔCT value in both samples. In chart B, the fold change in expression is 
shown. Hoxa5  and Meis1 transcripts show 2.9 fold and 1.9 fold higher expression in 
CA+/Mb1-Cre+ B cells, respectively, but the error rate is very high and the difference 
is not statistically significant. The P value for Hoxa5 is 0.43 and for Meis1, it is 0.08. 
  
 
118 
Summary:  
To summarise our work with the tissue-specific, inducible knock-in 
mouse model of CALM/AF10 (R26SLSCA mice), we could show that 
the CALM/AF10 fusion is only leukemogenic when expressed in cells 
that have Vav promoter activity. Thus CALM/AF10 needs to be 
expressed in the right cell at the right stage during hematopoietic 
development. When CALM/AF10 is expressed in the whole 
hematopoietic compartment after Vav-Cre-mediated recombination 
an aggressive AML develops with 100% penetrance and a median 
latency of about 1 year. In contrast, a more B cell compartment 
restricted expression of CALM/AF10 using CD19-Cre and Mb1-Cre-
mediated recombination, does not lead to the development of 
leukemia. Hematopoietic cells from the leukemic mice showed 
overexpression of HoxA cluster genes and the Hox co-factor Meis1. 
We could not detect overexpression of HoxA cluster genes or Meis1 
in the hematopoietic cells of non-leukemic mice that expressed 
CALM/AF10 (the CA+/Mb1-Cre+ mice).  
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3.2 A murine retroviral bone marrow transplantation model 
to examine the role of BMI1 in CALM/AF10-mediated 
leukemias 
A murine retroviral bone marrow transplantation model was 
developed to investigate the role of BMI1 in CALM/AF10-induced 
leukemia. BMI1 (B lymphoma Mo-MLV insertion region 1 homolog) 
is a polycomb group gene, and its transcript is consistently 
upregulated in CALM/AF10-positive T ALL and AML patients (Dik et 
al., 2005; Mulaw et al., 2012) and in a murine CALM/AF10 bone 
marrow transplantation leukemia model (Mulaw et al., 2012) 
To investigate the role of BMI1 in collaborating with CALM/AF10 in 
leukemogenesis, we co-expressed BMI1 with the CALM/AF10 fusion 
in murine bone marrow cells. To achieve this goal, we used two 
approaches. In the first approach, BMI1 was retrovirally expressed 
in the bone marrow cells from the transgenic mouse line IgH-
CALM/AF10. Alexandre Krause generated this mouse line, on the 
FVB background, in our lab. These animals express the CALM/AF10 
fusion under the control of the immunoglobulin heavy chain 
enhancer/promoter in mature B cells but do not develop leukemia 
(Krause, 2006). Bone marrow cells from the IgH-CALM/AF10 mice 
were retrovirally transduced with a BMI1 expressing retrovirus. 
Successfully transduced cells were transplanted via tail vein 
injection into syngeneic lethally irradiated wild type FVB recipient 
mice. 
In the second approach, bone marrow cells from FVB wild type mice 
were co-transduced with two retroviruses. One virus contained the 
CALM/AF10 open-reading frame (pMIG-CALM/AF10) and the other 
virus contained the BMI1 gene (pMIY-BMI1). Successfully 
cotransduced bone marrow cells would co-express both the green 
and the yellow fluorescent protein. The double transduced cells 
were flow-sorted and then injected into lethally irradiated wild type 
FVB recipients. 
3.2.1 Approach 1: Retroviral expression of BMI1 in the bone 
marrow cells from IgHCALM/AF10 transgenic FVB mice 
IgH(E/P)CALM/AF10 is a transgenic FVB mouse line in which the 
expression of the CALM/AF10 fusion gene is under the control of the 
B cell specific IgH promoter and enhancer. Expression of the 
CALM/AF10 fusion in these mice is found in mature B cells. These 
mice do not develop leukemia, even at old age (18 months). For the 
first transplantation model these mice were used as the bone 
marrow donors. In the bone marrow from these mice, human BMI1 
was overexpressed using retroviral transduction. Below is a 
schematic of the experimental design. 
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Fig 3.55: Flow chart of the first transplantation model. The bone marrow donors 
were the IgHCALM/AF10 transgenic FVB mice and the recipients were wild type FVB 
mice. 5FU treated bone marrow cells were transduced with the pMIY-BMI1 
retrovirus, and successfully transduced cells were transplanted into the wildtype 
recipients.  
3.2.1.1 The retrovirus producer cell line E86-BMI1-FLAG-YFP 
The E86-BMI1-FLAG-YFP cell line was kindly provided by Dr Keith 
Humphries (Terry Fox Laboratory, British Columbia Cancer Agency, 
Vancouver British Columbia, Canada). This E86-BMI1-FLAG-YFP cell 
line contains a MSCV vector with a C-terminally FLAG-tagged BMI1 
cDNA. The BMI1 cDNA is followed by Internal Ribosome Entry Site 
(IRES) and by the YFP gene (Figure 3.56).  
  
 
Figure 3.56: Map of the pMIY-BMI1 construct  
 
The E86-BMI1-FLAG-YFP cell line is a high titer pMIY-BMI1 
retrovirus producing cell line. We performed Western blot analysis 
to assay the production of the BMI1-FLAG protein. As can be seen in 
figure 3.57, the FLAG-tagged human BMI1 protein could be 
detected in extracts from the E86-BMI1-FLAG-YFP retrovirus 
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producer cell line and in retrovirally transduced bone marrow cells. 
The BMI1 protein could not be detected in E86 cells transduced with 
the empty pMIG vector or in non-transduced bone marrow cells. 
 
Fig 3.57: Western blot using anti-FLAG and anti hu-BMI1 antibodies. The first 
two lanes (1, 2) from each blot contain the protein extract from control E86-MIG cells, 
(E86 transduced with the empty vector pMIG), lanes 3 and 4 contain the extract from 
non-transduced murine bone marrow cells; lanes 5 and 6 contain the extract from the 
E86-BMI1-FLAG-YFP cell line and the last two lanes contain protein extracts from 
pMIY-BMI1 transduced murine bone marrow cells. In the upper panel the anti FLAG 
antibody was used. In the expected lanes (lane 5, lane 6, lane 7, lane 8), the BMI1-
specific band is visible at around 50 kDa. In the lower panel, the anti human BMI1 
antibody detects a specific band BMI1 band at around 50 kDA molecular weight.. 
3.2.1.2 Transplantation experiments with pMIY-BMI1 transduced 
IgH-CALM/AF10 bone marrow  
In order to express the CALM/AF10 fusion and BMI1 together in 
murine bone marrow, bone marrow cells from 5FU-treated IgH-
CALM/AF10 transgenic donor mice were retrovirally transduced 
using the E86-BMI1-FLAG-YFP cell line. YFP positive bone marrow 
cells were sorted using fluorescence activated cell sorting (FACS). 
0.5x106 YFP positive cells together with 0.5x106 non-transduced 
bone marrow cells were transplanted into the lethally irradiated FVB 
mice via tail vein injection.  
As controls, bone marrow cells from wild FVB mice transduced with 
pMIY-BMI1 or the empty vector (pMIY) were used. 0.5x106 YFP 
positive cells and 0.5x106 non-transduced cells were injected into 
the tail vein of FVB wild type mice. As a third control group, bone 
marrow cells from the transgenic IgH-CALM/AF10 mice were 
transduced with pMIY and transplanted together with non-
transduced cells into FVB wild type recipients. The number of 
transplanted animals in the different experimental groups is shown 
in table 3.3: 
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3.3 Summary of the transplantation experiments: The number of mice 
transplanted with different constructs is summarized in this table. The first column 
includes the different experimental groups; in the second column the constructs used 
for each group of experiment are listed. In the third and fourth columns the 
strain/genetic background of the donor and recipient mice are listed. The last column 
contains the number of transplanted animals for each group. 
Experimental 
group 
Construct Bone marrow 
donor 
Bone 
marrow 
recipient 
Number of  
recipients 
tr-IgH-
CA&BMI1 pMIY-BMI1 
FVB IgH-
CALM/AF10 
transgenic mice 
FVB wild type 12 
WT-FVB&BMI1 
pMIY-BMI1 FVB wild type  FVB wild type 
12 
tr-IgH-CA&MIY 
pMIY 
FVB IgH-
CALM/AF10 
transgenic mice 
FVB wild type 7 
WT-FVB&MIY 
pMIY FVB wild type FVB wild type 
9 
 
3.2.1.3 Transplanted BMI1 expressing bone marrow cells do not 
show any growth advantage in vivo 
To assay the engraftment of the transduced bone marrow cells, we 
collected peripheral blood 4 - 6 weeks after the transplantation and 
measured the percentage of YFP-positive cells using flow cytometry. 
The transplanted animals from all the experimental groups showed 
a wide range in the proportion of YFP-positive cells from a very low 
percentage in some mice to more than 70% YFP-positivity in others. 
The median YFP-positivity was 44%. In all cases we had 
transplanted the same number of YFP-positive, retrovirally 
transduced and non-transduced bone marrow cells. There was no 
significant growth advantage of the transduced cells over the non-
transduced cells in any of the experimental groups. 2 mice out of 
the total 12 transplanted mice in tr-IgHCA&BMI1 experimental 
group were not engrafted 
The percentage of YFP-positive cells in the peripheral blood from the 
mice of the experimental groups, 4 weeks after transplantation is 
show in figure 3.58. 
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 Fig 3.58:  Percentage of YFP-positive cells in the peripheral blood of 
transplanted mice from different experimental groups. The analysis was 
performed between 4 and 6 weeks after the transplantation. 
 
3.2.1.4 Eight of 12 mice from the tr-IgH-CA&BMI1 group developed 
leukemia  
Eight of the 12 mice from the tr-IgH-CA&BMI1 group became sick 
and had to be sacrificed.  
Of the 8 sick animals, 5 mice developed acute myeloid leukemia in 
101 days (5625A#1), 197 days (5625A#2), 246 days (5619A#2), 
314 days (5619B#1) and 461 days (5619B#2) post transplantation. 
The post mortem analysis revealed in all the sick mice signs and 
symptoms of leukemia like splenomegaly leukocytosis, and the 
presence of immature blastic cells in the peripheral blood. Only in 
one of the 5 mice (5619A#2), the number of WBCs in the peripheral 
blood was in the normal range (6 million/ml) and the spleen size 
was also normal (124 mg). But this mouse had abnormal numbers 
of myeloid marker positive cells and cKit positive immature cells in 
the peripheral blood bone marrow and spleen. 
2 out of 8 sick animals developed T-ALL in 101 days (5625B#2) and 
219 days (5619A#1) post transplantation. Both the mice had a very 
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high number of leukocytes in their peripheral blood. The FACs 
analysis revealed the presence an abnormal CD4/CD8 double 
positive immature T lymphocyte population in the peripheral blood, 
bone marrow and spleen cells of these two mice. These abnormal 
double positive cells were surprisingly YFP-negative. Cytospin 
preparations from the peripheral blood bone marrow and spleen 
cells of these two mice revealed the presence of immature 
lymphoblasts (∼ 80%). 
The remaining one mouse (5625B#1) out of the 8 sick animals was 
sacrificed 123 days post transplantation. Before it was sacrificed it 
showed signs of difficulties while eating moving and breathing. But 
the post-mortem analysis on this mouse did not lead us to a 
conclusive diagnosis. The mouse had a spleen slightly bigger than 
normal (175 mg) and WBC count in the peripheral blood was also 
higher than normal (12 million/ml). In the peripheral blood we did 
not detect any YFP positive cell. In the bone marrow and spleen 3% 
and 25%, respectively, of the cells were YFP positive. Flow 
cytometric analysis revealed that the mouse had a normal 
percentage of myeloid and lymphoid cells. However, Sca1 positive 
cells were abnormally high in blood (41%) and bone marrow 
(91%). We could detect immature blast cells of myeloid lineage in 
the peripheral blood smear and bone marrow cytospin of this 
mouse.  
Four out of the 12 mice from the tr-IgH-CA&BMI1 group remained 
healthy during the observation period. Of these 4 healthy mice, 2 
mice had very low percentages of YFP-positive cells (2-3%) in the 
peripheral blood 4 weeks after transplantation. The other 2 mice 
had no YFP-positive cells in their peripheral blood 6 weeks after 
transplantation.  
The leukemia phenotype, engraftment at the time they were 
sacrificed and diagnosis of the mice from the tr-IgH_CA&BMI1 
group is summarised in table 3.4.  
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3.4 Summary of the characteristics of the 8 leukemic mice of the tr-IgH-
CA&BMI1 group  
 
Mouse ID Latency 
(Days post 
transplanta
tion) 
Clinical 
features 
YFP+ cells 
(Measured 
when the 
mouse was 
sacrificed) 
Diagnosis Histology 
5625A#1 101 Splenomegaly
, weight 
650mg 
Leukocytosis 
PB-21% 
BM-36% 
Spl-44% 
Myeloid 
Leukemia 
Immature 
cells in PB, 
BM, Spl 
cytospins 
5625A#2 197 Splenomegaly
, weight 330 
mg 
Leukocytosis 
PB-30% 
BM-86% 
Spl-52% 
Myeloid 
leukemia 
Presence of 
immature 
cells in PB, 
BM, Spl 
cytospins 
5625B#1 123 Slightly bigger 
spleen, weight 
175 mg 
Leukocytosis 
PB- 0% 
BM-3% 
Spl-23% 
not 
diagnosed 
few immature 
blastic cells in 
the PB smear 
5625B#2 101 Small spleen, 
weight 90 mg, 
Leukocytosis 
PB- 0% 
BM-3% 
Spl-3% 
T-ALL Many blasts in 
the peripheral 
blood 
5619A#1 219 Splenomegaly
, spleen 
weight 515 
mg, 
Leukocytosis 
PB-1% 
BM-18% 
Spl-14% 
T-ALL Presence of 
lymphoblasts, 
in peripheral 
blood all the 
cells were 
CD4 and CD8 
double 
positive. 
5619A#2 246 Normal 
spleen, weight 
124 mg 
WBC count 
normal 
PB-9% 
BM-4% 
Spl-17% 
Myeloid 
leukemia 
A few 
immature 
blastic cells in 
the peripheral 
blood. 
5619B#1 341 Splenomegaly
, weight 771 
mg 
Leukocytosis 
PB-42% 
BM-43% 
Spl-23% 
Myeloid 
leukemia 
Not 
determined 
5619B#2 461 Slightly bigger 
spleen, weight 
168 mg, 
Leukocytosis 
PB-32% 
BM-12% 
Spl-28% 
Myeloid 
leukemia 
Immature 
myeloid cells 
in the 
peripheral 
blood smear 
and bone 
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marrow 
cytospin 
 
Leukocytosis 
Post mortem analysis revealed that 7 out of 8 leukemic mice of the 
tr-IgH-CA&BMI1 group had a high number of WBC in the peripheral 
blood when they were sacrificed. One mouse had a WBC count of 6 
million/mL, which is in the normal range. For the comparison we 
have used the WBC count of 5 wild type FVB mice as control. 
 
 
Fig 3.59: Distribution of the WBC counts in the 7 leukemic mice from the tr-IgH-
CA&BMI1 group at the time of diagnosis and wild type FVB controls 
Splenomegaly:  
The average weight of a normal sized spleen from wild type FVB 
mouse is 120 mg. 4 out of 8 leukemic mice from the tr-IgH-
CA&BMI1 group had very large spleens weighing from 330 mg to 
770 mg. Among the other 4 leukemic mice, spleen was slightly 
enlarged (168 mg, 175 mg) in 2 cases. One leukemic mouse had a 
normal-sized spleen weighing 124 mg. Another mouse with T-ALL 
had a very small spleen of 90 mg. 
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Fig 3.60: Spleens from leukemic mice from the tr-IgH-CA&BMI1 group and 
healthy mice.  
3.2.1.5 Engraftment of the leukemic mice from the tr-IgH-CA&BMI1 
group 
After sacrificing the leukemic animals, cells from the peripheral 
blood, bone marrow and spleen were extracted and the percentage 
of YFP-positive cells was determined. The percentage of YFP-
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positive cells in the PB, BM and spleen of the leukemic mice is 
shown in figure 3.61.  
  
Fig 3.61: The percentage of YFP-posistive cells in the peripheral blood, bone 
marrow and spleen of the leukemic mice from the tr-IgH-CA&BMI1 group. The 
animals are marked with the type of leukemia they developed. In mouse 5625B#1 
and 5625B#2 there were no YFP-positive cells in the peripheral blood.  
  
3.2.1.6 Presence of the blast cells in the peripheral blood of the 
leukemic mice from the tr-IgH-CA&BMI1 group 
We observed immature cells with big nuclei and bluish cytoplasm in 
the peripheral blood smear from the leukemic mice. 
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Fig 3.62: Giemsa-May-Grünwald stained peripheral blood smear of leukemic 
mice from the tr-IgH CA&BMI1 group.  Peripheral blood smears from 4 leukemic 
mice are shown in the figure (Magnification 63x). The cells marked with green arrows 
are blasts. In mouse 5619B#2, many myeloblasts are visible, whereas in mouse 
5625B#2, immature lymphoblasts can be seen. 
 
3.2.1.7 Flow cytometric analysis of cells from the hematopoietic 
organs of the leukemic mice from the tr-IgH-CA&BMI1 group 
The peripheral blood, bone marrow and spleen cells from the 
leukemic mice were analysed by flow cytometry. On the basis of the 
immunophenotype the mice were divided into two groups: one 
group consisting of two mice showing signs of acute T cell leukemia. 
In the other group consisting of 6 mice, 5 animals showed marked 
splenomegaly, high white blood cell count and a disturbed 
haematopoietic differentiation with a myeloid bias compatible with 
the diagnosis of AML.  1 mouse had a spleen slightly bigger than 
normal and many immature cells in the peripheral blood smear and 
bone marrow cytospins. 
In the following figures, the immunophenotype of the hematopoietic 
tissues of the leukemic animals from the two groups are compared 
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with the wild type controls. Cells from the peripheral blood, bone 
marrow and spleen from the leukemic and wild type control mice 
were analyzed by flow cytometry using the following antibody 
combinations: Gr1-PE/Mac1-APC; Sca1-PE/cKit-APC; B220-
PE/Ter119-APC; CD4-PE/CD8-APC (PE: phycoerithrin; APC: 
Allophycocyanin). The percentage of cells positive for each epitope 
from the individual leukemic animals is summarized in appendix 
table A8 
3.2.1.8 Immunophenotype of the two mice from the tr-IgH-
CA&BMI1 group that developed T-ALL 
Two mice from the tr-IgH-CA&BMI1 group (5619A#1 and 5625B#2) 
developed signs and symptoms of T-ALL. The immunophenotype of 
the cells from blood, bone marrow and spleen are summarized and 
are graphically represented in the following figures. For comparison 
we show the immunophenotype of the hematopoietic cells from wild 
type FVB mice. 
 
Fig 3.63: Immunophenotype of the peripheral blood cells from two mice of the 
tr-IgH-CA&BMI1 group that developed T-ALL and the wild type controls. A. 
Summary of the cell surface markers from leukemic blood and control blood; 
B. Flow cytometry of PB cells using CD4 and CD8 antibodies. In figure A the 
expansion of the lymphoid compartment (CD4+/CD8+ cells) is clearly visible. Most of 
the cells belong to an abnormal population of CD4/CD8 double positive cells. The 
myeloid compartment is considerably reduced. In figure B the scatter plot from the 
peripheral blood cells from mouse 5619A#1 shows that almost 80% of the PB cells 
are CD4 and CD8 double positive.  
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Fig 3.64: Immunophenotype of the bone marrow cells from the two mice from 
the tr-IgH-CA&BMI1 group with T-ALL. In the bone marrow a few CD4/CD8 double 
positive cells are detected. In mouse 5619A#1 number of Gr1+ cells and CD4+ cells 
are very high. In mouse 5625B#2 we could not detect any myeloid marker Mac1 
positive cell. Number of B220 positive cells is significantly reduced in both leukemic 
mice. 
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Fig 3.65: Immunophenotype of the spleen cells from the two mice from the tr-
IgH-CA&BMI1 group with T-ALL. In both leukemic mice, the number of B220+ B 
cells is reduced significantly. The number of CD4+ and CD8+ T cells is very high in 
mouse 5619A#1. The abnormal population of immature T cells staining both for CD4 
and CD8 is also present in both leukemic mice. 
 
 3.2.1.9 Immunophenotype of tr-IgH-CA&BMI1 mice with AML 
6 mice from tr-IgH-CA&BMI1 group developed AML. The 
immunophenotype of the hematopietic cells are summarized in the 
following figures. The immunophenotype of the hematopoietic cells 
from 3 wild type FVB mice are used as controls. In the following 
figures 3.66, 3.67 and 3.68, the immunophenotype of the tr-IgH-
CA&BMI1 mice with AML are summarized along with our standard 
controls. 
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Fig 3.66: Immunophenotype of the peripheral blood cells from the six mice 
from the tr-IgH-CA&BMI1 group with AML.. The myeloid compartment is 
expanded and the percentage of cKit-positive immature cells is higher in the 
peripheral blood of the leukemic mice than in the wild type mice. 
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Fig 3.67: Immunophenotype of the bone marrow cells from the six mice from 
the tr-IgH-CA&BMI1 group with AML. The myeloid compartment in the bone 
marrow is greatly expanded in the leukemic mice compared to the wild type animals. 
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Fig 3.68: Immunophenotype of the spleen cells from the six mice from the tr-
IgH-CA&BMI1 group with AML. There is some expansion of the myeloid 
compartement in the spleen as well. 
In the peripheral blood and the bone marrow cells of the 6 mice 
with AML, a significant exapansion of the myeloid compartment is 
seen. The percentage of Gr1 and Mac1 positive cells is significantly 
higher in both the PB and BM. 
3.2.1.10 Secondary Transplantation 
The unsorted leukemic bone marrow cells from 3 sick mice (2 mice 
with AML, 1 mouse with T-ALL) were retransplanted into one 
irradiated and one non-irradiated wild type FVB recipient mouse for 
each leukemia sample. For the transplantation, 1x106 cells from the 
leukemic bone marrow sample and 2x106 normal bone marrow cells 
were injected into the tail vein.  
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Leukemic cells from the AML mice 5619B#1 and 5625A#1 
generated acute myeloid leukemia within 20 days post 
transplantation proving that the leukemic cells observed in these 
two mice were indeed leukemic cells and capable of propagating the 
leukemic phenotype.  
However, the leukemic cells from mouse 5625B#2, which had 
developed ALL, did not lead to leukemia development in two 
transplanted animals even after a long observation period of 1 year.  
The Kaplan-Meier survival plot in figure 3.69 gives an overview of 
the survival of the mice in all four groups as well as the 6 animals of 
the secondary transplantation group. The actual days of survival of 
individual animals from each experimental group have been 
summarized in table A9 in the appendix. 
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Fig 3.69: Kaplan-Meier survival plot for FVB mice transplanted with pMIY-BMI1 
or pMIY transduced IgH-CALM/AF10 transgenic or wild type bone marrow cells. 
The survival plot of the following 5 groups is shown in the plot.  The observation 
period was 400 days and only the mice, which died of leukemia, are counted here. 
The non-leukemic animals we lost due to some other reason during our observation 
periods are censored. 4 mice from the tr-IgH-CA&BMI1 group were alive after 400 
days. 
Twelve mice transplanted with bone marrow cells from transgenic IgH-CALM/AF10 
mice transduced with pMIY-BMI1. This group is labeled as “tr-IgH-CA&BMI1” (n=12). 
Eight mice developed leukemia (6 AML and 2 T-ALL), four mice were still alive after 
400 days. 
Seven mice transplanted with bone marrow cells from transgenic IgH-CALM/AF10 
mice transduced with pMIY. This group is labeled as “tr-IgH-CA&MIY” (n=7). None of 
these animals developed leukemia. After 158 days post-transplantation 1 tr-IgH-
CA&MIY mouse had to be sacrificed because of infectious wound caused by fighting 
with another mouse. This animal was censored. 
Twelve mice transplanted with bone marrow cells from wild type FVB mice 
transduced with pMIY-BMI1. This group is labeled as “WT-FVB&BMI1” (n=12). None 
of these animals developed leukemia. 341 days post-transplantation, one WT-
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FVB&BMI1 mouse was sacrificed. A post mortem analysis revealed no leukemia. 
This animal has been censored. 
Nine mice transplanted with bone marrow cells from wild type FVB mice transduced 
with pMIY. This group is labeled as “WT-FVB&MIY” (n=9). None of these animals 
developed leukemia. Two animals from this group were sacrificed 182 days after 
transplantation because of severe injuries due to fighting with each other. These two 
animals were also censored. 
Six mice transplanted with the leukemic cells from the bone marrow of mice from the 
tr-IgH-CA&BMI1 group. Labeled as “secondary transplants”. Note that in this group 
only the four animals transplanted with cells from two mice with AML developed 
leukemia after a short latency of 20 days. 
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3.2.2. Approach 2: Co-transduction of wild type bone marrow 
cells with the CALM/AF10-minimal fusion gene and BMI1 and 
transplantation into FVB wild type recipients 
 
In our second approach to test the cooperation of CALM/AF10 with 
BMI1, bone marrow cells from wild type FVB mice were retrovirally 
co-transduced with two retroviruses, one expressing BMI1 and the 
other expressing the CALM/AF10 minimal fusion protein (MF). The 
successfully co-transduced bone marrow cells were transplanted 
into wild type FVB recipient mice. The workflow is shown in figure 
3.70: 
 
Fig 3.70: Schematic workflow of the transplantation model 2. 
3.2.2.1 The CALM/AF10 minimal fusion 
Deshpande et al. described a deletion mutant of the CALM/AF10 
fusion, which contains only the 248 C terminal amino acids of the 
CALM protein (aa 400-648) including the clathrin binding domain, 
and a small portion of AF10 including the octapeptide motif/leucine 
zipper (OM/LZ) domain of AF10 (aa 677 to 758) (Deshpande et al., 
2011) (Figure 3.71). This so-called CALM/AF10-minimal fusion (CA-
MF) was very active in transforming bone marrow cells in vitro. In 
contrast to the full length CALM/AF10 fusion, CA-MF led to the 
development of blast colonies in CFC assays. In the bone marrow 
transplantation model, expression of CA-MF resulted in the 
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development of an aggressive AML with a similar latency and 
phenotype as the full-length CALM/AF10 fusion.  
 
 
Fig 3.71: Diagrams of the CALM/AF10 full length and the CALM/AF10 minimal 
fusion proteins. ENTH: Epsin N-terminal homology domain; NES: nuclear export 
signal; OM/LZ: octapeptide motif/leucine zipper; PHD: plant homeo domain; NLS: 
nuclear localization signal; CATS: CALM/AF10 interacting protein expressed in 
thymus and spleen  
The CA-MF fusion gene was used for our second approach. A stable 
retroviral producer cell line expressing the CA-MF, E86-CA-MF-GFP, 
had been established by Aniruddha Deshpande (Deshpande et al., 
2011) and was used in our experiments. 
3.2.2.2 Experimental procedure 
To co-express CA-MF and BMI1 in bone marrow cells, we used two 
retrovirus producer cell lines: E86-CA-MF-GFP and E86-BMI1-YFP. 
These two virus producing cell lines were irradiated, mixed together 
according to their viral titres and cultured together. The bone 
marrow cells from the wild type FVB donor mice were collected and 
transduced using the cell mixture. Successfully co-transduced cells 
were positive for both YFP and GFP and were sorted using flow 
cytometry. 0.5x106 YFP+/GFP+ cells and 0.5x106 mock YFP/GFP 
negative cells were injected into irradiated syngenic wild type 
recipients. As controls, bone marrow cells transduced with only 
BMI1, only CALM/AF10-MF and the empty vetors were also 
transplanted into wild type recipients. Below is an overview of the 
transplantations performed. 
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3.5 Summary of the BMT model to transplantation experiment 
Number of mice transplanted with different constructs is summarized in this table. 
The first column includes the different experimental groups, in the second column the 
constructs used for each group of experiment are listed. The third column contains 
the number of transplanted animals for each group of experiments. All the donors 
and recipients were wilt type FVB mice. 
Experimental group Construct Number of 
transplants 
CA-MF&BMI1 pMIY-BMI1 
& 
pMIG-CA-MF 
10 
BMI1 pMIY-BMI1 12 
CA-MF pMIG-CA-MF 10 
MIY pMIY 9 
 
3.2.2.3 Bone marrow cells transduced with pMIG-CA-MF show high 
engraftment potential 
We transplanted the recipient mice with equal numbers of 
transduced and mock-transduced cells (0.5x106 cells). Mock-
transduced cells are cells that had undergone the same 
manipulations as the successfully transduced cells but had not 
taken up the retrovirus. 4 weeks after transplantation, we 
measured the percentage of YFP/GFP positive cells in the peripheral 
blood of the transplanted mice. The two groups transplanted with 
cells expression the CALM/AF10 minimal fusion (CA-MF and CA-
MF&BMI1) had slighty higher percentages of YFP/GFP positive cells 
(78±16.47 and 79±9.29%, respectively) indicating a growth 
advantage for these cells and higher engraftment potential (Figure 
3.72). 
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Fig 3.72: Engraftment as percentage of YFP/GFP positive cells the peripheral 
blood of the mice in the four experimental groups, 4 weeks after 
transplantation 
3.2.2.4 The mice in the CA-MF and CA-MF&BMI1 groups develop 
an acute myeloid leukemia after a short latency 
All the mice in the CA-MF and CA-MF&BMI1 groups developed an 
acute myeloid leukemia with a median latency of 101 and 110 days, 
respectively. In contrast, none of the mice from the BMI1 or MIY 
group developed leukemia after an observation period of more than 
1 year (Figure 3.73). The leukemic cells from one leukemic mouse 
from the CA-MF&BMI1 group were transplanted into two secondary 
recipients. Only one of the recipients had received conditioning 
lethal irradiation before transplantation. Both secondarily 
transplanted animals developed AML with a short latency of 3 
weeks. 
There was no significant difference between the CA-MF and CA-
MF&BMI1 groups in the latency time to leukemia development. The 
following Kaplan-Meier survival plot summarizes the results. The 
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percentage of survival of individual animals from each experimental 
group is summarized in the table A10 in the appendix. 
 
 
Fig 3.73: The Kaplan-meier survival curve for the CALM/AF10-MF+BMI1 mice 
along with the controls. 
10 wild type FVB mice transplanted with CALM/AF10 minimal fusion developed 
leukemia with a median latency of 101 days post transplantation. This group is 
labeled as CA-MF. 
10 wild type FVB mice transplanted with CALM/AF10-minimal fusion and BMI1 
developed leukemia after a median latency of 110 days post transplantation. This 
group is labeled as CA-MF&BMI1. 
12 wild type FVB mice were transplanted with BMI1 as control. None of them 
developed leukemia. The group is labeled as BMI1 
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9 wild type FVB mice were transplanted with empty vector MIY. None of them 
developed leukemia. The group is labeled as MIY. Note that two animals from this 
group were sacrificed 182 days after transplantation because of severe injuries due 
to fighting with each other. These two, non leukemic animals were censored. 
3.2.2.5 All the leukemic mice show high WBC count and 
splenomegaly 
All the leukemic mice from the CA-MF and the CA-MF&BMI1 group 
had splenomegaly and leukocytosis. 
  
Fig 3.74: Leukocytosis in CA-MF and CA-MF&BMI1 mice. The number of WBC in 
the mice transplanted with BMI1 and MIY were monitored monthly till 16 weeks post 
transplantation and they did not show any abnormality. The WBC counts from these 
two groups of mice are not included in the figure above. The figure shows the WBC 
counts after the mice were sacrificed 
3.2.2.6 All leukemic mice were highly engrafted  
The leukemic mice from the CA-MF and CA-MF&BMI1 groups 
showed a high percentage of GFP single positive or GFP/YFP double 
positive cells in their peripheral blood, bone marrow and spleen. 
Figure 3.75 shows the average percentage of GFP positive cells 
from 5 leukemic mice from the CA-MF group and GFP/YFP double 
positive cells from 7 leukemic from the CA-MF&BMI1 group. 
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The average percentage of GFP positive cells in the peripheral blood 
of the leukemic mice from CA-MF group was 66% with a standard 
deviation of 22%. In the bone marrow, the percentage of GFP+ 
cells ranged from 36% to 73% with a standard deviation of 14%. In 
the spleen the average number of GFP positive cells was 30% with 
a standard deviation of 13.4%. In the CA-MF&BMI1 group, the 
average number of GFP/YFP double positive cells in the peripheral 
blood, bone marrow and spleen was 62% with standard deviation of 
16.8%, 59% with a standard deviation of 23% and 49% with a 
standard deviation of 17%, respectively. The actual values of GFP 
positive and GFP/YFP double positive cells in different hematopoietic 
organs of individual leukemic animals from both groups (CA-MF and 
CA-MF&BMI1) are summarized in table A11 and A12 in the 
appendix. 
 
Fig 3.75: Percenatge of GFP+ cells in the peripheral blood, bone marrow and 
spleen of 5 leukemic mice from the experimental group CA-MF and the 
percentage of GFP/YFP double positive cells of 7 mice from the group CA-
MF&BMI1 
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3.2.2.7 GFP+/YFP+ double positive leukemic cells infiltrate multiple 
organs in mice from the CA-MF&BMI1 group 
To investigate if the transplanted cells contribute to the organ-
infiltrating leukemic bulk, cells from different hematopoietic organs 
of the sick mice of the CA-MF&BMI1 group were prepared and 
characterized with flow cytometry. In all the leukemic CA-MF&BMI1 
mice, the leukemic cells were GFP and YFP double positive. An 
example of the GFP-YFP scatter plots from the spleen cells from six 
CA-MF&BMI1 mice after they had developed leukemia and been 
sacrificed is shown in Fig. 3.76.  
 
  
Fig 3.76: Leukemic cells from the spleen of 6 mice from the CA-MF&BMI1 
group were positive for both GFP and YFP. The upper panel shows the GFP/YFP 
double positive population of the leukemic cells obtained from the spleens of three 
mice 5799A#133, 5799A#134,5807A#139. GFP/YFP double positive cells 
constituted 64%, 63% and 26% of all cells isolated from the spleens of these mice. In 
the lower panel spleen cells from mouse 5799B#142, 5807B#149 and 5788#158 are 
shown. Note that the GFP/YFP double positive cells constitute 40%, 45% and 39% of 
the total spleen cells of these three mice 
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3.2.2.8 Multiple organ infiltration with leukemic cells 
Histological sections were prepared from formalin-fixed organs of 
the leukemic animals from the CA-MF&BMI1 group and analyzed by 
HE staining and immunohistochemitry. Leukemic blasts were found 
in several non-hematopoietic organs, like the liver and kidney 
(Figure 3.77) 
 
Fig 3.77: Infiltration of malignant cells in organ sections from mice of the CA-
MF&BMI1 group. HE stained tissue sections of spleen, liver and kidney of a mouse 
with leukemia show diffuse and clustered infiltration of blast-like cells in these organs 
(arrows). 
 
3.2.2.9 The infiltrating cells have myeloid characteristics 
To characterize the infiltrating leukemic blasts, we performed 
immunohistochemistry. The infiltrating cells stained weakly positive 
for MPO (myeloperoxidase) and ASCDL (Chloracetate esterase) but 
negative for TdT. A few cells were B220 positive in the spleen, 
corresponding to residual B cells. These results show that the 
infiltrating cells are of myeloid origin and are compatible with the 
diagnosis of an acute myeloid leukemia in the mice of the CA-
MF&BMI1 group (Figure 3.78).  
 
Fig 3.78: Immunohistochemistry of organ sections from leukemic mice using 
myeloid markers. Liver and spleen sections show weak positive staining of 
myeloperoxidase (MPO) and chloracetate esterase (ASDCL) staining.  
3.2.2.10 The immunophenotypes of the leukemia from mice of the 
CA-MF&BMI1 and the CA-MF group are similar 
Flow cytometric analysis of peripheral blood, bone marrow and 
spleen cells from leukmic animals from the CA-MF&BMI1 and the 
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CA-MF group with our standard panel of antibodies showed a 
significant increase in the percentage of cells staining positive for 
the myeloid maker Mac1 and a marked decrease in Sca1 positive 
cells and CD4 and CD8 positive T cells in comparison to cells from 
healthy wild type FVB mice. There was no significant difference in 
the immunophenotype of the leukemias from the 7 animals from 
the CA-MF&BMI1 group compared to the leukemias from the 5 
animals from the CA-MF group (Figures 3.79-3.81). The individual 
values of surface marker positive cells from individual leukemic 
mice from both groups of mice are summarized in table A11 and 
A12 and A13 in the appendix. 
 
  
Fig 3.79: Immunophenotype of the peripheral blood mononuclear cells from 7 
leukemic mice from the CA-MF&BMI1 group and 5 leukemic animals from the 
CA-MF group compared to cells from 3 wild type FVB, the common control 
used for all the analysis. The leukemic cells show a higher percentage of Mac1 
positive cells as well as a significantly lower percentage of CD4 and CD8 positive T 
cells. 
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Fig 3.80: Immunophenotype of the bone marrow cells from 7 leukemic mice 
from the CA-MF&BMI1 group and 5 leukemic animals from the CA-MF group 
compared to cells from 3 wild type FVB mice. Similar to the peripheral blood, the 
leukemic cells show a higher percentage of Mac1 positive cells as well as fewer CD4 
positive T cells. 
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Fig 3.81:  Immunophenotype of the spleen cells from 7 leukemic mice from the 
CA-MF&BMI1 group and 5 leukemic animals from the CA-MF group compared 
to cells from 3 wild type FVB mice. The leukemic cells show a higher percentage 
of Mac1 positive cells as well as significantly lower percentages of Sca1, CD4 and 
CD8 positive cells.  
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4. Discussion 
4.1 A knock-in mouse model with tissue-specific expression 
of the CALM/AF10 fusion gene 
The CALM/AF10 fusion gene is the result of a rare but recurring 
t(10;11)(p13;q14) translocation, which is found in different 
hematologic malignancies including T-ALL, AML, and lymphoma. 
The CALM/AF10 fusion gene is able to cause leukemia in a murine 
retroviral bone marrow transplantation model (Deshpande et al., 
2006) and in a transgenic mouse model (Caudell et al., 2007). 
However, while the penetrance of CALM/AF10 driven leukemias is 
100% in the bone marrow transplantation model with a short 
median latency of just 10 weeks (Deshpande et al., 2006), only 
40% of the transgenic mice with a Vav promoter-driven CALM/AF10 
transgene developed leukemia with a long latency of 12 months 
(Caudell et al., 2007). In our group, we generated CALM/AF10 
transgenic mice, in which the CALM/AF10 transgene is driven by the 
immunoglobulin heavy chain enhancer/promoter or by the proximal 
Lck promoter(Krause, 2006).None of our transgenic CALM/AF10 
mice developed leukemia. These models show that the expression 
of CALM/AF10 alone is not sufficient to cause leukemia. CALM/AF10 
most likely needs to be expressed in the proper cellular context and 
requires additional, collaborating events to initiate leukemia 
development. By generating a knock-in mouse model with tissue-
specific expression of the CALM/AF10 fusion, we aimed to identify 
the cell type most susceptible to CALM/AF10-mediated leukemia 
development. The Rosa26loxP-stop-loxP-CALM/AF10 (R26LSLCA) 
knock-in mouse line allows the tissue specific expression of the 
fusion protein after Cre-mediated excision of the transcriptional stop 
cassette from the Rosa26loxP-stop-loxP-CALM/AF10 knock-in allele. 
By using mouse strains, which express the Cre recombinase in 
different tissues, we were able to control the expression of 
CALM/AF10 in a tissue-specific fashion. To express the fusion gene 
in all hematopoietic cells, the R26LSLCA mice were crossed with 
Vav-Cre mice. In addition, we performed crosses with the Mb1-Cre 
and CD19-Cre strains to restrict the expression of CALM/AF10 to the 
B cell compartment starting from early B lymphoid progenitors. 
4.2 A CALM/AF10 knock-in model with expression of 
CALM/AF10 in Vav-expressing cells leads to the development 
of AML with 100% penetrance.  
Vav-Cre mediated excision of the stop cassette and the subsequent 
expression of CALM/AF10 in all hematopoietic cells resulted in the 
development of an acute myeloid leukemia in all mice with an 
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average latency of 1 year. The leukemic mice had splenomegaly, 
anemia and leukocytosis. Tissue sections of the leukemic mice 
revealed massive infiltration of MPO-positive myeloid blast in 
different hematopoietic and non-hematopoietic organs. The myeloid 
nature of the leukemia was also confirmed by flow cytometry. The 
leukemic cells in the peripheral blood, bone marrow and spleen of 
the leukemic CA+/Vav-Cre+ mice were positive for the myeloid 
markers Gr1 and Mac1. A total of 23 CA+/Vav-Cre+ animals were 
observed. A post mortem analysis was possible for only 15 leukemic 
animals. 8 animals were found dead in their cages and could not be 
analyzed in detail. 6 out of 8 dead mice had slenomegaly, which 
strongly suggests that they died of leukemia. In 2 dead animals we 
could not do any analysis due to severe autolysis. 
4.3 Two phenotypically distinct types of AML developed in 
CA+/Vav-Cre+ mice 
The leukemic cells in the CA+/Vav-Cre+ mice were positive for the 
myeloid markers MPO and Mac1. Interestingly, in 40% of the 
leukemic animals (6 mice out of total 15 leukemic mice), the 
leukemic cells were also positive for the lymphoid marker B220+.  
The average percentage of Mac1+/B220+ cells was 40% of the total 
peripheral blood cells with a standard deviation of 6.43%, 36% of 
the total bone marrow cells with a standard deviation of 12.09% 
and 44% of the total cells isolated from leukemic spleens with a 
standard deviation of 4.58%. In contrast, in the other 9 leukemic 
animals, B220-positive cells were almost completely absent. Apart 
from the significant difference in the phenotype, no variation in the 
disease latency or the severity of the disease was observed 
between the two AML subgroups in the CA+/Vav-Cre+ mice. 
Interestingly, a mixed lineage or biphenotypic phenotype has been 
reported for some patients with the CALM/AF10 fusion (Kumon et 
al., 1999; Secco et al., 1996). In these cases, T lymphoid and 
myeloid antigens were found on the blasts. The development of a 
mixed myeloid/lymphoid phenotype in CALM/AF10 leukemia models 
is not surprising in the light of the fact that the CALM/AF10 fusion is 
found frequently in T-ALL patients and also in patients presenting 
with an AML (Bohlander et al., 2000) 
4.4 How does the CALM/AF10 fusion gene cause mixed 
lineage phenotype leukemia?  
Two alternative mechanisms for the development of the mixed 
lineage phenotype have been proposed, one is called ‘lineage 
infidelity’ theory (McCulloch, 1983) and the other is ‘lineage 
promiscuity’ (Greaves et al., 1986). These two alternative theories 
are not necessarily mutually exclusive.  
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According to the ‘lineage infidelity’ theory, unusual biphenotypic 
cells can arise when the transformed cells aberrantly express genes 
from another lineage under the influence of a particular oncogene.  
In the ‘lineage promiscuity’ setting, it is assumed that the 
transformed cell itself still had multilineage differentiation potential 
like a hematopoietic stem cell (HSC) or a multipotent progenitor 
(MPP). In a murine bone marrow transplantation model reported by 
Chi Wai So et al, the MLL-GAS7 fusion transformed MPPs resulting 
in myeloid, biphenotypic and lymphoid leukemias (So et al., 2003). 
In our CA+/Vav-Cre+ mice, the CALM/AF10 fusion gene was 
expressed in all hematopoietic cells that express the Vav gene, 
including fetal liver hematopoietic cells (de Boer et al., 2003; Ogilvy 
et al., 1999). So it is very likely that in our model the CALM/AF10 
fusion transformed HSCs and MPPs with some of these transforming 
events leading to predominantly myeloid and other to biphenotypic 
leukemia. Thus the results observed in our experiments are 
compatible with a lineage promiscuity model giving rise to “very” 
myeloid leukemias or to myeloid leukemias with co-expression of 
lymphoid markers. The variation in leukemia phenotype might not 
only depend on which cell was originally transformed but also on 
which additional, collaborating genetic events were acquired during 
the long latency period. 
Our immunohistochemistry analyses showed that mature 
granulocytes were present in both the myeloid and the biphenotypic 
leukemias in the CA+/Vav-Cre+ mice. 50% of the cells in the 
leukemic bulk stained positive for the mature 
monocytic/macrophage markers CD24+ and F4/80. So it appears 
that, although CALM/AF10 fusion impairs the proper differentiation 
of its target cells, these cells still retain some ability to terminally 
differentiate.  
4.5 Expression of the CALM/AF10 fusion gene is not 
oncogenic in the B cell compartment  
When we crossed the R26LSLCA knock-in mice with Mb1-Cre and 
CD19-Cre mice, no leukemia development was observed in the 
progeny. In the CA+/Mb1-Cre+ mice, the expression of the 
CALM/AF10 fusion starts at the very early pro-B cell stage with the 
activity of the Mb1 promoter (Hobeika et al., 2006). In the 
CA+/CD19-Cre+ cross, expression of the CALM/AF10 fusion starts a 
little later from the pre-B cell stage onward (Rickert et al., 1997).  
25 CA+/Mb1-Cre+ and 20 CA+/CD19-Cre+ mice were observed for 
one and half years. But none of the animals developed leukemia. 
The presence of the CALM/AF10 transcript was determined using 
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real-time RT-PCR in the B cells of 6 CA+/Mb1-Cre+ mice and 3 
CA+/CD19-Cre+ mice. The level of CALM/AF10 fusion transcript 
detected in the B cell of CA+/Mb1-Cre+ and CA+/CD19-Cre+ mice 
was quite comparable to the level of CALM/AF10 transcript found in 
the bone marrow and spleen of leukemic CA+/Vav-Cre+ mice. This 
result indicates that the level of CALM/AF10 fusion transcript is not 
critical for the development of leukemia. For leukemia development, 
it seems to be more important in which tissue or cell type 
CALM/AF10 is expressed. The CA+/Mb1-Cre+ model showed that 
expression of CALM/AF10 in early B cells progenitors does not lead 
to leukemia development.  
Using a murine retroviral bone marrow transplantation (BMT) 
model, Deshpande et al. showed that the expression of the 
CALM/AF10 fusion gene in murine bone marrow cells led to the 
development of an aggressive AML with a short median latency of 
15 weeks and 100% penetrance. Deshpande and colleagues were 
able to identify the leukemia-propagating cell in their model. While 
the majority of leukemic cells displayed only myeloid markers on 
their surface, there were some cells that had both myeloid and 
lymphoid surface markers and a very small percentage of cells that 
were myeloid marker negative but lymphoid marker B220 postive. 
Interestingly, the leukemia propagating cells were found with the 
highest frequency (about 1:34) in the only lymphoid marker 
positive cell population (Deshpande et al., 2006). The 
immunophenotype of the leukemia propagating cells was described 
as B220+/CD43+/AA4.1+/HAS+/CD19-. These lymphoid 
progenitors-like cells were able to seed leukemias that had the 
same, mainly myeloid, phenotype as the original leukemia. These 
observations led to the hypothesis that the cell, which is the target 
of CALM/AF10-mediated transformation, might be a lymphoid 
precursor cell or an early B cell progenitor (Deshpande et al., 
2006).  
However, our observation that the expression of CALM/AF10 in very 
early B cells in the CA+/Mb1-Cre+ mice does not lead to leukemia 
does not seem to be compatible with this hypothesis. To solve this 
contradiction, one has to distinguish carefully between the target 
cell for transformation and the leukemia propagating cell. Even 
though the limiting dilution assays performed by Deshpande and 
colleagues were able to identify the phenotype of the leukemia 
propagating cells, they were not designed to determine the 
phenotype of the target cell for transformation. 
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4.6 The target cell of CALM/AF10-mediated leukemogenesis 
is a hematopoietic stem cell 
Our CA+/Vav-Cre+ model strongly suggest that the CALM/AF10 
fusion needs to be expressed in a cell that is at the top of the 
hematopoietic hierarchy, possibly in a stem cell or in a multipotent 
progenitor cell, to exert its oncogenic effect. The observation that 
the CALM/AF10 fusion leads to bi-phenotypic leukemias in the 
CA+/Vav-Cre+ model is compatible with this hypothesis. 
Once leukemia has been initiated by CALM/AF10 in a HSC or MPP, 
the phenotype of the cells changes. This explains the fact that the 
leukemia propagating cells in the active leukemia can have a very 
different phenotype from the cell that was the initial target of 
transformation. Thus we see a B cell progenitor-like phenotype of 
the leukemia propagating cells in the BMT model of Deshpande et 
al., but no ability of CALM/AF10 to initiate leukemia when expressed 
in cells of a similar phenotype and differentiation stage in our 
CA+/Mb1-Cre+ (or CA+/CD19-Cre) mice. The 100% leukemia 
penetrance in our CA+/Vav-Cre+ model clearly shows that the 
target for CALM/AF10-mediated transformation has to be a 
hematopoietic stem cell or a very early multipotent progenitor cell. 
4.7 The expression of CALM/AF10 is not sufficient for 
leukemia development 
If we take into consideration that the median latency to leukemia 
development in the CA+/Vav-Cre+ mice was about one year, we 
have to conclude that additional mutations are required for 
CALM/AF10 to initiate leukemia. If there were no additional 
mutations required, all CA+/Vav-Cre+ mice should develop 
leukemia at a very young age. Presently, we do not know how 
many additional mutations are required in this process (one, two or 
more). There are estimates from sequencing the genomes of human 
AML samples that between 5 and 8 driver mutations are required 
for a leukemia to develop (2013). It is highly likely that these 
additional mutations arise in the hematopoietic stem cells in our 
model, because the lifetime of the MPPs is too short to accumulate 
additional mutations. One would also expect, if mutations in MPPs 
played a prominent role, that the latency of leukemia development 
in the CA+/Vav-Cre+ mice would be shorter. 
Some recent works show that adult hematopoietic stem cells with 
long-term repopulation capacity (LT-HSC) are not a homogenous 
population of cells. There are sub-types of HSCs showing 
heterogenous differentiation behaviour. Some HSCs show a low 
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lymphopoietic activity and were first described as ‘myeloid biased’ 
whereas some HSCs that showed a balanced output of myeloid and 
lymphoid cells were called ‘balanced HSCs’ (Muller-Sieburg et al., 
2004). Single cell transplantation assays in mice have been 
performed with LT-HSCs and depending on the ratio of clonally 
derived myeloid and lymphoid cells in the peripheral blood of the 
transplanted animals these subtypes of HSCs were identified. 
Connie J Eaves and colleagues have redefined this selectively 
lymphoid deficient sub-group of HSCs as ‘α HSCs’. β HSCs show an 
equal potential to differentiate into myeloid and lymphoid cells 
(Benz et al., 2012; Dykstra et al., 2007). The ratio of α and β HSCs 
also appear to be very dynamic. It has been recently shown that α 
HSCs become more predominant than the β HSCs during the adult 
hematopoiesis (Benz et al., 2012). Taking this emerging paradigm 
into consideration we can assume that the fate of the leukemia 
(lymphoid or myeloid) will be dependent on the sub-type of the 
transformed HSCs. In addition, the leukemia phenotype might 
depend on which additional mutation the HSC acquires during 
leukemogenesis. However, it also remains a possibility that the 
additional mutations are solely responsible for the phenotypic 
variation of the leukemia. 
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Fig 4.1: Schematic of the hematopoietic development showing the ‘Leukemia 
initiating cell’ in the R26LSLCA mouse model. 
4.8 Overexpression of Hoxa cluster genes and Hox co-factor 
Meis1 in CALM/AF10 fusion mediated leukemia 
Dik and colleagues reported that the Hoxa cluster genes are highly 
expressed in CALM/AF10 positive T-ALL patients (Dik et al., 2005). 
The Hoxa cluster genes were also highly expressed in a transgenic 
CALM/AF10 mouse leukemia model (Caudell et al., 2007; Okada et 
al., 2006). In our CA+/Vav-Cre+ mouse model, there was also 
overexpression of the Hoxa5, Hoxa7, Hoxa9 and Hoxa10 genes in 
the bone marrow and the spleen cells of mice with leukemia. In 
addition, we detected high expression levels of the Hox co-factor 
Meis1 in this model. Interestingly, Caudell and colleagues were able 
to detect high expression of the Hoxa cluster genes and Meis1 in 
the normal, non-leukemic bone marrow cells of their Vav promoter-
driven CALM/AF10 transgenic mice (Caudell et al., 2007). However, 
we were unable to detect high Hoxa cluster gene or Meis1 
expression in the non-leukemic B cells from CA+/Mb1-Cre+ mice, 
even though the CALM/AF10 fusion transcript in the non-leukemic 
cells was expressed at comparable levels to expression levels in 
leukemic cells. These data indicate that high expression levels of 
the Hoxa genes and Meis1 are specific to the leukemic cells in in our 
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CALM/AF10 knock-in mice. The Bmi1 gene was found to be 
upregulated in CALM/AF10 positive human leukemias by Dik and 
colleagues and in our laboratory (Dik et al., 2005; Mulaw et al., 
2012). BMI1 was one of the most prominent upregulated genes in 
CALM/AF10 positive leukemia samples compared to several other 
leukemia subtypes (Mulaw et al., 2012). However, there were only 
2 to 3 fold higher expression levels of Bmi1 transcripts in the 
leukemic cells from CA+/Vav-Cre+ mice compared to healthy 
controls. 
4.9 Overexpression of human BMI1 in tr-IgH-CALM/AF10 
bone marrow cells induces leukemia in a retroviral bone 
marrow transplantation model 
BMI1 was reported to be specifically upregulated in both human and 
murine CALM/AF10 leukemia (Dik et al., 2005; Mulaw et al., 2012). 
It is known that BMI1 is essential for the self-renewal of 
hematopoietic stem cells (Park et al., 2003). BMI1 plays a role in 
determining the proliferating capacity of normal and leukemic stem 
cells (Lessard and Sauvageau, 2003) and collaborates with BCR-ABL 
in leukemic transformation of human CD34+ cells (Rizo et al., 
2010). In a very recent study, BMI1 overexpression has been 
identified as a collaborating event in the development of human and 
murine myelodysplastic syndromes along with AML1 mutation 
(Harada et al., 2013). All these finding qualifies BMI1 as an 
interesting candidate to be investigated for its potential role in 
CALM/AF10 leukemia. 
 
To investigate the ability of BMI1 to collaborate with the CALM/AF10 
fusion in leukemia development, bone marrow cells from transgenic 
mice expressing the CALM/AF10 fuison protein under the control of 
the immunoglobulin heavy chain enhancer/promoter (tr-IgH-
CALM/AF10) were transduced with a pMIY retrovirus expressing a 
FLAG-tagged human BMI1  and transplanted into lethally irradiated 
non-transgenic FVB mice. As mentioned earlier, the tr-IgH-
CALM/AF10 mice express the CALM/AF10 fusion gene in mature B 
cells but do not develop leukemia. When bone marrow cells from tr-
IgH-CALM/AF10 mice transduced with pMIY-BMI1 were transplanted 
into the lethally irradiated syngeneic recipients, 67% (8 of 12) of 
the transplanted mice (the “tr-IgH-CA&BMI1” group) developed 
leukemia within 400 days of our observation period. Transgenic 
bone marrow cells transduced with the empty vector or non-
transgenic bone marrow cells transduced with the pMIY-BMI1 vector 
did not cause leukemia in the recipient mice. 5 of the 8 leukemic 
mice had an AML. The leukemic cells from two of the five AML mice 
were successfully retransplanted into the secondary recipient mice 
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with and without irradiation and led to the development of leukemia 
in the secondary recipients.  
Two mice from the tr-IgH-CA&BMI1 group developed T-ALL 101 
days and 219 days after transplantation. Giemsa-May-Grünwald 
staining of the peripheral blood smears from these mice showed 
immature lymphoblasts. All the hematopoietic organs in these two 
mice were infiltrated with CD4+/CD8+ T lymphocytes. But 
interestingly, the leukemic cells were YFP-negative. When unsorted 
bone marrow cells from one T-ALL mouse were transplanted into 2 
secondary recipients, the secondary recipients failed to develop 
leukemia.  
One mouse from the tr-IgH-CA&BMI1 group showed symptoms of 
leukemia like ruffled fur, difficulty in breathing and reduced 
movement. It was sacrificed 123 days after transplantation. The 
post mortem analysis revealed that the mouse had a slightly bigger 
spleen but high WBC counts in the peripheral blood. The cytospin 
preparations from the hematopoietic organs showed the presence of 
immature blast cells of myeloid lineage. Flow cytometric analysis 
showed that percentage of myeloid and lymphoid cells was normal 
in comparison to the wildtype FVB control mice but 41% of the total 
peripheral blood cells and 91% of the bone marrow cells were 
Sca1+. Sca1 is a marker of myeloid progenitors. The presence of a 
high number of Sca1+ cells in peripheral blood and bone marrow 
explains the immature cells identified in the blood smear and bone 
marrow cytospins. There were no YFP+ cells in the peripheral blood 
of this mouse. In the bone marrow and spleen, only 3% YFP-
positive cells could be detected.  The type of the hematological 
malignancy could not be conclusively determined by 
immunohistochemistry. 
4.10 Both CA-MF together with BMI1 and CA-MF alone induce 
an aggressive AML in a murine bone marrow transplantation 
model 
In our second approach to test the collaboration of BMI1 with 
CALM/AF10 to induce leukemia, bone marrow cells from wild type 
FVB mice were co-transduced with pMIG-CA-MF and pMIY-BMI1. 
The co-transduced, GFP and YFP double positive cells were 
transplanted into irradiated syngeneic recipient mice. The pMIG-CA-
MF retrovirus expresses a deletion mutant of CALM/AF10 (the 
minimal fusion), which has been shown to lead to an aggressive 
acute myeloid leukemia with similar latency and penetrance (100%) 
like the full length CALM/AF10 in bone marrow transplantation 
experiments (Deshpande et al., 2011). As expected, all 10 mice 
transplanted with CA-MF expressing bone marrow cells developed 
an AML with an average latency of 118 days and 100% penetrance. 
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Similarly, all 10 mice transplanted with bone marrow cells co-
transduced with both the pMIG-CA-MF and the pMIY-BMI1 viruses 
also developed an acute myeloid leukemia with a similar average 
latency of 120 days. There was no significant difference in the 
phenotype, the aggressiveness or the latency of the CA-MF and the 
CA-MF&BMI1 induced leukemias. It is very likely that the strong 
leukemogenic drive of the CA-MF gene in this model prevented us 
from noticing any differences, like changes in the latency or 
aggressiveness of the leukemia when BMI1 was coexpressed with 
CA-MF. Thus, this approach did not produce conclusive evidence 
that BMI1 is a strong collaborator of CALM/AF10-induced 
leukemogenesis. 
4.11 Evidence for collaboration of BMI1 with CALM/AF10 in 
leukemogenesis 
Even though our second approach, as discussed in the previous 
paragraphs, did not provide evidence for collaboration between 
CALM/AF10 and BMI1 in leukemogenesis, the results from our bone 
marrow transplantation experiments using transgenic CALM/AF10 
(tr-IgH-CA) bone marrow cells (approach 1) argue very strongly in 
favor of a collaborative effect of the overexpression of BMI1 in 
CALM/AF10-mediated leukemogenesis. Only when BMI1 was 
expressed in the transgenic tr-IgH-CA bone marrow cells did we see 
leukemia development (tr-IgH-CA&BMI1 group). Expression of BMI1 
in non-transgenic bone marrow or transduction of tr-IgH-CA cells 
with an empty retrovirus did not lead to leukemia development. The 
penetrance of leukemia in this group was 58%, if one counts only 
the clear cases of leukemia. Although, most likely, the penetrance is 
higher because an additional mouse in this experimental group did 
show signs of leukemia but a clear diagnosis of leukemia could not 
be made.  
While the CALM/AF10 fusion is frequently found in human T-ALL 
patients, up to now only cases of CALM/AF10-induced AML have 
been reported in mouse models. Interestingly, 2 mice in the tr-IgH-
CA&BMI1 group developed T-ALL. However, the leukemic 
CD4+/CD8+ population of leukemic blast was not YFP positive as 
would be expected. It is thus unclear whether the ALL in these two 
mice originated from the transplanted cells. An explanation for the 
absence of the YFP protein from these T cell leukemias could be a 
negative selection phenomenon against GFP-like proteins in 
lymphoid cells and especially in T ALL cells. It is known that GFP 
proteins affect RING E3 ubiquitin ligase dependent processes like 
NF-ĸB signaling in cell lines and in mice (Baens et al., 2006). Baens 
and colleagues showed that the expression of EGFP protein inhibits 
NF-ĸB signaling. In EGFP transgenic mice, there was reduced NF-kB 
ubiquitination and NF-ĸB signaling. The structural homologue of 
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GFP, dsRed, had a similar effect on the NF- ĸB signaling in vitro 
(Baens et al., 2006). It is known that in human T-ALL, the NF-ĸB 
pathway is highly activated (Vilimas et al., 2007). T-ALL cell lines 
are very sensitve to the inhibition of NF-ĸB signalling and in Notch1-
IC induced T-ALL, attenuation of NF-ĸB activity affects the 
progression and severity of the disease (Vilimas et al., 2007). 
Additional experiments, involving larger mouse cohorts would be 
required to prove that BMI1 and CALM/AF10 expression are really 
responsible for the development of T-ALL in this model. 
The presence of the CALM/AF10 fusion together with expression of 
BMI1 in mature B-cells led to the development of myeloid leukemia 
(N=5) in about 1/3 of the mice of the tr-IgH-CA&BMI1 group. This 
is a little surprising because one would expect a B ALL phenotype. It 
is very likely that the expression of CALM/AF10 synergizes with 
BMI1 to disturb the normal B cell differentiation pathway in these 
leukemias leading to a myeloid phenotype. 
Rizo and colleagues showed that elevated level of BMI1 expression 
acts as a collaborative event in BCR-ABL-induced transformation of 
human CD34+ cells (Rizo et al., 2010). Recently, BMI1 
overexpression was shown to collaborate with a RUNX1/AML1 
mutation in the development of human and murine myelodysplastic 
syndrome (Harada et al., 2013). The mechanism by which BMI1 
contributes to oncogensis is not clear. We know, BMI1 is essential 
for the self-renewal of Hsc and it is a key regulator of the 
proliferative potential of leukemic and normal stem and progenitor 
cells. (Lessard and Sauvageau, 2003; Park et al., 2003) (Iwama et 
al., 2004; Jacobs et al., 1999; Rizo et al., 2008). According to 
previous studies and the data from our mouse BMT model, it 
appears that expression of BMI1 alone is not leukemogenic in 
human CD34+ cells or in in vivo murine models (Jacobs et al., 
1999; Rizo et al., 2010). However, overexpression of BMI1 
promotes symmetrical divisions of HSC and induces proleferation of 
hematopoietic progenitors (Iwama et al., 2004). It is known that 
BMI1 represses the p16INK4a/p19ARF locus, which is an important 
mechanism for bypassing the senescence of embryonic fibroblasts. 
Deletion of BMI1 results in the increased expression of the cell cycle 
inhibitor proteins p16 and p19. However, overexpression of only 
BMI1 can increase number of progenitor cells, in the absence of p16 
and p19 repression, indicating there must be other targets of BMI1 
and that repression of the p16/p19 proteins is not solely responsible 
for the self-renewal stimulating property of BMI1. Thus, BMI1 could 
contribute to oncogenesis by bypassing senescence and increasing 
the life span of stem cells or by contributing to increased self-
renewal of progenitors by allowing symmetrical cell division. In a 
recent report, a novel mechanism of BMI1-mediated inactivation of 
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apoptotic barrier in neuroblastoma was described. This report shows 
that BMI1 reduces TP53 protein levels by direct binding and directly 
inducing its polyubiquitination and proteosomal degradation (Calao 
et al., 2013), leaving the embryonic cells susceptible to 
oncogenesis. 
The exact role of BMI1 in CALM/AF10 mediated leukemia remains 
elusive and requires further investigation. In a recent report Bmi1 is 
shown to synergise with BCR/ABL in transforming B-lymphoid 
progenitors by aberrant induction of HSC-specific gene expression 
in the mature progenitors (Sengupta et al., 2012). It is a possibility 
that overexpression of BMI1 along with CALM/AF10 induces 
aberrant expression of genes in the B lymphocytes of IgH-CA&BMI1 
mice, imparting survival advantage, rendering them susceptible to 
acquire additional mutations which help in the transformation of 
these cells leading to the development of AML or T-ALL. 
4.12 Is the BMI1 overexpression in CALM/AF10 fusion 
induced leukemia due to a position effect? 
The BMI1 gene in humans is located on chromosome 10, about 500 
kbp proximal to the AF10. The synteny between AF10 and BMI1 is 
conserved in mice. Together with 3 other neighbouring genes 
(COMMD3, SPAG6 and DNAJC1) BMI1 was found to be upregulated 
in CALM/AF10 positive leukemia patients (Dik et al., 2005; Mulaw et 
al., 2012). It was speculated that this upregulation of BMI1 and its 
neighbours might be due to a position effect as a result of the 
t(10;11)(p12;q14) translocation, which brings the very active CALM 
promoter to in proximity to the 3’ portion of the AF10 and the 
downstream genes DNAJC1, COMMD3, BMI1, and SPAG6 (Dik et al., 
2005). However, the murine Bmi1 was found to be upregulated 
together with Commd3 and Dnajc1 in samples from a murine bone 
marrow transplantation model (BMT) of CALM/AF10-induced 
leukemia (Mulaw et al., 2012).  Since there is no t(10;11)(p12;q14) 
translocation in this BMT model, the position effect explanation for 
the aberrant expression of Bmi1 could be ruled out and a role of the 
CALM/AF10 fusion protein itself in the upregulation of Bmi1 can be 
assumed. However, the mechanism of CALM/AF10-mediated 
transcriptional upregulation of Bmi1 remains unclear. In this study 
we were also able to detect a mild upregulation of Bmi1 in the 
leukemic cells of the CA+/Vav-Cre mice. More extensive and more 
precise studies of the interplay of CALM/AF10 and Bmi1 are 
required to clarify their role in leukemogenesis. 
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5. Summary 
The translocation t(10;11)(p13;q14), which results in the formation 
of the CALM/AF10 fusion gene, is associated with variety of 
hematological malignancies, including T-cell acute lymphoblastic 
leukemia (T-ALL), acute myeloid leukemia (AML), undifferentiated 
leukemia, and T cell lymphoma. In most cases, this translocation is 
associated with a very poor prognosis. Originally, the CALM/AF10 
fusion was cloned from the human cell line U937, derived from a 
patient with histiocytic lymphoma. The CALM/AF10 fusion transcript 
contains the complete open reading frame of the CALM gene except 
for the last 4 c-terminal amino acids, fused in-frame to almost the 
complete AF10 open-reading frame except for the first 82 amino 
acids. CALM is a 652 amino acid long protein, which is homologous 
to the neuronal specific endocytic protein AP180. CALM intereacts 
with clathrin and plays a role in clathrin-mediated endocytosis. 
AF10 is a putative transcription factor with an octapeptide motif and 
leucine zipper domain (OM/LZ), which was shown to be critical for 
CALM/AF10 mediated leukemogenesis. CALM/AF10, when expressed 
as a transgene in the whole hematopoietic compartment from the 
Vav-promoter leads to the development of AML in 40% of the 
transgenic mice after a median latency of 1 year. However, in a 
murine retroviral bone marrow transplantation model, the 
expression of CALM/AF10 leads to the development of aggressive 
AML in all the animals with a median latency of only 15 weeks. In 
this model, using a limiting dilution transplantation approach, 
Deshpande and colleagues were able to show that the frequency of 
the ‘leukemia-propagating cell’ was highest (1:34) in a lymphoid 
marker positive but myeloid marker negative (B220+/MM-) 
subpopulation. This finding led to the hypothesis that the 
CALM/AF10 fusion gene induces an aberrant myeloid development 
of B220+ early lymphoid progenitors  
To investigate the tissue-specific requirement for CALM/AF10 in 
leukemogenesis, we have generated a Cre-inducible knock-in 
mouse model of CALM/AF10. In this R26LSLCA mouse line, the 
cDNA of human CALM/AF10 fusion preceded by a LoxP-flanked 
transcriptional stop cassette is knocked into the Rosa26 locus. Using 
mouse lines that express Cre as transgene in a tissue-specific 
fashion under the control of various promoters (Vav, CD19 or Mb1) 
or as an estrogen receptor fusion gene, which is Tamoxifen 
activatable, the transcriptional stop cassette can be removed, 
leading to the tissue-specific or temporally-controlled expression of 
the CALM/AF10 fusion protein. To achieve the expression of 
CALM/AF10 in the all-hematopoietic cells, the Vav-Cre mouse line 
was crossed with the R26LSLCA mice. Crosses with the Mb1-Cre 
and CD19-Cre transgenic lines were employed to express 
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CALM/AF10 in the B cell compartment from early pro-B cell 
onwards. When CALM/AF10 was expressed in the whole 
hematopoietic compartment in the cross with the Vav-Cre line, all 
mice developed AML after a median latency of 1 year. Leukemic 
mice had splenomegaly, leukocytosis, and infiltration of myeloid 
blast cells in hematopoietic and several non-hematopoietic organs. 
The leukemic cells were characterized by the expression of myeloid 
markers like Gr1, Mac1. In 40% of the cases, the leukemic cells 
also co-expressed the lymphoid marker B220 in addition to the 
myeloid markers. The latency or the agressiveness of the two 
different types of leukemia in this model were not different. 
However, when CALM/AF10 was expressed just in the B cell 
compartment in the crosses with the Mb1-Cre and CD19-Cre lines, 
none of the mice developed leukemia, even after a long latency of 
18 months. The level of CALM/AF10 transcript was similar both in 
the bone marrow and spleen cells from the leukemic mice and in 
the B cells from non-leukemic mice. In the leukemic bone marrow 
and spleen cells, we detected high levels of Hoxa cluster gene 
transcripts, namely Hoxa5, Hoxa7, Hoxa9, Hoxa10, of the Hox co-
factor Meis1, and of Bmi1 compared to transcript levels in 
CALM/AF10 expressing B cells from the non-leukemic mice. From 
these observations we can draw the conclusion that CALM/AF10-
mediated leukemogenesis is only possible if CALM/AF10 is 
expressed in an early hematopoietic progenitor or, most likely, 
hematopoitic stem cell. The relatively long latency of the onset of 
leukemia in Vav-Cre induced mouse cohort strongly supports the 
hypothesis that CALM/AF10 requires additional genetic lesions for 
leukemogenesis. 
We used a candidate gene approach to test one putative 
collaborator of CALM/AF10 in leukemia development. We chose 
BMI1, a polycomb group gene, because it is specifically upregulated 
both in human and murine CALM/AF10 leukemia. Bmi1 was 
originally identified as a co-operating factor of c-Myc in B cell 
lymphomagenesis. To determine the role of BMI1 as a collaborator 
of CALM/AF10 in leukemogenesis, we developed a murine retroviral 
bone marrow transplanataion model. We used IgH-CALM/AF10 
transgenic mice as bone marrow donors. As previously mentioned, 
these mice express the CALM/AF10 fusion in their B cells but do not 
develop leukemia (Krause, 2006). The bone marrow cells of the 
donors were transduced with a human BMI1 expressing retrovirus 
and transplanted into non-transgenic, syngeneic recipients. Eight of 
12 transplanted mice developed acute leukemia within 1 year after 
transplantation (6 mice had AML, 2 mice had ALL). Mice 
transplanted with empty vector transduced cells transgenic cells or 
with non-transgenic cells expressing BMI1 did not develop 
leukemia. When we transplanted mice with wild type bone marrow 
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that had been retrovirally transduced to express CALM/AF10-MF (a 
very leukemogenic deletion mutant of CALM/AF10) alone or 
CALM/AF10 and BMI1, all transplanted animals in the two groups 
developed leukemia with a median latency of 10 weeks, and there 
was no difference in the leukemia phenotype between the two 
groups. Taken together, the results from these experiments 
strongly support the hypothesis that BMI1 is a collaborator of 
CALM/AF10 in leukemogenesis. 
In summary, two key assumptions are strongly supported by the 
results of our experiments:  
1) CALM/AF10 has to be expressed in the right cell type to lead to leukemia 
2) CALM/AF10 needs collaborators in leukemogenesis. It could be shown that the 
overexpression of BMI1 is one such collaborating event. 
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6. Zusammenfassung  
Die t(10;11)(p13;q14) Translokation, die zur Bildung des 
CALM/AF10 Fusionsgens führt, findet sich bei verschiedenen, 
malignen hämatologischen Erkrankungen wie der akuten T-Zell 
lymphoblastischen Leukämie (T-ALL), der akuten myeloischen 
Leukämie (AML), der undifferenzierten Leukämie und bei T-Zell 
Lymphomen. In den meisten dieser Fälle ist diese Translokation mit 
einer sehr schlechten Prognose verbunden. Ursprünglich wurde die 
CALM/AF10 Fusion in der U937 Zelllinie kloniert, die von einem 
Patienten mit histiozytischem Lymphom stammt. Das CALM/AF10 
Fusionstranskript besteht aus dem offenen Leserahme des CALM 
Gens mit Ausnahme der 4 letzten Aminosäuren, der im Leseraster 
mit der codierenden Region fast des gesamten AF10 Gens mit 
Ausnahme der ersten 82 Aminosäuren fusioniert ist. CALM ist ein 
652 Aminosäure langes Protein, das Homologien zu dem Neuronen-
spezifischen endozytotischen Protein AP180 aufweist. CALM 
interagiert mit Clathrin und spielt eine Rolle bei der Clathrin-
mediierten Endozytose. AF10 is ein mutmaßlicher 
Transkriptionsfaktor mit einem Octapeptide/LeuzinZipper Motif 
(OM/LZ), von dem gezeigt wurde, dass es wichtig für die 
CALM/AF10 mediierte Leukämogenese ist. Wenn CALM/AF10 als 
Transgen in allen hämatopoetischen Zellen unter der Kontrolle des 
Vav-Promoters exprimiert wird, führt es zur Entstehung einer AML 
bei ca. 40% der transgenen Mäuse nach einer medianen Latenzzeit 
von einem Jahr. In einem Mausknochenmarktransplantationsmodell 
führt CALM/AF10 jedoch schon nach einer Latenzzeit von nur 15 
Wochen zur Entwicklung einer aggressiven AML bei allen 
transplantierten Tieren. Desphande und Kollegen konnten in diesem 
Model zeigen, dass die Häufigkeit der Leukämie propagierenden 
Zellen mit 1:34 am höchsten in einer Zellpopulation war, die positiv 
für lymphatische Marker, aber negativ für myeloische Marker war 
(B220+/MM-). Diese Ergebnisse haben zu der Hypothese geführt, 
dass das CALM/AF10 Fusionsgen eine aberrante myeloische 
Entwicklung von B220+ frühen lymphatischen Progenitorzellen 
induziert. 
Um zu untersuchen, welche gewebsspezifischen Voraussetzungen 
CALM/AF10 bei der Leukämogenese braucht, haben wir ein Cre-
induzierbares Knock-in Modell für CALM/AF10 entwickelt. In dieser 
R26SLSCA Mauslinie ist die cDNA der humanen CALM/AF10-Fusion, 
der eine mit LoxP-Stellen flankierte transkriptionelle Stopp-Kassette 
vorangestellt ist, in den Rosa26 Locus integriert. Mithilfe von 
Mauslinien, die die Cre-Rekombinase als Transgen unter der 
Kontrolle von verschiedenen gewebsspezifischen Promotoren (Vav, 
CD19 oder Mb1) oder als eine Fusion mit dem Östrogenrezeptor, 
  
 
167 
der Tamoxifen aktivierbar ist, exprimieren, kann die 
transkriptionelle Stopp-Kassette entfernt werden, was zu einer 
gewebsspezifischen oder zeitlich kontrollierten Expression des 
CALM/AF10 Fusionsproteins führt. Um die Expression von 
CALM/AF10 in allen hämatopoetischen Zellen zu erreichen, wurden 
die R26SLSCA Mäuse mit dem Vav-Cre Mausstamm gekreuzt. 
Verpaarungen mit den Mb1-Cre und den CD19-Cre transgenen 
Linien wurden benutzt, um eine Expression von CALM/AF10 im B-
Zellkompartiment ab dem frühen pro-B-Zellstadium zu erreichen. 
Die Expression von CALM/AF10 im allen hämatopoetischen Zellen 
durch die Kreuzung mit den Vav-Cre Mäusen führte zur Entwicklung 
von AML bei allen Mäusen mit einer medianen Latenzzeit von einem 
Jahr. Die leukämischen Mäuse hatten eine Splenomegalie, 
Leukozytose und Infiltrationen von myeloischen Blasten in allen 
hämatopoetischen und einigen nicht-hämatopoetischen Organen. 
Die leukämischen Zellen war charakterisiert durch die Expression 
der myeloischen Oberflächenmarker Gr1 und Mac1. Bei 40% dieser 
Leukämien fand sich auch eine Koexpression des lymphatischen 
Markers B220 zusätzlich zu den myeloischen Markern. Die 
Latenzzeit und die Aggressivität dieser zwei Leukämietypen 
unterschied sich nicht voneinander. Die Expression von CALM/AF10 
nur im B-Zellkompartiment in den Mäusen der Kreuzungen mit den 
Mb1-Cre und den CD19-Cre führte bei keiner der Mäusen zu einer 
Leukämieentwicklung, selbst nach einer langen Beobachtungszeit 
von bis zu 18 Monaten. Die Expressionshöhe des CALM/AF10 
Transkripts war sowohl in den Zellen des Knochenmarks und der 
Milz der Mäuse mit der Leukämie als auch in den B-Zellen der nicht 
leukämischen Mäuse ungefähr gleich. In den leukämischen 
Knochenmarks- und Milzzellen konnten wir im Vergleich zu den 
CALM/AF10 exprimierenden B-Zellen der nicht-leukämischen 
Mäusen eine hohe Expression der Hoxa Clustergene Hoxa5, Hoxa7, 
Hoxa9, Hoxa10, des Hox Kofaktors Meis1 und von Bmi1 
nachweisen. Aus diesen Beobachtungen läßt sich schlußfolgern, 
dass eine Leukämienentwicklung durch die Expression von 
CALM/AF10 nur zustande komme, wenn CALM/AF10 in einer frühen 
hämatopoetischen Progenitorzelle und möglicherweise einer 
hämatopoetischen Stammzelle exprimiert wird. Die relativ lange 
Latenzzeit bis zur Leukämieentwicklung in der Vav-Cre induzierten 
Mauskohorte deutet darauf hin, dass CALM/AF10 zusätzliche 
genetische Veränderungen für die Leukämogenese benötigt. 
Wir wendeten einen Kandidatengenansatz an, um einen 
mutmaßlichen Kooperationsfaktor für CALM/AF10 bei der 
Leukämogenese zu testen. Wir wählten hierzu BMI1, ein Gen der 
Polycomb Gruppe, weil es spezifisch in menschlichen und murinen 
CALM/AF10 assoziierten Leukämien hoch exprimiert wird. Bmi1 
wurde ursprünglich als kooperierender Faktor von c-Myc bei der B-
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Zelllymphomentwicklung identifiziert. Um die Rolle von BMI1 als 
kooperierender Faktor für CALM/AF10 bei der Leukämogenese zu 
untersuchen, entwickelten wir ein murines 
Knochenmarktransplantationsmodell. Wir verwendeten IgH-
CALM/AF10 transgene Mäuse als Knochenmarkspender. Wie bereits 
erwähnt, exprimieren diese Mäuse die CLAM/AF10 Fusion in ihren B-
Zellen, aber enwickeln keine Leukämie (Krause, 2006). Die 
Knochenmarkzellen der Spender wurden mit menschlichem BMI1 
exprimierenden Retroviren transduziert und in nicht transgene 
syngene Empfängermäuse transplantiert. Acht der 12 
transplantierten Mäuse entwickelten eine akute Leukämie innerhalb 
eines Jahres nach der Transplantation (6 Mäuse hatten AML und 2 
Mäuse eine ALL). Mäuse, die mit transgenen Knochemarkszellen, 
die mit dem leeren Vektor transduziert wurden, oder mit nicht 
transgenen Knochenmarkszellen, die mit dem BMI1 exprimierenden 
Vektor transduziert wurden, entwickelten keine Leukämien. Als wir 
Mäuse mit nicht transgenem Knochenmark, das mit CALM/AF10-MF 
(einer sehr leukämogenen Deletionsmutante von CALM/AF10) 
exprimierenden Retroviren transduziert wurde, oder mit 
CALM/AF10-MF und BMI1 exprimierenden Retroviren, kam es zu 
einer sehr schnellen Leukämieenwicklung mit einer medianen 
Latenzzeit von 10 Wochen in beiden Gruppen, und es zeigte sich 
auch kein Unterschied in dem leukämischen Phänotyp. Die 
Ergebnisse dieser Experimente untermauern sehr stark die 
Hypothese, dass BMI1 ein Kooperationspartner von CALM/AF10 in 
der Leukämogenese ist. 
Zusammenfassend können wir sagen, dass zwei wichtige Annahmen 
durch die Ergebnisse unseres Experiments untermauert werden: 
1) CALM/AF10 muss im richtigen Zelltyp exprimiert werden, um 
eine Leukämie auszulösen. 
2) CALM/AF10 braucht kollaborierende Kofaktoren für die 
Leukämogenese. Es konnte gezeigt werden, dass eine hohe 
Expression von BMI1 einer dieser Kofaktoren ist. 
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8. Appendix 
Table A1: Tamoxifen treated cohort of the double positive (CALM/AF10+/Cre-
ERT2+) mice: 
 Genotype Mouse No 
Period of 
Treatment 
1 CALM/AF10+/ Cre ERT2 + 30 18.07.10-23.07.10 
2 CALM/AF10+/ Cre ERT2 + 32 18.07.10-23.07.10 
3 CALM/AF10+/ Cre ERT2 + 33 18.07.10-23.07.10 
4 CALM/AF10+/ Cre ERT2 + 52 18.07.10-23.07.10 
5 CALM/AF10+/ Cre ERT2 + 53 18.07.10-23.07.10 
6 CALM/AF10+/ Cre ERT2 + 79 13.09.10-17.09.10 
7 CALM/AF10+/ Cre ERT2 + 94 13.09.10-17.09.10 
8 CALM/AF10+/ Cre ERT2 + 95 13.09.10-17.09.10 
9 CALM/AF10+/ Cre ERT2 + 114 13.09.10-17.09.10 
10 CALM/AF10+/ Cre ERT2 + 116 13.09.10-17.09.10 
11 CALM/AF10+/ Cre ERT2 + 117 13.09.10-17.09.10 
12 CALM/AF10+/ Cre ERT2 + 118 13.09.10-17.09.10 
13 CALM/AF10+/ Cre ERT2 + 121 13.09.10-17.09.10 
14 CALM/AF10+/ Cre ERT2 + 138 13.09.10-17.09.10 
15 CALM/AF10+/ Cre ERT2 + 139 13.09.10-17.09.10 
16 CALM/AF10+/ Cre ERT2 + 140 13.09.10-17.09.10 
17 CALM/AF10+/ Cre ERT2 + 141 13.09.10-17.09.10 
18 CALM/AF10+/ Cre ERT2 + 143 13.09.10-17.09.10 
19 CALM/AF10+/ Cre ERT2 + 144 13.09.10-17.09.10 
 
Table A.2: Tamoxifen treated cohort of only CALM/AF10 positive 
(CALM/AF10+/Cre-ERT2-) control mice: 
 Genotype Mouse No Period of Treatment 
1 CALM/AF10+/ Cre ERT2- 22 18.07.10-23.07.10 
2 CALM/AF10+/ Cre ERT2- 23 18.07.10-23.07.10 
3 CALM/AF10+/ Cre ERT2- 24 18.07.10-23.07.10 
4 CALM/AF10+/ Cre ERT2- 85 18.07.10-23.07.10 
5 CALM/AF10+/ Cre ERT2- 152 13.09.10-17.09.10 
6 CALM/AF10+/ Cre ERT2- 153 13.09.10-17.09.10 
7 CALM/AF10+/ Cre ERT2- 154 13.09.10-17.09.10 
8 CALM/AF10+/ Cre ERT2- 156 13.09.10-17.09.10 
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Table A3: Tamoxifen treated cohort of only Cre-ERT2 positive (CALM/AF10-
/Cre-ERT2+) control mice: 
 Genotype Mouse No Period of Treatment 
1 CALM/AF10-/ Cre ERT2+ 30 18.07.10-23.07.10 
2 CALM/AF10-/ Cre ERT2+ 32 18.07.10-23.07.10 
3 CALM/AF10-/ Cre ERT2+ 33 18.07.10-23.07.10 
4 CALM/AF10-/ Cre ERT2+ 52 18.07.10-23.07.10 
5 CALM/AF10-/ Cre ERT2+ 53 18.07.10-23.07.10 
6 CALM/AF10-/ Cre ERT2+ 124 13.09.10-17.09.10 
7 CALM/AF10-/ Cre ERT2+ 125 13.09.10-17.09.10 
8 CALM/AF10-/ Cre ERT2+ 126 13.09.10-17.09.10 
 
Table A4 Days of survival and diagnosis of the leukemic CA+/Vav-Cre+ animals 
Mouse ID Age at the time of 
death (days) 
Comment 
Vav 29 452 Analyzed bipheotypic 
leukemia 
Vav 31 451 Analyzed, myeloid 
leukemia 
Vav 32 352 Analyzed, bipheotypic 
leukemia, detailed 
histology and 
immunohistochemistry 
was performed. 
Vav 42 414 Analyzed, myeloid 
leukemia, detailed 
histology and 
immunohistochemistry 
was performed. 
Vav 51 403 Analyzed, myeloid 
leukemia 
Vav 57 432 Analyzed, myeloid 
leukemia, detailed 
histology and 
immunohistochemistry 
was performed. 
Vav 65 355 Analysed, bipheotypic 
leukemia 
Vav 71 396 Analyzed, myeloid 
leukemia 
Vav 72 497 Analyzed, myeloid 
leukemia 
Vav 74 343 Analyzed, myeloid 
leukemia, detailed 
histology and 
immunohistochemistry 
was performed. 
Vav 80 285 Analyzed, pre-leukemic 
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Vav 81 421 Analyzed, bipheotypic 
leukemia 
Vav 84 404 Analysed, myeloid 
leukemia 
Vav 86 293 Analyzed, bipheotypic 
leukemia, detailed 
histology and 
immunohistochemistry 
was performed. 
Vav 95 261 Analyzed, bipheotypic 
leukemia, detailed 
histology and 
immunohistochemistry 
was performed. 
Vav 12 559 Found dead, 
Splenomegaly, pale 
organs 
Vav 14 318 Found dead, autolysis of 
organs,No analysis 
Vav 16 354 Found dead, autolysis of 
organs No analysis 
Vav 18 403 Found dead, 
Splenomegaly, pale 
organs 
Vav 27 321 Found dead, 
Splenomegaly,whitish 
spots on spleen 
Vav 45 320 Found dead, 
Splenomegaly, pale 
organs 
Vav 60 261 Found dead, 
Splenomegaly, pale 
organs 
Vav 66 263 Found dead, 
Splenomegaly, pale 
organs 
Vav 89 349 Found dead, 
Splenomegaly, pale 
organs 
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Table A5 Average, standard deviation and statistical analysis of different 
surface markers on the cells from peripheral blood of leukemic CA+/Vav-Cre+ 
mice (myeloid leukemia N=7, biphenotypic leukemia N=6) and the mice from 
control group (N=8) 
 
Surface 
Marker 
 
Control Sample, 
N=8 
Average 
%±St.deviation 
Leukemic Sample 
Average % ±St.deviation  
  
Myeloid 
N=7 
P 
Value 
Biphenotypi
c,N=6 
P Value 
Gr1+ 15.12±8.83 45.57±12.
90 
0.000
12 
31.66±16.39 0.03 
Mac1+ 15.75±13.5 63±20.76 0.000
15 
72.66±10.48 1.93E-6 
Gr1+/Ma
c1+ 
6.75±4.26 43±13.51 6.74E
-6 
29.66±18.93 0.005 
Sca1+ 26±10.86 19.14±5.6
3 
0.158 6.16±5.19 0.001 
cKit+ 0.7±1.38 5.2±4.45 0.017 2.5±1.76 0.05 
B220* 12±5.34 15.86±8.4
7 
0.304 51±15.34 2.07E-5 
CD43+ 60±22.33 79.71±7.6
7 
0.04 56.33±29.28 0.79 
CD19+ 6±3.5 8.28±7.15 0.43 3.6±2.3 0.204 
CD4+ 10.62±6.94 9.42±5.59 0.02 1.6±1.50 0.009 
CD3+ 22.25±9.79 3.42±2.57 0.009 4.66±3.01 0.001 
CD8+ 15.75±6.06 7±5.6 0.01 2.16±1.83 0.0002 
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Table A6 Average, standard deviation and statistical analysis of different 
surface markers on bone marrow cells from leukemic CA+/Vav-Cre+ mice 
(myeloid leukemia N=7, biphenotypic leukemia N=6) and the mice from control 
group (N=11) 
Surface 
Marker 
Control 
Sample, N=11 
Average 
%±St.deviation 
Leukemic Sample 
Average %±St.deviation 
 
  
Myeloid 
N=7 
P 
Value 
Biphenotypic,N=6 P 
Value 
Gr1+ 
34.54±18.56 75.85±5.87 3.77E-
5 
43±16.93 0.26 
Mac1+ 
28.9±21.98 80.85±9.52 2.41E-
5 
75.5±12.81 0.0002 
Gr1+/Mac1+ 
24.11±18.84 70.14±6.61 1.34E-
5 
36.66±15.95 0.188 
Sca1+ 
10.63±5.27 3.14±3.18 0.003 1.16±1.16 0.0006 
cKit+ 
18.45±2.76 15.85±9.044 0.38 11.66±5.12 0.002 
B220* 
9±3.12 7±3 0.206 45.33±17.44 1.26E-
5 
CD43+ 
64.9±21.54 73.57±16.0 0.381 53.83±34.67 0.44 
CD19+ 
7.2±3.96 5.85±12.87 0.75 1.16±1.16 0.002 
CD4+ 
8.45±4.03 2.71±1.49 0.02 1.33±1.50 0.0009 
CD3+ 
6.02±1.21 3.71±3.45 0.08 2.5±2.07 0.0007 
CD8+ 
2.95±1.49 0.71±0.75 0.002 0.33±0.51 0.0009 
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Table A7 Average, standard deviation and statistical analysis of different 
surface markers on the spleen cells from the leukemic CA+/Vav-Cre+mice 
(myeloid leukemia N=7, biphenotypic leukemia N=6) and the mice from our 
control group (N=11) 
Surface 
Marker 
Control Sample, N=11 
Average%±St.deviation 
Leukemic Sample 
(Average %±St.deviation)  
  
Myeloid 
N=7 
P 
Value 
Biphenotypic
,N=6 
P 
Value 
Gr1+ 14.09±7.8 37±19.4
0 
0.002 22.5±12.46 0.105 
Mac1+ 10.9±9.85 32.28±1
2.32 
0.0008 57.5±8.87 8.23E-
8 
Gr1+/Ma
c1+ 
5.9±6.87 24.28±1
3.40 
0.001 20.66±14.03 0.009 
Sca1+ 59.63±9.35 31.57±1
2.43 
5.14E-
5 
11.83±6.79 1.45E-
8 
cKit+ 4.75±4.7 21.71±2
4.86 
0.03 7.33±3.50 0.25 
B220* 30.27±12.58 25.14±1
2.37 
0.408 57.5±6.44 0.000
1 
CD43+ 68±10.56 64.14±1
9.30 
0.602 39.33±27.17 0.008 
CD19+ 23.3±12.41 11.28±7.
91 
0.04 8.5±6.09 0.01 
CD4+ 21.09±9.57 13.14±6.
93 
0.003 5±3.16 0.001 
CD3+ 42.4±17.29 7.71±4.1
5 
0.0007 7.66±5.31 0.000
3 
CD8+ 19.54±7.04 7.14±4.8
7 
0.0009 3.33±1.75 6.49E-
5 
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Table A8: The latency of the leukemia, YFP positivity and immunophenotype of 
the hematopoietic tissues of the individual leukemic animals from tr-IgH-
CA&BMI1 experimental group. PB-peripheral blood, BM- bone marrow, Spl-spleen 
Mouse Id Latency
(days) 
 GFP
% 
Gr1
% 
Mac1
% 
GM
% 
Sca1
% 
cKit
% 
B22
0% 
CD4
% 
CD8
% 
CD4/
CD8
% 
5619A#1 219 PB 1 13 0 0 28 0 6 98 75 99 
  BM 18 58 17 17 27 11 3 53 4 4 
  Spl 14 45 4 4 66 5 13 92 63 63 
5619A#2 246 PB 9 55 65 65 53 37 50 30 38  
  BM 4 80 78 80 25 44 35 26 16  
  Spl 17 22 26 26 88 14 63 56 25  
5619B#1 341 PB 42 46 76 75 42 0 2 16 3  
  BM 43 55 66 73 51 1 3 27 1  
  Spl 23 35 37 44 65 0 23 23 4  
5619B#2 461 PB 32 24 46 29 66 2 23 38 9  
  BM 12 62 50 37 11 4 6 10 2  
  Spl 28 15 13 9 60 1 33 23 8  
5625A#1 101 PB 21 8 11 1 8 12 1 7 10  
  BM 12 62 50 37 11 4 6 10 2  
  Spl 28 15 13 9 60 1 33 23 8  
5625A#2 197 PB 30 41 19 19 65 18 25 36 25  
  BM 86 65 13 13 91 34 22 54 3  
  Spl 52 41 7 7 73 11 20 48 6  
5625B#1 123 PB 0 11 8 7 40 1 0 9 23  
  BM 3 51 60 51 7 19 0 4 4  
  Spl 3 10 14 12 29 14 17 10 12  
5625B#2 101 PB 0 10 1 0 85 0 0 79 77 77 
  BM 3 26 6 0 16 23 4 19 8 2 
  Spl 23 9 0 0 75 3 24 37 13 6 
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Table A9: Summary of the percentage of survival of the leukemic and non 
leukemic animals from the following experimental group: tr-IgH-CA&BMI1,WT-
FVB&BMI1,WT-FVB&MIY, tr-IgH-CA&MIY and the secondary transplanted 
animals. 
Days 
(Post 
transplanta
tion) 
Survival 
IgH-
CA&BMI1 
(N=12) 
(%) 
Survival 
WTFVB&BMI
1 
(N=12) 
(%) 
Survival 
WTFVB&M
IY(N=9) 
(%) 
Survival 
IgH-
CA&MIY(N
=7) 
(%) 
Survival 
Secondary 
transplant(N
=6) 
(%) 
0 100 100 100 100 100 
18 100 100 100 100 66.7 
25 100 100 100 100 33.4 
101 83.34 100 100 100 33.4 
123 75.01 100 100 100 33.4 
158 75.01 100 100 85.7 
(censored) 
33.4 
182 75.01 100 77.78 
(censored) 
85.7 33.4 
197 66.68 100 77.78 85.7 33.4 
219 58.35 100 77.78 85.7 33.4 
246 50.02 100 77.78 85.7 33.4 
341 41.69 75.01 
(censored) 
77.78 85.7 33.4 
416 33.36 75.01 77.78 85.7 33.4 
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Table A10: Summary of the percentage of survival of the leukemic and non 
leukemic animals from the following experimental group: CA-MF, CA-
MF&BMI1, WT-FVB&BMI1, WT-FVB&MIY 
Days 
(post-
transplantati
on) 
Survival 
CA-MF 
N=11 
(%) 
Survival 
CA-
MF&BMI1,N
=10 
(%) 
Survival 
WTFVB&MIY(%), N=9 
Survival 
WTFVB&BMI, N=7 
(%) 
Survival 
Secondary 
transplant,N=
2 
(%) 
0 100 100 100 100 100 
31 100 100 100 100 0 
43 90.91 100 100 100 0 
71 81.82 100 100 100 0 
78 72.73 100 100 100 0 
86 63.64 90 100 100 0 
86 54.33 90 100 100 0 
99 45.46 90 100 100 0 
103 36.37 80 100 100 0 
108 36.37 70 100 100 0 
110 27.28 50 100 100 0 
114 27.28 40 100 100 0 
127 27.28 30 100 100 0 
133 27.28 20 100 100 0 
137 27.28 10 100 100 0 
171 18.19 0 100 100 0 
176 18.19 0 77.78 (censored) 100 0 
182 9.1 0 77.78 100 0 
261 0 0 77.78 100 0 
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Table A.11: Summary of the latency of leukemia, GFP positivity and the 
immunophenotype of the cells from different hematopoietic organs of mice 
transplanted with CALM/AF10-minimal fusion. PB-peripheral blood, BM- bone 
marrow, Spl-spleen 
Mouse Id Latency 
(days) 
 GFP
% 
Gr1
% 
Mac1
% 
GM
% 
Sca1
% 
cKit
% 
B22
0% 
CD4
% 
CD8
% 
            
5781A#120 110  PB 84 22 61 6 8 0 17 6 2 
  BM 36 88 80 74 2 0 0 2 0 
  Spl 43 42 32 20 2 0 10 1 0 
5800#144 
71 
PB 60 60 98 72 27 34 66 4 3 
  BM 49 84 95 84 18 61 76 14 24 
  Spl 32 51 76 51 12 17 74 17 10 
5800#143 
86 
PB 92 68 87 62 35 6 17 0 0 
  BM 73 91 82 82 0 0 11 3 0 
  Spl 10 50 32 30 1 0 44 0 0 
5800#145 
86 
PB 56 40 90 46 17 68 66 0 0 
  BM 44 75 89 74 6 41 58 0 0 
  Spl 42 33 57 33 10 20 45 0 0 
5806#147 
103 
PB 38 8 18 6 7 5 12 0 5 
  BM 55 56 72 56 10 17 12 8 0 
  Spl 26 21 38 8 8 10 55 3 3 
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Table A.12: Summary of the latency of leukemia, GFP positivity and the 
immunophenotype of the cells from different hematopoietic organs of mice 
transplanted with CALM/AF10-minimal fusion and BMI1 (CA-MF&BMI1)  
PB-peripheral blood, BM- bone marrow, Spl-spleen 
Mouse Id Latency 
(days) 
 GFP
% 
Gr
1
% 
Mac
1% 
GM
% 
Sca
1% 
cKi
t% 
B2
20
% 
CD4
% 
CD8
% 
5799A#133 86 PB 53 23 85 23 22 16 32 0 0 
  BM 45 25 84 25 15 38 74 13 21 
  Spl 32 14 69 14 17 26 85 12 18 
5799A#134 110 PB 86 8 66 0 9 61 0 0 0 
  BM 83 4 62 0 2 75 0 0 0 
  Spl 79 6 54 2 4 60 5 0 0 
5799B#142 133 PB 60 2 62 11 2 50 20 0 0 
  BM 51 4 47 4 0 53 15 0 0 
  Spl 44 0 32 0 4 38 0 0 0 
5788A#158 127 PB 64 6 8 6 7 5 0 0 0 
  BM 83 42 54 42 2 29 0 0 0 
  Spl 64 68 57 57 7 26 11 0 0 
5807A#138 103 PB 65 16 37 16 7 4 0 0 0 
  BM 59 11 90 9 1 17 0 0 0 
  Spl 49 10 24 4 8 15 8 0 0 
5807A#139 108 PB 76 4 33 4 7 21 39 0 26 
  BM 74 46 69 25 2 48 44 4 32 
  Spl 43 20 70 12 4 45 80 2 9 
5807A#149 110 PB 33 31 59 31 4 14 51 1 3 
  BM 20 66 86 68 1 5 67 0 0 
  Spl 30 25 48 12 2 4 3 0 0 
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Table A13: Summary of the average percentage and the standard deviation of 
different surface markers in the different hematopoietic tissues from the wild 
type controls and the leukemic mice from group CA-MF&BMI1 and CA-MF   
PB-peripheral blood, BM- bone marrow, Spl-spleen 
Surface 
marker 
 CA-MF&BMI1, 
N=7 
CA-MF, N=5 
 
WT-FVB, N=3 
 
 PB 12.81±10.87 39.60±25.16 23.66±9.60 
Gr1 BM 28.29±23.85 78.80±32.61 36±3.46 
 Spl 20.43±22.58 39.40±12.58 24.33±4.04 
 PB 50±25.59 70.80±32.61 17.33±4.01 
Mac1 BM 70.29±16.84 83.60±8.79 21.33±4.16 
 Spl 50.57±17.45 47.00±19.18 11.66±1.52 
 PB 13±11.08 38.40±31.00 8.33±3.21 
Gr1/Mac1 BM 24.71±24.01 74.00±11.05 18±3.46 
 Spl 14.43±19.56 28.40±15.98 6±1 
 PB 8.29±6.47 18.80±12.13 41.66±6.50 
Sca1 BM 3.29±5.22 7.20±7.16 20±2 
 Spl 6.57±5.03 6.60±4.88 60.33±5.50 
 PB 24.43±22.28 22.60±28.67 0.66±0.57 
cKit BM 37.86±23.47 23.80±26.73 26±6.92 
 Spl 30.57±18.80 9.40±9.32 7±1 
 PB 20.29±21.08 35.60±27.83 23±2 
B220 BM 28.57±32.69 31.40±33.45 29.33±1.15 
 Spl 27.43±37.81 45.60±23.27 50.33±9.29 
 PB 0.14±0,38 2.00±2.83 34.66±26.10 
CD4 BM 3.29±4.92 5.40±5.64 33.33±9.07 
 Spl 2±4.47 4.20±7.26 32.33±4.04 
 PB 4.14±9.70 2.00±2.12 37.33±9.01 
CD8 BM 7.57±13.31 4.80±10.73 21±1 
 Spl 3.86±7.08 2.60±4.34 30.33±4.61 
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